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ABSTRACT 
 
Xiaofan Xu: Associations between Inorganic Arsenic Exposure and the Development of Type 2 
Diabetes: Dietary and Genetic Susceptibility 
(Under the direction of Penny Gordon-Larsen) 
 
 
Compelling evidence has linked high exposure to inorganic arsenic (iAs) with increased 
risk of Type 2 diabetes (T2D). There is growing concern that low-to-moderate level of iAs 
exposure may contribute substantially to the epidemic of T2D. Nevertheless, the results of the 
current perspective studies are inconsistent, which could be attributable to varied susceptibility 
due for example to differences in intake of beneficial nutrients and existence of genetic variants 
of enzymes involved in iAs metabolism.  
We capitalized on China Health and Nutrition Survey with measured baseline (i.e. 2009) 
iAs exposure using toenail; Mg and Zn intake at baseline; fasting glucose and insulin at follow-
up (i.e. 2015). Using multivariable adjusted regression models, we investigated the associations 
between baseline toenail arsenic and T2D incidence and indicators of glucose homeostasis at 
follow-up. We also examined potential effect modification by Mg and Zn intake at baseline on 
iAs-associated diabetes. In addition, we determined the gene-environment interaction using data 
from Mexico. 
We found a positive association between baseline iAs exposure and fasting glucose as 
well as odds of incident T2D. In addition, our findings suggest that instead of insulin resistance, 
pancreatic β-cell dysfunction is primarily involved in iAs-associated T2D. Moreover, though the 
association between baseline iAs exposure and pancreatic β-cell dysfunction at follow-up was 
  
iv 
stronger among participants with adequate Zn intake, the joint association between iAs exposure 
and dietary intake of Mg and Zn supports the beneficial effects of adequate Mg and Zn intake. In 
addition, our findings confirm that several genetic variants of arsenic methyl transferase 
(AS3MT) are in part responsible for the inter-individal differences in iAs metabolism, and roles 
of the variants may differ among populations with different levels of iAs exposure.  
Our study adds to the research on iAs and T2D by determining how, in the population 
with low-to-moderate iAs exposure, baseline iAs exposure relates to the development of T2D 
over 6 years. The proposed study also informs efforts to maximize the effectiveness of Mg and 
Zn intake to combat the diabetogenic effects of iAs and identifies genetically susceptible 
subgroups due to impaired iAs metabolism. 
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CHAPTER 1. INTRODUCTION 
 
Background 
The prevalence of type 2 diabetes (T2D), which is a well-recognized cause of premature 
death and disability, has increased globally over the past two decades, especially in China1-5. It 
has become abundantly clear that both pancreatic β-cell dysfunction and insulin resistance are 
involved in the development of T2D, but the interplay between pancreatic β-cell dysfunction and 
insulin resistance remains highly complex and somewhat undefined6,7. Though obesity is a well-
known risk factor for T2D and is associated with insulin resistance, it has been suggested that 
obesity alone cannot fully explain the escalating epidemic of T2D, especially in regions where 
the prevalence of obesity is low3,8-12. Recent studies stress on the importance of pancreatic β-cell 
dysfunction in the development of diabetes as participants with insulin resistance are still be able 
to maintain normal glucose tolerance as pancreatic β-cells with normal function are able to 
compensate for insulin resistance7,13,14. Thus, there is urgent need to identify and understand 
other T2D risk factors beyond obesity and insulin resistance, especially factors involved in 
pancreatic β-cell dysfunction15. 
Inorganic arsenic (iAs) is widely distributed in the environment, such as drinking water, 
contaminated food, rice, air, dust, and soil16. Growing literature has linked exposure to high 
levels of iAs with increased risk of T2D. There is growing concern that low-to-moderate levels 
of iAs exposure, which is much more common worldwide, may contribute substantially to the 
epidemic of T2D. However, few epidemiological studies have been conducted in low-to-
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moderately exposed populations, and most studies have been cross-sectional19,22-24. This is of 
concern as T2D has been shown to affect the metabolism of iAs, posing the risk that altered iAs 
biomarkers in diabetic individuals may be a consequence—vs. a cause—of T2D in cross-
sectional studies17. Thus, longitudinal studies are urgently needed in the low-to-moderately iAs 
exposed population, such as China and Mexico, to examine the association between iAs 
exposure and development of diabetes3,8-12.  
Effective strategies to counter the adverse effects of low-to-moderate iAs exposure are 
critical as it is challenging to eliminate iAs from daily life18,19. Recently, Petriello et al.20 
advocated identifying nutritional strategies to mitigate cardio-metabolic effects of toxic metals, 
such as iAs. Laboratory data also suggests that the adverse health effects of toxic metals could be 
reduced with optimal intake of dietary essential metals, such as magnesium (Mg) and zinc (Zn), 
which may decrease uptake or counter adverse metabolic effects of toxic metals21-27. However, 
human evidence on the effectiveness of such dietary strategies to reduce the adverse health 
effects of iAs is limited, and epidemiological studies have yet to access whether susceptibility to 
the diabetogenic effects of iAs may vary depending on levels of Mg and Zn intake28-30.  
Arsenic (+3 oxidation state) methyltransferase (AS3MT) is a key enzyme in the pathway 
for the methylation of iAs31. Previous studies have linked several polymorphic sites in AS3MT to 
significant differences in urinary measures of iAs metabolism—namely proportions of the 
methylated metabolites—in various populations32-40. However, to our knowledge, no population 
study has formally explored to what extent associations between AS3MT variants and measures 
of iAs metabolism may vary depending on levels of iAs exposure. Such heterogeneity, if present, 
could lead to inconsistencies across populations with varying iAs exposure in the extent to which 
genetic variants either relate to measures of iAs metabolism, or modify health risks associated 
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with environmental iAs exposure. 
To sum up, the literature is lacking how, in a population with low-to-moderate iAs 
exposure, baseline (i.e.2009) iAs exposure relates to the development of T2D during follow-up 
(i.e.2015), and potential effect modification by Mg and Zn intake at baseline on the iAs-
associated T2D. In the proposed study, we took advantage of the genetic data from Mexico as 
well as rich longitudinal data from the ongoing longitudinal China Health and Nutrition Survey 
(CHNS), which include: toenail concentration of arsenic that reflects iAs exposure level in recent 
months at baseline; baseline dietary Mg and Zn intake captured using 3-day 24 hour recall; 
fasting glucose and insulin at follow-up (i.e. 2015). Using these unique data, we sought to 1) 
determine how, in a population with low-to-moderate iAs exposure, iAs exposure at baseline 
relates to the T2D incidence and indicators of glucose homeostasis at follow-up; 2) determine 
whether adequate intake of Mg and Zn at baseline may mitigate the diabetogenic effects of iAs; 
3) determine gene-environment interactions between genetic variants of AS3MT and iAs 
exposure. 
Research Aims 
The primary goal of this dissertation was to determine the associations between baseline 
(i.e.2009) iAs exposure, which was captured using toenail arsenic concentration, and T2D 
incidence during 6-years follow-up as well as the indicators of glucose homeostasis, which was 
characterized by fasting glucose, fasting insulin, glycated hemoglobin, pancreatic β-cell 
dysfunction, and insulin resistance at follow-up (i.e. 2015). We also aimed to examine potential 
effect modification by Mg and Zn intake at baseline on the associations between baseline iAs 
exposure and development of T2D over 6 years. In addition, we also aimed to determine the 
gene-environment interactions between genetic variants of AS3MT and iAs exposure. 
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Aim 1: Determine the associations between baseline iAs exposure and the development of 
T2D over 6 years. Measures of T2D development include a) indicators of glucose homeostasis 
at follow-up: fasting glucose (FG), fasting insulin (FI), pancreatic β-cell function and insulin 
resistance, which were assessed using the updated homeostasis model assessment (HOMA2)41-43, 
and b) incidence of pre-diabetes (FG≥110mg/dL and <126mg/dL) and T2D (FG≥126mg/dL) 
over 6 years of follow-up.  
We hypothesize that among adults without diabetes at baseline, higher toenail arsenic at 
baseline will be associated with elevated FG and decreased pancreatic β-cell function at follow-
up. We hypothesize null association between baseline toenail arsenic and insulin resistance at 
follow-up since β-cell dysfunction, rather than insulin resistance, is thought to be primarily 
involved in iAs-associated T2D. We also hypothesize positive associations between toenail 
arsenic at baseline and odds of incident T2D and pre-diabetes over 6 years. 
Aim 2: Determine the associations between intake of Mg and Zn at baseline and iAs-
associated T2D. We prospectively assess whether the susceptibility to the diabetogenic effects 
of low-to-moderate iAs exposure may vary depending on levels of Mg and Zn intake at baseline. 
We also examine the associations between Mg and Zn intake at baseline and the T2D incidence 
and indicators of glucose homeostasis at follow-up. 
We hypothesize that the fasting glucose and odds of incident T2D are lower among 
participants with adequate intake of Mg and Zn at baseline, and there are significant interactions 
between toenail arsenic and dietary intake of Mg and Zn at baseline for the development of T2D. 
The associations between iAs exposure and measures of T2D development are attenuated among 
participants with adequate intake of Mg and Zn at baseline (intake ≥ recommended dietary 
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allowance (RDA) and < tolerable upper intake level) comparing with people have Mg and Zn 
deficiencies (intake <RDA). 
Aim 3: Examine the consistency of previously established associations between multiple 
AS3MT variants and the profiles of urinary arsenic metabolites and determine evidence of 
heterogenic in the magnitude of these associations depending on exposure level.  
We hypothesize AS3MT SNPs previously reported to be associated with higher DMAs% 
are consistently associated with higher DMAs% in our study. We also hypothesize the 
magnitudes of the associations between AS3MT genetic variants and urinary arsenic profiles are 
stronger among participants with relatively high exposure level. 
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CHAPTER 2. LITERATURE REVIEW 
 
Inorganic arsenic is widely distributed in our environment and thought to contribute to the 
global epidemic of Type 2 diabetes 
Type 2 diabetes (T2D) which is a well-recognized cause of premature death and 
disability, is a complex disease with multiple contributing factors, such as obesity, environmental 
pollution, diet, and genetic components1-5,44-48. China has the greatest number of diabetes cases—
an estimated 98.4 million—worldwide, and the prevalence of T2D doubles during the last two 
decades4. Though obesity is a well-known risk factor for T2D and is associated with insulin 
resistance, it has been suggested that obesity alone cannot fully explain the escalating epidemic 
of T2D, especially in regions where the prevalence of obesity is low3,8-12. Recent studies stress 
on the importance of pancreatic β-cell dysfunction in the development of diabetes as participants 
with insulin resistance are still be able to maintain normal glucose tolerance as pancreatic β-cells 
with normal function are able to compensate for insulin resistance7,13,14. Thus, there is a urgent 
need to identify and understand other T2D risk factors beyond obesity and insulin resistance, 
especially factors involved in pancreatic β-cell dysfunction15. 
iAs is widely distributed in our environment, such as in drinking water, contaminated 
food, rice, air, dust, and soil16. Previous studies reported that more than 100 million people 
worldwide are exposed to unsafe levels of iAs in drinking water16. Compelling laboratory data 
and growing epidemiological literature indicates that high iAs exposure, normally defined as 
≥150μg/L iAs in drinking water, is associated with increased risk of T2D, and the 2011 National 
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Institute of Environmental Health Science-National Toxicity Program panel has agreed that 
existing data support an association between high exposure of iAs and increased risk of T2D49-54. 
There is growing concern that low-to-moderate level of iAs exposure, which is the exposure 
level much more common worldwide, may contribute substantially to the epidemic of T2D. 
Nevertheless, the results of the few prospective studies conducted in the low-to-moderately 
exposed populations are inconsistent51,55-57. The mixed results could be due in part to factors that 
include: 1) varied susceptibility due for example to differences in intake of beneficial nutrients, 
such as magnesium and zinc21,58-60; 2) misclassification of disease: laboratory studies have 
indicated the association between iAs exposure and hemoglobin concentration61,62, which raises 
concern about using HbA1c to diagnose diabetes among participants exposed to iAs63,64. 
Furthermore, the established association between biomarkers of iAs exposure and T2D is subject 
to criticism as it comes largely from cross-sectional studies. Yet diabetes has been shown to 
affect iAs metabolism and excretion53, posing the risk that altered iAs biomarker in diabetic 
individuals may be a consequence—vs. a cause—of disease17. 
Adequate intake of essential metals—notably Magnesium (Mg) and Zinc (Zn)—may 
mitigate iAs uptake and improve the glucose homeostasis 
It is challenging to eliminate iAs from daily life due to the diverse sources of iAs 
exposure and limited awareness of being exposed18,19. Thus, effective strategies to counter the 
adverse health effects of low-to-moderate iAs exposure are critical. Recently, Petriello et al.20 
has advocated identifying nutritional strategies to mitigate cardio-metabolic effects of toxic 
metals, such as iAs. Laboratory data also suggests that the adverse health effects of toxic metals 
could be reduced with optimal intake of dietary essential metals, such as magnesium (Mg) and 
zinc (Zn), which may decrease uptake or counter adverse metabolic effects of toxic metals21-27. 
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However, human evidence on the effectiveness of such dietary strategies to reduce the adverse 
health effects of iAs is limited, and epidemiological studies have yet to access whether 
susceptibility to the diabetogenic effects of iAs may vary depending on levels of Mg and Zn 
intake28-30. Indeed, population differences in intake of Mg and Zn may contribute to the 
heterogeneous findings on iAs-associated diabetes to date, especially among the population low-
to-moderately exposed to iAs21,26,30,58,59. 
In addition, deficiencies of Mg and Zn intake, which is defined as intake < recommended 
dietary allowance (RDA), are common worldwide, including China and the US54,65-69. The 
existing evidence thus indicates that promoting adequate intake of Mg and Zn, defined as intake 
≥RDA and < tolerable upper intake level (UL), could potentially be an effective strategy to 
counter the adverse effects of iAs, such as T2D. However, human evidence that such dietary 
strategies effectively counter iAs-associated T2D is limited.  
Toenail arsenic better captures chronic exposure to iAs than spot urine especially in low-to-
moderately exposed populations 
There is now increasing interest in using of nails as a routine biomarker of iAs 
exposure70-72. On ingestion, soluble iAs is absorbed from the gastro-intestinal tract and 
distributed to all bodily systems in the blood. iAs is thought to accumulate in hair and nails as a 
result of its affinity for sulfhydryl groups and remains isolated from the body’s metabolic 
processes after nail formation73. In addition, researchers found toenails preferentially sequester 
inorganic arsenic species, which is a more toxic form than organic arsenic70-72.  
Though urinary arsenic was widely used in studies as the biomarker of iAs exposure, the 
long-term accumulation of iAs in nails makes the toenail arsenic more useful as the biomarker of 
chronic iAs exposure70-72,74. A previous study conducted by Meharg et al showed considerable 
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variation (up to 13-fold) in an individual’s total iAs urine content throughout the day75, calling 
into question the robustness of the routinely used spot urine sampling for iAs analysis, especially 
in the population that is low-to-modernly exposed to iAs. 
Collectively, studies indicate toenail arsenic is a better biomarker for chronic iAs 
exposure comparing with spot urine, which is frequently used, especially among people low-to-
moderately exposed to iAs. 
China provides a special opportunity to conduct this study 
First, Chinese are at higher risk of T2D at relatively lower body mass index, which 
highlight the need to better understand the T2D risk factors beyond obesity3,4,47,76. Secondly, to 
determine the association between low-to-moderate iAs exposure and development of T2D, 
studies are largely needed to be conducted among populations with low-to-moderate iAs 
exposure, which is the exposure level in most part of China77. Thirdly, the prevalence of Mg and 
Zn deficiency are high in China54,65,67. The Chinese then provide a great opportunity for us to 
determine whether adequate intake of Mg and Zn could be an effective strategy to counteract the 
adverse metabolism effects of iAs. Lastly, the China Health and Nutrition Survey (CHNS) with 
rich longitudinal data, especially high-quality dietary data and toenail concentration of arsenic 
that reflects iAs exposure level in recent months at baseline (i.e. 2009), provides a special 
opportunity for us to conduct this study. All these factors make China a unique model to conduct 
the proposed study. 
The role of AS3MT gene in iAs metabolism 
In humans, the primary pathway for metabolism of iAs involves sequential methylation 
to form monomethylated As (MAs) and dimethylated As (DMAs) metabolites, which are 
excreted in the urine 31. Higher percentages of total urinary As represented by DMAs (DMAs%), 
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and lower percentages of MAs or the unmethylated iAs (MAs% and iAs%, respectively) in urine 
have been hypothesized to be indicators of higher capacity to metabolize iAs 31,78,79. The ratios of 
MAs to iAs (MAs/iAs) and of DMAs to MAs (DMAs/MAs) in urine have also been widely used 
as indicators of capacity for the first and second methylation steps. However, the measures of 
iAs metabolism most predictive of increased health risks remain to be established, given the 
conflicting associations reported in recent studies 31,80-83. 
Arsenic (+3 oxidation state) methyltrasferase (AS3MT) is a key enzyme in the pathway 
for the methylation of iAs, and variants in the AS3MT have been shown to be associated with 
inter-individual differences in iAs metabolism 32-35,84,85. Previous studies have linked 
polymorphic sites in this gene to significant differences in urinary measures of iAs metabolism in 
various populations 32-35,84,86. It has been suggested that iAs exposure level may modify iAs 
metabolism, as reflected by changes in urinary As methylation profiles, with a shift in the 
proportions of urinary metabolites among persons exposed to levels approximately >50ppb vs. 
≤50ppb 85,87-89. We have previously reported based on laboratory experiments that levels and 
proportions of the methylated products, including DMAs/MAs ratio, differ between recombinant 
variants of human AS3MT and depend on the substrate concentration 36. However, to our 
knowledge, no population study has formally explored to what extent associations between 
AS3MT variants and measures of iAs metabolism may vary depending on levels of iAs exposure. 
Such heterogeneity, if present, could lead to inconsistencies across populations with varying iAs 
exposure in the extent to which genetic variants either relate to measures of iAs metabolism, or 
modify health risks associated with environmental iAs exposure.  
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Summary 
The proposed study better informs how, in a population low-to-moderately exposed to 
iAs, baseline dietary Mg and Zn intake relates to the association between baseline iAs exposure 
and development of T2D during six years of follow-up. In addition, we examined whether the 
influence of genetic variants in AS3MT on iAs metabolism varied by level of iAs exposure. In 
this dissertation, we used geographically–diverse longitudinal CHNS data to address these 
questions. First, we determined the association between baseline iAs exposure, which was 
captured by toenail arsenic at baseline, and T2D incidence as well as indicators of glucose 
homeostasis, which were characterized by fasting glucose, fasting insulin, glycated hemoglobin, 
pancreatic β-cell function, and insulin resistance at follow-up (i.e.2015). Second, we determined 
whether adequate intake of Mg and Zn at baseline, which was defined as intake≥ RDA and <UL, 
might protect against the development of T2D associated with iAs exposure. We used the 
updated homeostasis model assessment (HOMA2)41-43 to estimate the pancreatic β-cell 
dysfunction and insulin resistance at follow-up. By determining the associations between iAs 
exposure and pancreatic β-cell dysfunction vs. insulin resistance, our study can better inform the 
underlying mechanism of iAs-associated T2D.  
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CHAPTER 3. EXPOSURE TO INORGANIC ARSENIC AND DEVELOPMENT OF 
TYPE 2 DIABETES: A LONGITUDINAL STUDY IN A POPULATION OF LOW TO 
MODERATE INORGANIC ARSENIC EXPOSURE 
 
Overview 
Compelling evidence has linked high inorganic arsenic (iAs) exposure with increased risk 
of type 2 diabetes (T2D), however, inconsistent results were seen among populations low-to-
moderately exposed to iAs. The inconsistent results could due in part to most studies are cross-
sectional, whereas longitudinal study should be conducted to better capture the association 
between baseline iAs exposure and development of T2D. Though the underlying mechanism for 
iAs-associated T2D is not well established, laboratory studies indicate β-cell dysfunction, rather 
than insulin resistance, is predominately involved.  
In this population with low-to-moderate level of iAs exposure, we determined how 
toenail arsenic at baseline (i.e.2009) related to T2D incidence and indicators of glucose 
homeostasis at follow-up (i.e.2015). We found a positive association between baseline iAs 
exposure and development of diabetes, as defined by higher FG, lower pancreatic β-cell function, 
as well as higher odds of incident prediabetes and diabetes. Our results further confirm the 
diabetogenic effects of low-to-moderate iAs exposure, which may contribute greatly to the 
current epidemic of T2D especially in populations with low prevalence of obesity. Moreover, our 
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findings also suggest that instead of insulin resistance, pancreatic β-cell dysfunction is primarily 
involved in iAs-associated diabetes.  
In addition, we also found that men, younger adults, participants who consumed alcohol, 
and participants from North China were more susceptible to the diabetogenic effects of iAs. In 
addition, though previous studies suggested reduced susceptibility of iAs-associated adverse 
health outcomes among obese individuals, our findings support that iAs exposure promoted rapid 
progression to more severe diabetes for obese individuals.
Introduction:  
The prevalence of T2D, which is a well-recognized cause of premature death and 
disability, has increased globally over the past two decades, especially in China1-5. It has become 
abundantly clear that both pancreatic β-cell dysfunction and insulin resistance are involved in the 
development of T2D, but the interplay between pancreatic β-cell dysfunction and insulin 
resistance remains highly complex and somewhat undefined6,7. Though obesity is a well-known 
risk factor for T2D and is associated with insulin resistance, it has been suggested that obesity 
alone cannot fully explain the escalating epidemic of T2D, especially in regions where the 
prevalence of obesity is low3,8-12. Recent studies stress on the importance of pancreatic β-cell 
dysfunction in the development of diabetes as participants with insulin resistance are still be able 
to maintain normal glucose tolerance as pancreatic β-cells with normal function are able to 
compensate for insulin resistance7,13,14. Thus, there is urgent need to identify and understand 
other T2D risk factors beyond obesity and insulin resistance, especially factors involved in 
pancreatic β-cell dysfunction15. 
Compelling evidence has linked exposure to high levels of inorganic arsenic (iAs), a 
common contaminant in drinking water and foods such as rice, with increased risk of T2D16,49-52. 
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Recent reviews and meta-analyses of the epidemiological literature also suggest that exposure to 
levels of iAs in drinking water >150µg/L may increase the risk of T2D55,57,90. There is growing 
concern that low-to-moderate level of iAs exposure, which is much more common worldwide, 
may contribute substantially to the current epidemic of T2D, especially in countries with low 
prevalence of obesity. However, evidence of an association between iAs and development of 
T2D at low to moderate level of iAs exposure is limited and inconsistent51,55-57. In addition, most 
previous studies are cross-sectional, which is problematic since diabetes has been shown to affect 
iAs metabolism53, posing the risk that altered iAs biomarker in diabetic individuals may be a 
consequence—as opposed to a cause—of disease17. Thus, longitudinal studies are urgently 
needed in the low-to-moderately iAs exposed population, such as China, to examine the 
association between iAs exposure and development of diabetes3,8-12. 
In vitro studies of the pathogenesis of iAs-associated T2D have implicated the 
involvement of several biological processes, including impairments in the cellular adaptive 
response of oxidative stress and inhibition of glucose-dependent insulin secretion as a 
consequence of pancreatic β-cell dysfunction53,91-96. However, the pathway (i.e. insulin resistance 
vs. β-cell dysfunction) primarily involved in diabetogenic effects of iAs remains unclear. To 
date, few epidemiological studies have examined associations between low-to-moderate iAs 
exposure and pancreatic β-cell function vs. insulin resistance. Such studies are especially needed 
to provide insight into the potential pathogenesis of iAs-associated T2D.  
To address this gap, we examined the association between baseline (i.e.2009) iAs 
exposure and measures of T2D development, characterized by fasting glucose, fasting insulin, 
glycated hemoglobin, and odds of incident prediabetes and diabetes six years later, in a 
population-based cohort with low-to-moderately exposure to iAs. In addition, we also aimed to 
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examine the associations between iAs exposure and insulin resistance vs. pancreatic β-cell 
function, which were assessed using the updated homeostasis model assessment (HOMA2)41-43, 
to inform the understanding of iAs-associated T2D.  
Method 
China Health and Nutrition Survey. The China Health and Nutrition Survey (CHNS) is 
an ongoing longitudinal survey, which collected health, economic, sociological, and 
demographic data in nine diverse provinces throughout China from 1989-2015. Using a 
multistage random cluster design, a stratified probability sample was used to select counties and 
cities stratified by income using State Statistical Office definitions, and then communities and 
households were selected from these strata. The CHNS cohort initially mirrored national age-
gender-education profiles and the nine provinces in the CHNS constituted 44% of China’s 
population in 2009 (according to 2009 census). Questionnaires were used to collect 
demographic, socioeconomic, anthropometric, behavioral and health information. Biomarker 
data, including fasting glucose (FG), fasting insulin (FI), and glycated hemoglobin (HbA1c), 
were collected at baseline (i.e. 2009) and follow-up (i.e. 2015). Toenail clippings were collected 
at baseline and analyzed for arsenic concentration. Survey procedures have been described 
elsewhere97,98. The study was approved by the Institutional Review Board at the University of 
North Carolina at Chapel Hill, the China-Japan Friendship Hospital, National Institute for 
Nutrition and Health in China, and the Chinese Center for Disease Control and Prevention. 
Analysis sample. We restricted analyses to non-pregnant adults (≥18y) at time of 
measurement (i.e. baseline and follow-up) with toenail arsenic data available at baseline 
(N=6843). We excluded participants who missed baseline data on body mass index (N=511), 
smoking or drinking status (N=5), diet (N=80), urbanization index (N=96), physical activity 
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(N=34), province (N=7), any blood biomarkers (FG, FI, and HbA1c, N=478). For the complete 
case analysis, we further excluded participants missed any blood biomarkers (i.e. FG, FI, and 
HbA1c) at follow-up (N=3479). Participants with extreme biomarkers, defined as 6 standard 
deviation above or below the mean, were also excluded (N=15). We further excluded individuals 
with diabetes at baseline to reduce the possibility of reverse causality (N=220), resulting in final 
analytic samples for the complete case analysis N=1918.  
Ascertainment of diabetes. Blood samples of all participants were collected by 
venipuncture after an overnight fasting. Whole blood was immediately centrifuged, serum was 
aliquoted and frozen at -70 degrees. Aliquots were collected in EDTA-coated vacutainers 
containing sodium fluoride to prevent glucose degradation. All blood samples were analyzed in a 
national central lab in Beijing (medical laboratory accreditation certificate ISO15189:2007). 
Both baseline and follow-up FG were measured by colorimetric assay methods (GOD-PAP; 
Randox Laboratories Ltd, UK) using a Hitachi 7600 analyzer (Hitachi Inc., Tokyo, Japan). Both 
baseline and follow-up HbA1c was measured with high performance liquid chromatography 
(HPLC) system (model HLC-723 G7; Tosoh Corporation, Tokyo, Japan). FI at baseline was 
measured using a radioimmunoassay (North Institute of Bio-Tech,China) and a gamma counter 
(XH-6020), while FI at follow-up was measured using a chemiluminescent immunoassay. 
Diabetes was defined by FG≥126mg/dL, or HbA1c≥6.5%, or self-reported diabetes 
diagnosis or medication use. Pre-diabetes was defined by FG≥110mg/dL to <126mg/dL, or 
HbA1c≥5.7% to <6.5%. Measured FI and FG were used to calculate steady state pancreatic β-
cell function and insulin resistance (IR) using the Homeostasis Model Assessment (HOMA2) 
calculator updated in 2015 (University of Oxford, 
website; http://www.dtu.ox.ac.uk/homacalculator/index.php). The HOMA2 calculator is an 
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updated version (computer model) of the original HOMA model (HOMA1). HOMA2 is 
suggested as a more accurate method than the original HOMA1, since HOMA2 accounts for 
variations in hepatic and peripheral glucose resistance and the reduction of peripheral glucose-
stimulated glucose uptake41,42. Regular HOMA2, including regular HOMA2-IR and regular 
HOMA2-β, were calculated for baseline as it is suggested for insulin measured using 
radioimmunoassay. Specific HOMA2s (i.e. HOMA2-IRs and HOMA2-βs) were calculated for 
follow-up since specific HOMA2s were suggested to be used when insulin were measured using 
a chemiluminescent immunoassay41,42.  
Measurement of toenail arsenic. Participants were asked to let toenails grow for at least 
two weeks, and stainless-steel nail scissors were used to collect toenail clippings from all ten 
toes. Toenail clippings were washed and sonicated for 30 minutes and dried at 80℃. After 
microwave-assisted digestion, toenails were analyzed using inductively coupled plasma mass 
spectroscopy99. The limit of detection (LOD) for arsenic by this method is 0.01μg/g. Toenail 
arsenic concentrations lower than the LOD were imputed at half of the LOD as 0.005μg/g 
(N=82/1918). 
Dietary assessment. Dietary intake was assessed using three consecutive days 24-hour 
recalls (two weekdays and one weekend day) at the individual level and a food inventory at the 
household level during the same 3-day period. Trained investigators interviewed the participants 
to collect detailed types and amounts (in grams) of all foods and beverages consumed during the 
preceding 24 hours with the assistance of food pictures to aid quantification. Daily intake was 
calculated by the mean of three days 24-hour recalls. China Food Composition Table was used to 
calculate the daily total energy intake, which was validated with the doubly labeled water 
method in the Human Nutrition Research Center, Tufts University (correlation coefficients 
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between the two methods were 0.56 for men and 0.60 for women)100,101. Daily total energy and 
rice intake were calculated and categorized into tertiles. After combining all kinds of fish, we 
characterized participants as consumers vs. non-consumers of fish during the survey period. We 
used the tailored Alternate Healthy Eating Index (tAHEI), which was generated by tailoring the 
Harvard AHEI 2010, to assess diet quality in our study191. Details of tAHEI have been described 
elsewhere191. 
Other variables. Standard height (in meters) and weight (in kilograms) were measured 
using standard protocol by trained nurses. Body mass index (BMI) was calculated as weight in 
kilograms divided by the square of the height in meters (kg/m2). We generated weight status 
based on BMI according to the World Health Organization cutoffs for Asian adults (<18kg/m2 
for underweight, 23.0-27.4kg/m2 for overweight, and ≥27.5kg/m2 for obese)102,103. Information 
on age (in years), sex, smoking (current, former, never smokers), drinking status (< vs. ≥once per 
month) was collected using questionnaires.  
We used a validated urbanization index to measure degrees of urbanization104. The index 
contains 10 validated components including communication, economic, housing, transportation 
infrastructure, the availability of schools, markets, and health care, environmental sanitation, and 
population size and density. The urbanization index, which was positively correlated with degree 
of urbanization, ranged from 10 to 100 and was categorized into tertiles. We categorized the nine 
provinces in CHNS into three geographic regions (North: Heilongjiang, Liaoning; Central: 
Shandong, Henan, Jiangsu; South: Hunan, Hubei, Guangxi, Guizhou). Individual physical 
activity data was collected through an in-depth interview on time (hours) spent on domestic, 
occupational, transportation, and leisure-time activity. Separate questions were asked for each of 
the four domains. We calculated energy expenditure from each activity domain by multiplying 
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time (hours) spent on each type of physical activities by its specific metabolic equivalent (MET) 
intensity value, resulting in measures of total MET-hours/week for each domain. We calculated 
the overall energy expenditure for each individual by summing MET-hours spent in each domain 
and categorizing into tertiles.  
Statistical analyses. We used natural log-transformed toenail arsenic to account for the 
non-normal distribution of toenail arsenic. ANOVA (continuous variables) and chi-square tests 
(categorical variables) were used to determine the significance of differences in baseline 
characteristics across tertiles of iAs exposure.  
Multinomial (diabetes, prediabetes, vs. neither) logistic regression models were used to 
determine the association between baseline toenail arsenic and odds of incident prediabetes and 
diabetes during follow-up. Multivariable-adjusted linear regression models were used to examine 
the association between baseline toenail arsenic and FG, FI, HbA1c, HOMA2-IRs, and HOMA2-
βs for both cross-sectional and longitudinal complete case analysis.  
As shown in the directed acyclic graphs (DAG) (Figure 3.1a), all potential confounders 
for the association between baseline iAs exposure and development of T2D during over 6-years 
follow-up were adjusted in the full model (Model 1). These variables included age, sex, drinking 
status, smoking status, urbanization index, dietary quality index, baseline weight status (weight 
status may influence the excretion and storage of iAs105-107 and it is a well-known risk factor for 
T2D), fish intake (an important source of non-toxic organic arsenic compounds (arsenobetaine 
and arsenosugars)108,109 and is associated with T2D risk110,111), rice intake (an important source of 
iAs exposure in the study population112 and is also associated with risk of T2D113). We included 
daily total energy intake and physical activity level in the model since they were associated with 
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risk of T2D. We also adjusted for the geographic region due to substantial regional variation in 
exposure sources, diet, cooking method, and lifestyle factors across China.  
In the model 2, we adjusted for the confounders that were identified based on stepwise 
backward selection (p<0.10) in our study. The confounders identified in our study include age, 
sex, weight status, drinking status, physical activity level, rice intake, and region (Figure 3.1b). 
Gribble et al.114 found there was substantial change in the associations between iAs exposure and 
development of T2D before vs. after adjusting for region. To better understand how region is 
related to iAs-induced T2D, we examined the associations between iAs exposure and 
development of T2D adjusting for all identified confounders in our study except region (Model 
3).  
Gribble et al.114 found several characteristics of the population were associated with the 
risk of adverse health effects of iAs exposure. To better compare with previous studies and 
examine the consistency of the associations between iAs exposure and development of T2D by 
participant characteristics, we tested the interactions between iAs exposure and characteristics of 
the population that were suggested to be associated with iAs-associated adverse health outcomes. 
We also stratified our analyses by the characteristics, i.e. age (<55, 55-64, or ≥65 years), sex, 
body mass index (<18, 23.0-27.4, or ≥27.5kg/m2), smoking status (current, former, or never), 
drinking status (<, or ≥once/month), and geographic region (North, Central, South).  
We conducted sensitivity analysis to account for the impact of aging on the metabolism 
of iAs and risk of T2D by comparing the associations between iAs exposure and development of 
T2D before vs. after excluding participants age>70; results did not differ meaningfully (data not 
shown). Rice intake was identified as a confounder in our study (p for stepwise backward 
regression model<0.10) and was adjusted in the models. Since rice is an important source of iAs 
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exposure in our study population112, we conducted sensitivity analysis by including all identified 
confounders in our study except rice intake to demine the impact of adjusting source of iAs 
exposure in our study. We also compared the associations between baseline toenail arsenic and 
development of diabetes (i.e. FG, FI, HbA1c, and HOMA2s) before vs. after excluding 
participants with pre-diagnosed diabetes at follow-up (N=18), who might have adjusted their 
behaviors (e.g. reduced rice consumption); results did not differ meaningfully. In addition to 
complete case analysis, we conducted multiple imputation using predictive mean matching (five 
closest observations was drawn) to account for the impact of missing data. 
Statistical significance of main effects was set at p<0.05 with p<0.10 indicating marginal 
significance. All the statistical analyses were performed in Stata, version 13.1 (StataCorp LP, 
College station, Texas). 
Results  
Baseline (i.e. 2009) sociodemographic and anthropometric characteristics, as well as 
biomarkers at both baseline and follow-up (i.e. 2015), arsenic exposure level at baseline 
characterized by toenail arsenic are provided in Table 3.1. The concentrations of baseline toenail 
arsenic ranged from below the limit of detection (LOD) to 115.6μg/g, with a median of 0.32μg/g. 
Participants from Southern China had significantly higher toenail arsenic compared to 
participants from North and Central China (Supplemental Table 3.1). 
For the participants involved in the complete case analysis, baseline FG was significantly 
lower than FG at follow-up (92.1±10.9 vs. 96.8±16.0 mg/dL), whereas we found no statistically 
significant difference between baseline vs. follow-up HbA1c (5.4±0.4 vs. 5.6±0.6%). Due to 
different methods were used to measure FI at baseline vs. follow-up (i.e. radioimmunoassay vs. 
chemiluminescent immunoassay), differences in FI and HOMAs at baseline vs. follow-up cannot 
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be estimated. The mean FI at baseline was 12.1µU/mL, mean baseline HOMA2-IR and 
HOMA2-β were 1.5 and 119.5%, respectively. The mean follow-up FI was 7.1µU/mL, mean 
HOMA2-IRs and HOMA2-βs at follow-up were 1.1 and 86.5%, respectively.  
Overall, 6.7% and 46.6% of the study participants developed diabetes and prediabetes 
during the six years of follow-up. Compared to participants in the lower tertiles of baseline 
toenail arsenic distribution, participants in the highest tertile of toenail arsenic exposure (toenail 
arsenic concentration>0.44μg/g) had marginally higher incidence of prediabetes during follow-
up (Tertile 3, Tertile 2, Tertile 1: 49.3, 45.5, 44.8%, p=0.06). 
Baseline characteristics of participants across tertiles of toenail arsenic concentration 
were shown in Table 3.1. Toenail arsenic concentration at baseline was positively associated 
with rice intake as well as physical activity, and negatively associated with weight status and 
urbanization index. There was no significant difference in age, sex, smoking status, drinking 
status, and total energy intake for participants across tertiles of toenail arsenic.  
Participants with lower toenail arsenic at baseline had significantly higher baseline FI (T1 
vs. T2 vs. T3: 12.9± 10.5 vs. 11.8± 9.5 vs. 11.7±7.7µU/mL), HbA1c (5.5±0.4 vs. 5.4±0.4 vs. 
5.3±0.4%), and HOMA2-β (123.8±47.5 vs. 117.0± 43.5 vs. 117.7± 44.7%), while we found no 
significant difference in baseline FG and HOMA2-IR. In contrast, we found no significant 
difference in follow-up FI and HbA1c among participants in different tertiles of baseline toenail 
arsenic, while participants with higher baseline toenail arsenic had significantly higher FG (T1 
vs. T2 vs. T3: 95.1±15.8 vs. 96.7±14.4 vs. 98.7±17.4 mg/dL) and lower HOMA2-βs (89.9±32.8 
vs. 86.1±32.3 vs. 83.7±32.9%) at follow-up. 
In the cross-sectional analyses for the full analytic sample, natural log transformed 
baseline toenail arsenic was associated with significantly lower baseline FI (-0.32±0.18µU/mL) 
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and HbA1c (-0.05±0.01%), and the associations remained statistically significant after adjusting 
for region (Supplemental Table 3.2). We also found statistically significant negative association 
between baseline toenail arsenic and odds of diabetes at baseline (OR: 0.85, 95% CI: 0.74 - 
0.97), and the association remained statistically significant after adjusting for region. In contrast, 
we found no significant association between baseline toenail arsenic and baseline FG, HOMA2-
β, HOMA2-IR, as well as odds of prediabetes at baseline.  
Our findings for the prospective analyses were different from the cross-sectional 
analyses. In multivariable-adjusted models (Model 3, Table 3.2), natural log transformed 
baseline toenail arsenic was associated with significantly higher FG (1.44±0.30mg/dL) and lower 
HOMA2-βs (-1.98±0.60%) at follow-up. Moreover, we found baseline ln-toenail arsenic was 
positively associated with odds of incident prediabetes (OR:1.14, 95% CI:1.05-1.24) and 
diabetes (OR:1.24, 95% CI: 1.10-1.46) during follow-up. The associations remained statistically 
significant but were attenuated after further adjustment for regions (Model 2, Table 3.2). We 
found no significant association between baseline toenail arsenic and FI, HbA1c, and HOMA2-
IRs at follow up before and after adjusting for region.  
We found statistically significant interactions between baseline toenail arsenic and sex 
for FG at follow-up (Figure 3.2). The positive association between ln-toenail arsenic and FG at 
follow-up was statistically significantly stronger among men vs. women (2.07±0.54 vs. 
0.92±0.34mg/dL), and it remained statistically significant after adjusting for region. We also 
found statistically significant modification effect of region on the association between baseline 
iAs exposure and FG at follow-up. The association between ln-toenail arsenic and FG was 
strongest among participants from Northern China (1.31±0.47mg/dL). 
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For the HOMA2-βs at follow-up, we noticed marginally significant interactions between 
ln-toenail arsenic and age group as well as drinking status before adjusting for regions (Figure 
3.2). The negative association between ln-toenail arsenic at baseline and HOMA2-βs at follow-
up was stronger and only statistically significant among participants age<55 (-3.20±0.78%, 
P<0.05) compared with participants with age ≥55. The magnitude of the negative association 
between ln-toenail arsenic at baseline and HOMA2-βs at follow-up was stronger among 
participants who drank alcohol vs. non-drinkers (-3.59±1.09 vs. -1.29±0.72%, respectively). We 
also found marginally significant interaction between ln-toenail arsenic and region for HOMA2-
βs at follow-up, participants from North had significantly stronger negative association between 
ln-toenanil arsenic and HOMA2-βs at follow-up (North vs. Central vs. South: -3.14±1.11 vs. 
0.00±1.25 vs. -0.95±1.12%).  
For the odds of incident prediabetes, we found a statistically significant interaction 
between toenail arsenic and sex, and it remained significant after adjusting for region. The 
association was significantly stronger in men versus women (OR:1.17 vs. 1.03). We also found 
significant interaction between drinking status and ln-toenail arsenic for odds of incident 
diabetes, the association was significantly stronger among alcohol consumers (OR: 1.30 vs. 
1.01). 
We compared baseline characteristics of participants included in the complete case 
analysis and those excluded due to missing data. As shown in Supplemental Table 3.3, those who 
were younger, with normal weight status (BMI≤23.0), current smokers, and drinkers were more 
likely to be excluded due to missing data. In addition, we found no significant difference in the 
association between iAs exposure and development of T2D using the multiple imputed dataset 
(Supplemental Table 3.4). The results further implicate that the data analysis samples used in our 
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study reflect the full population. Moreover, there was no significant change of the associations 
between iAs exposure and development of T2D before vs. after adjusting for rice intake, which 
is an important source of iAs exposure in our study population and was identified as one of the 
confounders in our study. However, the magnitude of the associations between iAs exposure and 
fasting glucose as well as HOMA2-βs attenuated after adjusting for rice intake (Supplemental 
Table 3.5). 
Discussion 
The results of our study support the association between chronic low-to-moderate iAs 
exposure and development of diabetes which supports the previous literature, although our study 
is the first to use longitudinal study data in the context of low-to-moderate iAs 
exposure55,57,90,115,116.  
Toenail arsenic was used as a measurement of individual chronic iAs exposure since 
toenails have shown to preferentially sequester iAs species, which is a more toxic form than 
organic arsenic70-72,74,117. Most previous studies have estimated iAs exposure level based on iAs 
concentration in the primary drinking water. However, there is a growing concern that iAs from 
other sources, such as rice especially among Asians with rice based diet118,119. A few studies 
estimated individual iAs exposure based on urinary arsenic, which is generally regarded as the 
most reliable indicator of recent exposure to iAs. Nonetheless, a rice-feeding trial conducted by 
Meharg et al showed considerable variation (up to 13-fold) in an individual’s total iAs urine 
content throughout the day, calling into question the robustness of the routinely used spot urine 
samples, especially among participants low-to-moderately exposed75. The long-term 
accumulation of iAs in toenails makes the toenail arsenic measure more reliable as a biomarker 
of chronic iAs exposure 74,117. 
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Endemic arsenism in China is mainly caused by breathing indoor air contaminated by iAs 
from coal or charcoal combustion and drinking water contaminated by iAs from natural sources, 
such as mining120,121. Consistent with the patterns of mineral exploitation in China, mining areas 
and endemic arsenism caused by coal combustion is mainly observed in rural areas of southern 
China, such as Guizhou122,123. Recent studies suggest that rice is another important source of iAs 
since rice accumulates iAs in the soil and groundwater, and iAs-contaminated rice is an 
important concern especially in southern China where people are more likely to have a rice-
based diets124-131. In some areas near mining districts in southern China, arsenic content in rice is 
around 0.7mg/kg, 2.5 times greater than the acceptable limit proposed by the Minister of Health 
in China121,132,133. As expected, the distribution of toenail arsenic measured in our study is 
consistent with the distribution of the primary sources of iAs exposure across regions: 
participants from southern China had higher toenail arsenic. 
HbA1c has been proposed as an optional assay for diagnosing diabetes134-136. It is widely 
used, including studies exploring the association between iAs exposure and risk of T2D, due to 
the convenience and superior technical attributes of HbA1c relative to FG134-137. However, the 
use of HbA1c to diagnose diabetes is inappropriate in some cases, especially for patients with 
hemoglobinopathies134-136. Previous laboratory studies have indicated the association between 
iAs exposure on hemoglobin concentration61,62, which raises concern about using HbA1c to 
diagnose diabetes among population exposed to iAs. In line with several studies indicate null 
association between iAs exposure and HbA1c80,138,139, we did not find statistically significant 
association between baseline (i.e.2009) iAs exposure and HbA1c at follow-up (i.e.2015) though 
baseline iAs exposure was significantly associated with higher FG at follow-up. Our findings 
further support the idea that FG is more feasible to capture the change in glucose hemostasis 
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induced by iAs exposure. The real association between iAs exposure and development of 
diabetes could be ignored if only HbA1c is used to define diabetes139. Additional research is 
needed to assess the association between iAs exposure and hemoglobin, and the validity of using 
HbA1c to diagnose diabetes in the population exposed to iAs.  
A few studies have examined the association between iAs exposure and insulin 
resistance, which has been regarded as the mechanism underlying typical T2D7,140, however, 
with inconsistent results. In line with our findings, Rotter et al.83 and Baek et al.141,142 found null 
association between iAs exposure and insulin resistance. In contrast with our findings, Lin et 
al.143 found higher insulin resistance associated with iAs exposure among obese children and 
adolescents, and Del Razo et al.80 found negative association between iAs exposure and insulin 
resistance. As most of these studies are cross-sectional, the inconsistent results could be partially 
due to presence of individuals with T2D who may progressively develop insulin resistance over 
time, even if it is not the primary pathway leading to iAs-associated T2D144.  
We found significantly negative association between baseline iAs exposure and 
pancreatic β-cell function at follow-up, even after adjusting for region. Notably, In line with our 
findings, several in vitro and in vivo studies investigating the pathogenesis of iAs-induced T2D 
have implicated the involvement of β-cell dysfunction, which may be attributed to the 
inflammatory and oxidative damage induced by iAs145-149. Collectively, these results indicate that 
instead of insulin resistance, which is the mechanism underlying typical T2D, pancreatic β-cell 
dysfunction is primarily involved in diabetogenic effects of iAs.  
There have been growing concerns that cross-sectional study design cannot capture the 
temporal relationship between iAs exposure and development of diabetes, and diabetes might 
affect iAs metabolism53,17. The results of our study fully agreed with this concern, as we found 
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different results for the association between toenail arsenic and risk of diabetes using 
longitudinal vs. cross-sectional analysis. The longitudinal analysis suggests higher FG, 
aggravated β-cell dysfunction and higher odds of incident diabetes and prediabetes associated 
with chronic iAs exposure, whereas the cross-sectional analysis suggests lower odds of diabetes 
associated with iAs exposure. Our findings further suggest that the inconsistent results for the 
association between iAs exposure and risk of diabetes reported in previous studies could be 
partially explained by the different study designs.  
We found the magnitude of the associations between baseline toenail arsenic and FG as 
well as odds of incident prediabetes was significantly stronger among men vs. women. Similarly, 
the magnitude of the association between baseline iAs exposure and HOMA2-βs was stronger 
among men vs. women, though the interaction was not statistically significant. Consistent with 
our findings, others have reported that men are more susceptible to toxic effects related to 
chronic exposure to iAs than women due to their higher capacity for iAs metabolism150-152.  
Consistent with current literature, we found obese individuals tended to have lower 
toenail arsenic. The reasons for the inverse association between biomarkers of iAs exposure and 
obesity remain uncertain. Several researchers have hypothesized that the inverse association 
between biomarkers of iAs exposure and adiposity may ascribe to the improvement in the 
efficiency of iAs metabolism and secretion among obese individuals105,106,153. Alternatively, 
another possible explanation is that exposure to iAs may itself promote reduce adiposity and 
adipocyte differentiation154-159. Little is known about how obesity may modify the association 
between iAs exposure and development of diabetes though Fatmi et al.160 found obese 
participants were less susceptible to iAs-associated adverse health outcomes. We found the 
magnitude of the associations between baseline iAs exposure with FG and HOMA2-βs was 
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stronger among obese participants though the interaction between toenail arsenic and weight 
status was not statistically significant. The association between baseline toenail arsenic and odds 
of incident diabetes was only significant among obese participants. In line with our findings, 
Tseng et al.161 also found stronger association between iAs exposure and risk of diabetes among 
the obese participants in the cross-sectional study conducted in Taiwan. Our findings suggest that 
iAs exposure may promote rapid progression to severe diabetes for those who are obese. Since 
Chinese are known to have lower BMI but higher percent body fat162-164, further research is 
needed to examine the association between obesity with iAs-associated diabetes, especially in 
the population with double burden from iAs contamination and obesity.  
Our analyses were robust to adjustment for several sociodemographic and diabetes risk 
factors. Consistent with what was observed in the Strong Heart Study, adjustment for region 
attenuated the associations between iAs exposure and development of diabetes114. The 
associations between iAs exposure and FG, HOMA2-βs, and odds of incident diabetes were 
stronger among participants from North China, though the interaction was not significant for 
odds of incident diabetes. Our findings suggest that participants from North may be more 
susceptible to iAs-associated diabetes, though participants from North had lower baseline iAs 
exposure. The results could be partially due to other potential confounders highly correlated with 
region153, thus further research is needed to examine the association between other region-
correlated factors with iAs-associated diabetes, such as intake of macronutrients.  
To the best of our knowledge, this is the first prospective longitudinal study designed to 
understand the association between baseline iAs exposure and development of T2D in a 
population with the low-to-moderate level of iAs exposure. Our findings contribute to the current 
literature as there are growing concerns about risk factors involved in the pancreatic β-cell 
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dysfunction. The consistency of our multivariable-adjusted results and those from sensitivity 
analysis excluding participants age>70 or pre-diagnosed diabetes at follow-up also supports the 
positive association between iAs exposure and development of diabetes in the population with 
low-to-moderate iAs exposure.  
Strengths of our study include the standard protocol used to collect data over the follow-
up period, high-quality laboratory methods used for individual and direct measurement of 
chronic iAs exposure. In addition, we excluded participants with diabetes at baseline to better 
capture the early stage changes of iAs-associated glucose homeostasis indicators. Moreover, we 
take accounted for different measures of T2D (insulin resistance vs. pancreatic β-cell 
dysfunction), by testing the associations between iAs exposure and insulin resistance vs. β-cell 
dysfunction, thus informing understanding of the underlying biological mechanism of iAs-
associated diabetes.  
Our study has several limitations. First, our study used toenail arsenic as the 
measurement of iAs exposure. Though toenail arsenic has been suggested as a reliable biomarker 
for iAs exposure over an integrated period of months, toenail arsenic cannot separate different 
forms of iAs, such as trivalent vs. pentavalent, which may associate with health outcomes 
differently90. Therefore, we were unable to examine the associations between different forms of 
iAs exposure and measures of T2D development. Moreover, compared with urinary arsenic 
profiles, toenail arsenic was not able to capture the information about iAs metabolism, a more 
expanded knowledge of the correlations between toenail arsenic and existing biomarkers (i.e. 
urinary arsenic) is needed to better interpret our findings. In addition, though our sample size 
was larger than many previous studies, we had limited cell sizes for stratified analyses. The small 
cell sizes may have reduced our power to detect the interactions. Thus, statistical significance 
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should be interpreted with caution, especially for the interactions and stratified analyses. 
Moreover, missing data is one of the important concerns in our study. We took into account of 
missing data by conducting multiple imputation, and our multiple imputation results are highly 
consistent with the complete case analysis, which ensures that data analysis samples in our study 
reflect the full population.   
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Tables and figures 
Table 3.1. Characteristics of the Study Participants by Concentration of Toenail Arsenic at baseline (i.e. 2009) 
  Toenail arsenic (µg/g) tertiles at 2009 
Characteristics All participants <0.23 ≥0.23 and <0.44 >0.44 
Total N 1918 640 639 639 
Baseline (i.e.2009) characteristics   
Toenail arsenic, µg/g 0.32 (0.19, 0.54) 0.15 (0.10, 0.18)** 0.31 (0.26, 0.36) 0.68 (0.52, 1.02) 
Age, years 51.6±13.0 51.5±13.0 51.5±12.5 52.0±12.9 
Male 813 (42.4) 255 (39.8) 273 (42.7) 285 (44.6) 
Body mass index, 
kg/m2      
23.0-27.4 821 (42.8) 287 (44.8)** 292 (45.7) 242 (37.9) 
≥27.5 238 (12.4) 109 (17.0) 66 (10.3) 63 (9.9) 
Smoking     
Current 445 (23.2) 138 (21.6) 165 (25.8) 142 (22.2) 
Former 61 (3.2) 21 (3.3) 20 (3.1) 20 (3.1) 
Drinkersa 489 (25.5) 163 (25.5) 172 (26.9) 154 (24.1) 
Total energy intake, 
kcal/day 2167.3±647.0 2156.7±644.1 2188.2±645.8 2157.1±651.7 
Rice intake, g/day 640.0±420.2 514.0±380.0** 675.0±428.0 731.2±421.0 
Recent fish consumer  752 (39.2) 242 (37.8)* 275 (43.0) 235 (36.8) 
Urbanization     
Low 642 (33.5) 154 (24.1)** 251 (39.3) 237 (37.1) 
Medium 720 (37.5) 238 (37.2) 205 (32.1) 277 (43.4) 
High 556 (29.0) 248 (38.8) 183 (28.6) 125 (19.6) 
Total physical activity, 
METS/week 228.5±221.5 202.5±212.1** 231.9±220.7 251.2±228.9 
Region     
North 389 (20.3) 219 (34.2)** 110 (17.2) 60 (9.4) 
Central 628 (32.7) 288 (45.0) 217 (34.0) 123 (19.3) 
South 901 (47.0) 133 (20.8) 312 (48.8) 456 (71.4) 
Baseline Fasting 
glucose, mg/dL 92.1±10.9 91.7±11.1 91.8±10.8 92.6±10.9 
Baseline Fasting 
insulin, µU/mL 12.1± 9.3 12.9± 10.5*  11.8± 9.5  11.7±7.7 
Baseline Hemoglobin 
A1c, % 5.4±0.4 5.5±0.4** 5.4±0.4 5.3±0.4 
Baseline HOMA2-βb, 
%  119.5±45.4  123.8±47.5**  117.0± 43.5   117.7± 44.7 
Baseline HOMA2-IRc  1.5±0.8  1.5±0.9  1.4±0.8 1.5±0.8 
Outcome measures at 6-years follow up 
(i.e.2015)   
Follow-up Fasting 
glucose, mg/dL 96.8±16.0 95.1±15.8** 96.7±14.4 98.7±17.4 
Follow-up Fasting 
insulin, µU/mL 7.1±4.1 7.1±3.9 7.1±4.0 7.2±4.4 
Follow-up Hemoglobin 
A1c, % 5.6±0.6 5.6±0.5 5.6±0.6 5.6±0.6 
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Follow-up HOMA2-
βsd, % 86.5±32.8 89.9±32.8** 86.1±32.3 83.7±32.9 
Follow-up HOMA2-
IRse 1.1±0.6 1.1±0.6 1.1±0.6 1.1±0.7 
Follow-up 
Dysglycemiaf     
Diabetes 128 (6.7) 32 (5.0)** 49 (7.7) 47 (7.4) 
Prediabetes 893 (46.6) 287 (44.8)** 291 (45.5) 315 (49.3) 
Data are n (%), mean±SD, or median (25th-75th percentile) among individuals involved in the complete case 
analysis (N=1918). a Any alcohol consumption ≥once per month. b HOMA2-β: Regular β-cell function calculated by 
Homeostasis Model Assessment (HOMA2) calculator updated in 2015 (University of Oxford, 
website; http://www.dtu.ox.ac.uk/homacalculator/index.php) based on fasting glucose and fasting insulin, regular 
HOMA2 is suggested for insulin measured using radioimmunoassay. c HOMA2-IR: Regular insulin resistance 
calculated by HOMA2. d HOMA2-βs: Specific β-cell function calculated by HOMA2, specific HOMA2 is suggested 
when insulin is measured using a chemiluminescent immunoassay. e HOMA2-IRs: Specific insulin resistance 
calculated by HOMA2. f Diabetes: FG≥126mg/dL, or HbA1c≥6.5%, or self-reported diabetes diagnosis or 
medication use. Prediabetes: FG≥110mg/dL to <126mg/dL, or HbA1c≥5.7% to <6.5%. *p<0.10, **p<0.05 for 
differences across tertiles of toenail arsenic using one-way analysis of variance (ANOVA), Pearson's chi-square, or 
Kruskal-Wallis test. 
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Figure 3.1 
a. Potential Confounders Based on Literature Showed in Directed Acyclic Graphs (DAG) 
 
 
 
b. Confounders Identified by Stepwise Backward Selection (p<0.10) Showed in DAG 
 
 
Potential confounders identified based on previous literature in our study included age, sex, drinking status, smoking 
status, urbanization index, dietary quality index, baseline weight status (weight status may influence the excretion 
and storage of iAs and it is a well-known risk factor for T2D), fish intake (an important source of non-toxic organic 
arsenic compounds and is associated with T2D risk), rice intake (an important source of iAs exposure in the study 
population and is also associated with risk of T2D). We included daily total energy intake and physical activity level 
in the model since they were associated with risk of T2D. We also adjusted for the geographic region due to 
substantial regional variation in exposure sources, diet, cooking method, and lifestyle factors across China.  
Confounders that were identified based on stepwise backward selection (p<0.10) in our study include age, sex, 
weight status, drinking status, physical activity level, rice intake, and region. 
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Table 3.2. Associations between Baseline (i.e.2009) Toenail Arsenic and Measures of Diabetesa Development during Follow-up, (i.e.2015) Characterized by 
Follow-up Fasting Glucose, Fasting Insulin, Glycated Hemoglobin, Pancreatic β-cell Function, Insulin Resistance, and Odds of Incident Prediabetes and Diabetes 
  ln-toenail arsenic at baseline 
 
Model 1: 
Age, sex, weight statusb, smoking, drinking 
status, daily total energy intake, dietary 
quality index, rice intake, fish intake, 
urbanization index, physical activity level, 
and region adjusted 
Model 2: 
Age, sex, weight statusb, drinking status, rice 
intake, physical activity level, and region 
adjusted 
Model 3: 
Age, sex, weight statusb, drinking 
status, rice intake, and physical 
activity level adjusted 
Fasting glucose 0.94±0.33** 1.01±0.32** 1.44±0.30** 
Fasting insulin -0.08±0.08 -0.07±0.08 0.06±0.08 
Hemoglobin A1c 0.01±0.01 0.01±0.01 0.01±0.01 
HOMA2-βsc -1.3740±0.67** -1.59±0.65** -1.98±0.60** 
HOMA2-IRsc -0.01±0.01 -0.01±0.01 0.01±0.01 
Dysglycemia    
Diabetes 1.18 (0.98 - 1.42)* 1.19 (0.99, 1.42)* 1.24 (1.05 - 1.46)** 
Prediabetes 1.08 (0.99 - 1.19)* 1.10 (0.92 - 1.31)** 1.14 (1.05 - 1.24)** 
Results are derived from multivariable-adjusted linear regression (continuous outcomes) or multinomial logistic regression (diabetes, prediabetes, vs. neither) 
models. Model 1 adjusted for potential confounders based on literature (Figure 3.1a), including age and sex, weight status (body mass index<18, 23.0-27.4, or 
≥27.5), smoking, drinking status, daily total energy intake, dietary quality index, rice intake, fish intake, urbanization index, physical activity level and region. 
Model 2 adjusted for all the confounders in our study identified by stepwise backward selection (p<0.10) (Figure 3.1b). Model 3 adjusted for all identified 
confounders in our study except region. a Diabetes: FG≥126mg/dL, or HbA1c≥6.5%, or self-reported diabetes diagnosis or medication use. Prediabetes: 
FG≥110mg/dL to <126mg/dL, or HbA1c≥5.7% to <6.5%. b Weight status defined as Underweight: BMI<18kg/m2; Normal weight: BMI≥23.0 to <27.5kg/m2; 
Obese: BMI≥27.5kg/m2. c Specific pancreatic β-cell function (HOMA2-βs) and specific insulin resistance (HOMA2-IRs) calculated by Homeostasis Model 
Assessment (HOMA2) calculator updated in 2015 (University of Oxford, website; http://www.dtu.ox.ac.uk/homacalculator/index.php) based on fasting glucose 
and fasting insulin. *p<0.10, **p<0.05 for coefficients of associations between baseline ln-transformed toenail arsenic and measures of diabetes development at 
follow-up. Coefficients were bolded when they reached significance (P< 0.10). 
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Figure 3.2. Adjusted Mean (SE) Differences in Indicators of Glucose Homeostasis at Follow-up (i.e.2015) as well as 
Odds Ratio of Incident Type 2 Diabetes (T2D) Associated with Toenail Arsenic at Baseline (i.e.2009) Stratified by 
Sex, Age, Weight Status, Smoking and Drinking Status, and Region. 
 
 
 
Results are derived from multivariable-adjusted linear regression (continuous outcomes) or multinomial logistic 
regression (diabetes, prediabetes, vs. neither) models adjusted for all the confounders in our study identified by 
stepwise backward selection (p<0.10), except region. The confounders identified in our study include age, sex, 
weight status, drinking status, physical activity level, rice intake. a HOMA2-βs: Specific β-cell function calculated 
by Homeostasis Model Assessment (HOMA2) calculator updated in 2015 (University of Oxford, 
website; http://www.dtu.ox.ac.uk/homacalculator/index.php) based on fasting glucose and fasting insulin. b 
HOMA2-IRs: Specific insulin resistance calculated by HOMA2. *p<0.05, **p<0.01 for differences in indicators of 
glucose homeostasis (i.e. FG, FI, HOMA2-IRs, and HOMA2-βs at follow-up) or odds of incident prediabetes and 
diabetes. ǂ p< .0.05, ƚ p<0.10 for significance of interaction between ln-transformed toenail arsenic at baseline× sex, 
age, weight status, smoking and drinking status, and region. 
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Supplemental Table 3.1. Characteristics of Study Participants by Regions 
  Regions 
Characteristics All participants North Central South 
Total N 1918 389 628 901 
Baseline (i.e.2009) characteristics   
Toenail arsenic, 
µg/g 0.32 (0.19, 0.54) 0.21 (0.10, 0.35)** 0.25 (0.16, 0.40) 0.44 (0.29, 0.74) 
Age, years 51.6±13.0 51.0±11.8 52.3±12.9 51.5±13.2 
Male 813 (42.4) 170 (43.7) 256 (40.8) 387 (43.0) 
Body mass index, 
kg/m2     
23.0-27.4 821 (42.8) 178 (45.8)** 299 (47.6) 344 (38.2) 
≥27.5 238 (12.4) 60 (15.4) 95 (15.1) 83 (9.2) 
Smoking     
Current 445 (23.2) 109 (28.0) 130 (20.7) 206 (22.9) 
Former 61 (3.2) 15 (3.9) 21 (3.3) 25 (2.8) 
Drinkersa 489 (25.5) 98 (25.2) 174 (27.7) 217 (24.1) 
Total energy intake, 
kcal/day 2167.3±647.0 2125.4±566.8 2195.8±702.6 2165.5±638.8 
Rice intake, g/day 640.0±420.2 636.7±326.3** 395.4±432.8 811.9±358.3 
Recent fish 
consumer  752 (39.2) 137 (35.2)** 220 (35.0) 395 (43.8) 
Urbanization     
Low 642 (33.5) 189 (48.6)** 200 (31.9) 253 (28.1) 
Medium 720 (37.5) 99 (25.5) 239 (38.1) 382 (42.4) 
High 556 (29.0) 101 (26.0) 189 (30.1) 266 (29.52) 
Total physical 
activity, 
METS/week 228.5±221.5 303.8±295.6** 208.7±199.2 209.8± 189.9 
2009 Fasting 
glucose, mg/dL 92.11±10.99 89.27±11.93** 93.31±10.09 92.50±10.96 
2009 Fasting 
insulin, µU/mL 12.16± 9.35 11.97±8.94**  13.20±11.22 11.52±7.93 
2009 Hemoglobin 
A1c, % 5.44±0.46 5.45±0.35**  5.68±0.39  5.27±0.46 
2009 HOMA2-IRb  1.51±0.89 1.48±0.93** 1.60±0.92 1.47±0.86 
2009 HOMA2-β, %c  119.53±45.40 125.33±48.46** 121.98±47.44 115.33±42.11 
Outcome measures at 6-years follow up (i.e.2015)   
2015 Fasting 
glucose, mg/dL 96.8±16.0 91.6±15.0** 97.1±14.5 98.9±16.9 
2015 Fasting 
insulin, µU/mL 7.1±4.1 6.8±3.9* 6.8±3.5 7.5±4.5 
2015 Hemoglobin 
A1c, %  5.6±0.6 5.6±0.5 5.6±0.5 5.6±0.6 
2015 HOMA2-IRsd 1.1±0.6 1.0±0.6** 1.0±0.5 1.1±0.7 
2015 HOMA2-βs, 
%e 86.5±32.8 93.6±35.3** 83.6±28.9 85.6±33.8 
2015 Dysglycemiaf     
Diabetes 128 (6.7) 21 (5.4)** 29 (4.6) 78 (8.7) 
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Prediabetes 893 (46.6) 146 (37.5)** 319 (50.8) 428 (47.5) 
Data are n (%), mean±SD, or median (25th-75th percentile) among individuals involved in the complete case 
analysis (N=1918). a Any alcohol consumption ≥once per month. b HOMA2-IR: Regular insulin resistance calculated 
by Homeostasis Model Assessment (HOMA2) calculator updated in 2015 (University of Oxford, 
website; http://www.dtu.ox.ac.uk/homacalculator/index.php) based on fasting glucose and fasting insulin, regular 
HOMA2 is suggested for insulin measured using radioimmunoassay. c HOMA2-β: Regular β-cell function 
calculated by HOMA2. d HOMA2-IRs: Specific insulin resistance calculated by HOMA2, specific HOMA2 is 
suggested when insulin is measured using a chemiluminescent immunoassay. e HOMA2-βs: Specific β-cell function 
calculated by HOMA2. fDiabetes: FG≥126mg/dL, or HbA1c≥6.5%, or self-reported diabetes diagnosis or 
medication use. Prediabetes: FG≥110mg/dL to <126mg/dL, or HbA1c≥5.7% to <6.5%. *p<0.10, **p<0.05 for 
differences across regions using one-way analysis of variance (ANOVA), Pearson's chi-square, or Kruskal-Wallis 
test. 
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Supplemental Figure 3.1. Adjusted Mean (SE) Differences in Indicators of Glucose Homeostasis at Follow-up 
(i.e.2015) as well as Odds Ratio of Incident Type 2 Diabetes (T2D) Associated with Toenail Arsenic at Baseline 
(i.e.2009) Stratified by Sex, Age, Weight Status, Smoking and Drinking Status, and Region. 
 
 
Results are derived from multivariable-adjusted linear regression (continuous outcomes) or multinomial logistic 
regression (diabetes, prediabetes, vs. neither) models adjusted for all the confounders in our study identified by 
stepwise backward selection (p<0.10) (Figure 3.1b). The confounders identified in our study include age, sex, 
weight status, drinking status, physical activity level, rice intake, and region. a HOMA2-βs: Specific β-cell function 
calculated by Homeostasis Model Assessment (HOMA2) calculator updated in 2015 (University of Oxford, 
website; http://www.dtu.ox.ac.uk/homacalculator/index.php) based on fasting glucose and fasting insulin. b 
HOMA2-IRs: Specific insulin resistance calculated by HOMA2. *p<0.05, **p<0.01 for differences in indicators of 
glucose homeostasis (i.e. FG, FI, HOMA2-IRs, and HOMA2-βs at follow-up) or odds of incident prediabetes and 
diabetes. ǂ p< .0.05, ƚ p<0.10 for significance of interaction between ln-transformed toenail arsenic at baseline× sex, 
age, weight status, smoking and drinking status, and region. 
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Supplemental Table 3.2. Cross-sectional Associations between Baseline (i.e. 2009) Toenail Arsenic and Measures of Glucose Homeostasis as well as Odds of 
Prediabetes and Diabetesa at Baseline 
  ln-toenail arsenic at baseline 
 
Model 1: 
Age, sex, weight statusb, smoking, 
drinking status, daily total energy 
intake, dietary quality index, rice 
intake, fish intake, urbanization 
index, physical activity level, and 
region adjusted 
Model 2: 
Age, sex, weight statusb, 
drinking status, rice intake, 
physical activity level, and 
region adjusted 
Model 3: 
Age, sex, weight statusb, drinking status, rice 
intake, and physical activity level adjusted 
Fasting glucose -0.51±0.36 -0.53±0.36 -0.33±0.33 
Fasting insulin -0.30±0.17* -0.33±0.19* -0.32±0.18* 
hemoglobin A1c -0.03±0.01* -0.03±0.01* -0.05±0.01** 
HOMA2-βc -0.52±0.92 -0.56±0.92 -1.23±0.85 
HOMA2-IRc -0.03±0.02 -0.03±0.02 -0.02±0.02 
Dysglycemia    
Diabetes 0.82 (0.70 - 0.98)** 0.83 (0.73 - 0.98)** 0.85 (0.74 - 0.97)** 
Prediabetes 1.00 (0.90 - 1.06) 1.00 (0.92 - 1.10) 1.00 (0.92 - 1.09) 
Results are derived from multivariable-adjusted linear regression (continuous outcomes) or multinomial logistic regression (diabetes, prediabetes, vs. neither) 
models. Model 1 adjusted for potential confounders based on literature (Figure 3.1a), including age and sex, weight status (body mass index<18, 23.0-27.4, or 
≥27.5), smoking, drinking status, daily total energy intake, rice intake, fish intake, urbanization index, physical activity level and region. Model 2 adjusted for all 
the confounders in our study identified by stepwise backward selection (p<0.10) (Figure 3.1b). Model 3 adjusted for all identified confounders in our study 
except region. a Diabetes: FG≥126mg/dL, or HbA1c≥6.5%, or self-reported diabetes diagnosis or medication use. Prediabetes: FG≥110mg/dL to <126mg/dL, or 
HbA1c≥5.7% to <6.5%. b Weight status defined as Underweight: BMI<18kg/m2; Normal weight: BMI≥23.0 to <27.5kg/m2; Obese: BMI≥27.5kg/m2. c Regular 
pancreatic β-cell function (HOMA2-β) and insulin resistance (HOMA2-IR) calculated by Homeostasis Model Assessment (HOMA2) calculator updated in 2015 
(University of Oxford, website; http://www.dtu.ox.ac.uk/homacalculator/index.php) based on fasting glucose and fasting insulin. *p<0.10, **p<0.05 for 
coefficients of associations between baseline toenail arsenic and baseline measures of glucose homeostasis as well as odds of prediabetes and diabetes. 
Coefficients were bolded when they reached significance (P < 0.10).
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Supplemental Table 3.3. Baseline (i.e. 2009) Characteristics among Participants Included in The Complete Case 
Analysis vs. Excluded Due to Missing Data.  
 
Characteristics 
Participants included in 
complete case analysis 
Participants excluded 
due to missing data 
Age, years 52 (41, 62)** 49 (38, 61) 
Men 42.4%** 50.6% 
Body mass index, kg/m2  
23.0-27.4 42.8%** 35.6% 
≥27.5 12.4% 9.4% 
Smoking   
Current 23.2%** 30.0% 
Former 3.2% 3.6% 
Drinker 25.5%** 29.6% 
Urbanization  
Low 33.5% 35.7% 
Medium 37.5% 30.5% 
High 29.0% 33.9% 
Region   
North 20.3% 21.6% 
Central 32.7% 33.2% 
South 47.0% 45.2% 
Toenail arsenic, µg/g 0.32 (0.19, 0.54) 0.30 (0.18, 0.52) 
 
Data are percentage or median (25th-75th percentile) *p<0.10, **p<0.05 for differences among participants 
involved in complete case analysis vs. excluded due to missing data using one-way analysis of variance (ANOVA), 
or Kruskal-Wallis test. 
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Supplemental Table 3.4. Associations between Baseline (i.e. 2009) Toenail Arsenic and Measures of Glucose Homeostasis as well as Odds of Prediabetes and 
Diabetesa at Follow-up (i.e. 2015) based on Multiple Imputation 
  ln-toenail arsenic at baseline 
 
Model 1: 
Age, sex, weight statusb, smoking, 
drinking status, daily total energy 
intake, dietary quality index, rice 
intake, fish intake, urbanization 
index, physical activity level, and 
region adjusted 
Model 2: 
Age, sex, weight statusb, 
drinking status, rice intake, 
physical activity level, and 
region adjusted 
Model 3: 
Age, sex, weight statusb, drinking status, rice 
intake, and physical activity level adjusted 
time 0.73±0.23** 0.77±0.27** 0.97±0.27** 
Fasting insulin 0.03±0.15 0.06±0.15 0.20±0.15 
hemoglobin A1c -0.00±0.01 -0.00±0.01 0.01±0.01 
HOMA2-βc -2.01±0.82** -2.05±0.88** -1.59±0.90* 
HOMA2-IRc 0.00±0.02 0.00±0.02 0.02±0.01 
Dysglycemia    
Diabetes 1.03 (0.95 - 1.18) 1.06 (0.95 - 1.18) 1.12 (1.00 - 1.26)* 
Prediabetes 1.05 (1.01 - 1.11)* 1.05 (1.00 - 1.11)* 1.07 (1.01 - 1.13)** 
Results are derived from multivariable-adjusted linear regression (continuous outcomes) or multinomial logistic regression (diabetes, prediabetes, vs. neither) 
models. Model 1 adjusted for potential confounders based on literature (Figure 3.1a), including age and sex, weight status (body mass index<18, 23.0-27.4, or 
≥27.5), smoking, drinking status, daily total energy intake, rice intake, fish intake, urbanization index, physical activity level and region. Model 2 adjusted for all 
the confounders in our study identified by stepwise backward selection (p<0.10). Model 3 adjusted for all identified confounders in our study except region. a 
Diabetes: FG≥126mg/dL, or HbA1c≥6.5%, or self-reported diabetes diagnosis or medication use. Prediabetes: FG≥110mg/dL to <126mg/dL, or HbA1c≥5.7% to 
<6.5%. b Weight status defined as Underweight: BMI<18kg/m2; Normal weight: BMI≥23.0 to <27.5kg/m2; Obese: BMI≥27.5kg/m2. c Regular pancreatic β-cell 
function (HOMA2-β) and insulin resistance (HOMA2-IR) calculated by Homeostasis Model Assessment (HOMA2) calculator updated in 2015 (University of 
Oxford, website; http://www.dtu.ox.ac.uk/homacalculator/index.php) based on fasting glucose and fasting insulin. *p<0.10, **p<0.05 for coefficients of 
associations between baseline toenail arsenic and baseline measures of glucose homeostasis as well as odds of prediabetes and diabetes. Coefficients were 
bolded when they reached significance (P < 0.10).
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Supplemental Table 3.5. Sensitivity Analysis of Associations between Baseline (i.e.2009) Toenail Arsenic and Measures of Diabetesa Development during 
Follow-up, (i.e.2015) 
 Age, sex, weight status
b, drinking status, 
physical activity level, and region adjusted 
Fasting glucose 1.06±0.33** 
Fasting insulin -0.07±0.08 
Hemoglobin A1c 0.01±0.01 
HOMA2-βsc -1.62±0.67** 
HOMA2-IRsc -0.01±0.01 
Dysglycemia  
Diabetes 1.19 (0.99, 1.42)* 
Prediabetes 1.10 (0.92 - 1.31)** 
Results are derived from multivariable-adjusted linear regression (continuous outcomes) or multinomial logistic regression (diabetes, prediabetes, vs. neither) 
models. Adjusted for all identified confounders (p for stepwise backward regression <0.10) in our study except rice intake. a Diabetes: FG≥126mg/dL, or 
HbA1c≥6.5%, or self-reported diabetes diagnosis or medication use. Prediabetes: FG≥110mg/dL to <126mg/dL, or HbA1c≥5.7% to <6.5%. b Weight status 
defined as Underweight: BMI<18kg/m2; Normal weight: BMI≥23.0 to <27.5kg/m2; Obese: BMI≥27.5kg/m2. c Specific pancreatic β-cell function (HOMA2-βs) 
and specific insulin resistance (HOMA2-IRs) calculated by Homeostasis Model Assessment (HOMA2) calculator updated in 2015 (University of Oxford, 
website; http://www.dtu.ox.ac.uk/homacalculator/index.php) based on fasting glucose and fasting insulin. *p<0.10, **p<0.05 for coefficients of associations 
between baseline ln-transformed toenail arsenic and measures of diabetes development at follow-up. Coefficients were bolded when they reached significance 
(P< 0.10). 
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CHAPTER 4. THE ASSOCIATIONS BETWEEN INTAKE OF MAGNESIUM AND 
ZINC—ALONE AND IN COMBINATION WITH INORGANIC ARSENIC 
EXPOSURE—AND DEVELOPMENT OF type 2 DIABETES: A LONGITUDINAL 
STUDY IN A POPULATION LOW TO MODERATELY EXPOSED TO INORGANIC 
ARSENIC 
 
Overview 
Laboratory data suggests that the adverse health effects of toxic metals, such as inorganic 
arsenic (iAs), could be reduced with optimal intake of dietary essential metals, such as 
magnesium (Mg) and zinc (Zn), which may decrease uptake or counter adverse metabolic effects 
of toxic metals. In addition, previous studies also found that adequate intake of Mg and Zn may 
independently reduce the risk of Type 2 diabetes (T2D) given their roles as cofactors in enzymes 
and proteins critical for insulin synthesis and secretion from pancreatic β-cells. However, human 
evidence that whether such dietary strategies could effectively counter iAs-associated T2D is 
limited.  
Using unique data from China, a population with low-to-moderate level of iAs exposure 
and comparatively low prevalence of obesity, we examined the association between baseline 
(i.e.2009) Mg and Zn intake—alone and in combination with iAs exposure—and the 
development of T2D over six years. We took advantage of rich longitudinal data from the China 
Health and Nutrition Survey (CHNS). The dataset has detailed measurements of fasting glucose 
and insulin at follow-up (i.e.2015), toenail concentration of arsenic that reflects iAs exposure 
level in recent months at baseline, as well as dietary intake of Mg and Zn estimated from the 
  
45 
 
mean of the three consecutive days high-quality 24-hour recalls reported by each individual 
using the Chinese food composition table.  
Our results further confirmed the association between deficiency of Zn intake and 
development of T2D, and the association was most apparent for measures of β-cell dysfunction 
through which Zn deficiency may influence the development of T2D. In contrast with previous 
literature, we found no statistically significant association between Mg intake and development 
of T2D in a population with relatively high prevalence of Mg deficiency. 
Our findings support the idea that the susceptibility of iAs-associated diabetes varies 
depending on levels of Zn intake, and participants with adequate intake of Zn are more 
susceptible to iAs-associated β-cell dysfunction. Our results also indicate that the mixed results 
between low-to-moderate iAs exposure and development of T2D could be partially correlated 
with the varied susceptibility among participants due to different intake of essential metals, such 
as Zn.  
Though the association between iAs exposure and development of T2D was stronger 
among participants with adequate intake of Zn, the estimated joint associations of Zn intake and 
iAs exposure in association with T2D stress the importance of having adequate Zn intake. Our 
findings support the idea that promoting intake of Zn may potentially be an effective strategy to 
counter the diabetogenic effects of iAs. 
Introduction:  
Type 2 diabetes (T2D), which is a well-recognized cause of premature death and 
disability, is a complex disease with multiple contributing factors, such as obesity, environmental 
pollution, diet, and genetic components1,44-48. Compelling evidence has linked high exposure of 
inorganic arsenic (iAs), a common contaminant in drinking water and foods such as rice, with 
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increased risk of T2D55,57,90. There is growing concern that low-to-moderate level of iAs 
exposure, which is much more commonly worldwide, may contribute substantially to the current 
epidemic of T2D, especially in the countries with low prevalence of obesity such as China51,55-57.  
Effective strategies to counter the adverse health effects of low-to-moderate iAs exposure 
are critical as it is challenging to eliminate iAs from daily life18,19. Recently, Petriello et al.20 has 
advocated identifying nutritional strategies to mitigate cardio-metabolic effects of toxic metals, 
such as iAs. Laboratory data also suggests that the adverse health effects of toxic metals could be 
reduced with optimal intake of dietary essential metals, such as magnesium (Mg) and zinc (Zn), 
which may decrease uptake or counter adverse metabolic effects of toxic metals21-27. However, 
human evidence on the effectiveness of such dietary strategies to reduce the adverse health 
effects of iAs is limited, and epidemiological studies have yet to access whether susceptibility to 
the diabetogenic effects of iAs may vary depending on levels of essential metals intake28-30. 
Indeed, population differences in intake of essential metals may contribute to the heterogeneous 
findings on iAs-associated diabetes to date, especially among the population low-to-moderately 
exposed to iAs21,26,30,58,59. Thus, studies are urgently needed to examine the association between 
intake of essential metals and iAs-associated diabetes, especially in the population low-to-
moderately exposed to iAs.   
Essential metals, notably Mg and Zn, which are cofactors in enzymes and proteins critical 
for insulin synthesis and secretion from pancreatic β-cells, may also independently affect glucose 
homeostasis165-173. Growing data suggests Mg and Zn may reduce the risk of diabetes, but 
findings on Zn are inconsistent169,174-183. Recent reviews conclude that evidence is insufficient to 
promote the intake of essential metals to prevent or control diabetes184,185. Longitudinal studies 
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are urgently needed to examine the association between Mg and Zn intake with the development 
of T2D.  
To address this gap, we prospectively assessed whether the susceptibility to the 
diabetogenic effects of low-to-moderate iAs exposure may vary depending on levels of Mg and 
Zn intake at baseline (i.e.2009). We also examined the association between baseline Mg and Zn 
intake with the development of T2D, characterized by fasting glucose, fasting insulin, glycated 
hemoglobin, and odds of incident prediabetes and diabetes six years later (i.e. 2015), in a 
population-based cohort with relatively high prevalence of Mg and Zn deficiency. We used the 
Homeostasis Model Assessment (HOMA2) calculator updated in 2015 (University of Oxford, 
website; http://www.dtu.ox.ac.uk/homacalculator/index.php) to calculate steady state pancreatic 
β-cell function and insulin resistance based on measured fasting glucose and fasting insulin at 
follow-up (i.e.2015)41-43. The associations between baseline intake of Mg and Zn—alone and in 
combination with iAs exposure—and the measures of specific mechanism of T2D at follow-up 
(i.e. β-cell function and insulin resistance) can help us better understand the early stage change in 
glucose hemostasis associated with intake of Mg and Zn. 
Method 
China Health and Nutrition Survey. The China Health and Nutrition Survey (CHNS) is 
an ongoing longitudinal survey, which collected health, economic, sociological, and 
demographic data in nine diverse provinces throughout China from 1989-2015. Using a 
multistage random cluster design, a stratified probability sample was used to select counties and 
cities stratified by income using State Statistical Office definitions, and then communities and 
households were selected from these strata. Questionnaires were used to collect demographic, 
socioeconomic, anthropometric, behavioral and health information. Biomarker data, including 
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fasting glucose (FG), fasting insulin (FI), and hemoglobin A1c (HbA1c) were collected at both 
baseline (i.e.2009) and follow-up (i.e.2015). Toenail clippings were collected at baseline and 
analyzed for arsenic concentration. Survey procedures have been described elsewhere97,98. The 
CHNS cohort initially mirrored national age-gender-education profiles and the nine provinces in 
the CHNS constituted 44% of China’s population in 2009 (according to 2009 census). 
The study was approved by the Institutional Review Board at the University of North 
Carolina at Chapel Hill, the China-Japan Friendship Hospital, National Institute for Nutrition and 
Health in China, and the Chinese Center for Disease Control and Prevention. 
Analysis sample. We restricted analyses to non-pregnant adults (≥18y) at time of 
measurement (i.e. 2009 and 2015) with toenail arsenic data available at the 2009 exam 
(N=6843). We excluded participants who missed baseline (i.e. 2009) data of body mass index 
(N=511), smoking or drinking status (N=5), diet (N=80), urbanization index (N=96), physical 
activity (N=34), province (N=7), any blood biomarkers (FG and HbA1c, N=478). We further 
excluded participants missed any blood biomarkers (i.e. FG, FI, and HbA1c) in 2015 (N=3479). 
Participants with extreme biomarkers, which were defined as 6 standard deviation above or 
below the means, were also excluded (N=15). Individuals with diabetes at baseline were 
excluded to reduce the possibility of reverse causality (N=220). In addition, participants age>70 
at baseline (N=143) were excluded due to differences in metabolism of Mg and Zn in this age 
group186,187, resulting in final analytic samples for the complete case analysis N=1775. 
Ascertainment of diabetes. Blood samples of all participants were collected by 
venipuncture after an overnight fast. Whole blood was immediately centrifuged, serum was 
aliquoted and frozen at -70 degrees. Aliquots were collected in EDTA-coated vacutainers 
containing sodium fluoride to prevent glucose degradation. All blood samples were analyzed in a 
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national central lab in Beijing (medical laboratory accreditation certificate ISO15189:2007). 
Both 2009 and 2015 FG were measured by colorimetric assay methods (GOD-PAP; Randox 
Laboratories Ltd, UK) using a Hitachi 7600 analyzer (Hitachi Inc., Tokyo, Japan). Both 2009 
and 2015 HbA1c was measured with high performance liquid chromatography (HPLC) system 
(model HLC-723 G7; Tosoh Corporation, Tokyo, Japan). FI in 2015 was measured using 
chemiluminescent immunoassay.  
Diabetes was defined by FG≥126mg/dL, or HbA1c≥6.5%, or self-reported diabetes 
diagnosis or medication use. Pre-diabetes was defined by FG≥110mg/dL to <126mg/dL, or 
HbA1c≥5.7% to <6.5%. Measured FG and FI were used to calculate steady state pancreatic β-
cell function and insulin resistance using the Homeostasis Model Assessment (HOMA2) 
calculator updated in 2015 (University of Oxford, 
website; http://www.dtu.ox.ac.uk/homacalculator/index.php). The HOMA2 calculator is an 
updated version (computer model) of the original HOMA model (HOMA1). HOMA2 is 
suggested as a more accurate method than the original HOMA1, since HOMA2 accounts for 
variations in hepatic and peripheral glucose resistance and the reduction of peripheral glucose-
stimulated glucose uptake41,42. Specific HOMA2, including specific HOMA2-insulin resistance 
(HOMA2-IRs) and specific HOMA2-β cell function (HOMA2-βs), was calculated for 2015 since 
specific HOMA2 is suggested for insulin measured using chemiluminescent immunoassay41,42. 
Measurement of toenail arsenic. Toenail arsenic was used as a measurement of individual 
chronic iAs exposure since toenails have shown to preferentially sequester iAs species, which is 
a more toxic form than organic arsenic, and better reflects iAs exposure in recent months 
compared with routinely used spot urine samples, especially among participants low-to-
moderately exposed70-72,75. Participants were asked to let toenails grow for at least two weeks, 
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and stainless-steel nail scissors were used to collect toenail clippings from all ten toes. Toenail 
clippings were washed and sonicated for 30 minutes and dried at 80℃. After microwave-assisted 
digestion, toenails were analyzed using inductively coupled plasma mass spectroscopy99. The 
limit of detection (LOD) for arsenic by this method is 0.01μg/g. Toenail arsenic concentrations 
lower than the LOD were imputed at half of the LOD as 0.005μg/g (N=71/1775). Toenail arsenic 
was either categorized in tertiles or natural log-transformed to normalize the distribution. 
Dietary assessment. Dietary intake was assessed using three consecutive days 24-hour 
recalls (two weekdays and one weekend day) at the individual level and a food inventory at the 
household level during the same 3-day period. Trained investigators interviewed the participants 
to collect detailed types and amounts (in grams) of all foods and beverages consumed during the 
preceding 24 hours with the assistance of food pictures to aid quantification. Daily intake was 
calculated by the mean of the three days 24-hour recalls. Chinese food composition table was 
applied to estimate the mean daily energy intake (kcal), Mg intake (mg), and Zn intake 
(mg)100,101 and tertiles of their distributions. In addition, we characterized dietary adequacy of 
Mg and Zn intake according to the US Recommended Dietary Allowance188,189 and the 
Recommended Nutrient Intake190. We used the tailored Alternate Healthy Eating Index (tAHEI), 
which was generated by tailoring the Harvard AHEI 2010, to assess diet quality in our study191. 
Details of tAHEI have been described elsewhere191.  
Other variables. Standard height (in meters) and weight (in kilograms) were measured 
using standard protocol by trained nurses. Body mass index (BMI) was calculated as weight in 
kilograms divided by the square of the height in meters (kg/m2). Weight status was then 
generated based on BMI according to the World Health Organization cutoffs for Asian adults 
(<18kg/m2 for underweight, 23.0-27.4kg/m2 for overweight, and ≥27.5kg/m2 for obese)102,103. 
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Information on age (in years), sex, smoking (current, former, never smokers), drinking status (< 
vs. ≥once per month) was collected using questionnaires.  
A validated urbanization index was used to measure degrees of urbanization104. The 
index contains 10 validated components including communication, economic, housing, 
transportation infrastructure, the availability of schools, markets, and health care, environmental 
sanitation, and population size and density. The urbanization index, which was positively 
correlated with degree of urbanization, ranged from 10 to 100 and was categorized into tertiles. 
The nine provinces in CHNS were categorized into three geographic regions (North: 
Heilongjiang, Liaoning; Central: Shandong, Henan, Jiangsu; South: Hunan, Hubei, Guangxi, 
Guizhou). 
Individual physical activity data was collected through an in-depth interview on time 
(hours) spent in domestic, occupational, transportation, and leisure-time activity. Separate 
questions were asked for each of the four domains. Energy expenditure from each activity 
domain was calculated by multiplying time (hours) spent on each type of physical activities by 
its specific metabolic equivalent (MET) intensity value, resulting in measures of total MET-
hours/week for each domain. Overall energy expenditure for each individual was then calculated 
by summing up MET-hours spent in each domain and categorizing into tertiles.  
Statistical analyses. Toenail arsenic was either categorized in tertiles or natural log-
transformed to make the distribution more normal. Dietary intake of Mg and Zn were 
categorized into adequate vs. deficient based on US Recommended Dietary Allowances (RDA) 
to better compare with previous literature189,192,193. ANOVA (continuous variables) and chi-
square tests (categorical variables) were used to determine the significance of differences in 
baseline characteristics across regions.  
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To determine whether development of T2D during follow-up (i.e.2015) is related to the 
intake of Mg and Zn at baseline, we first compared indicators of glucose homeostasis (i.e. FG, 
FI, HbA1c, HOMA2-βs, and HOMA2-IRs) at follow-up among participants with adequate vs. 
deficient baseline Mg and Zn intake. Medians were used rather than means given the highly non-
normal distribution of the indicators of glucose homeostasis (Shapiro-Wilk P<0.01). We used a 
non-parametric Kruskall-Wallis test to identify statistically significant differences in each of the 
indicators of glucose homeostasis across adequate vs. deficient levels of Mg and Zn intake. We 
also compared baseline intake of Mg and Zn among participants with vs. without prediabetes and 
diabetes at follow-up.  
We further evaluated associations between deficiency of baseline Mg and Zn intake (vs. 
adequacy) and T2D development using multivariable-adjusted linear regression models for 
indicators of glucose homeostasis, and multinomial logistic regression models for odds of 
incident prediabetes and diabetes. Coefficients from these models were used to estimate the 
mean differences in each measure of T2D development during follow-up among participants 
with deficient vs. adequate baseline Mg and Zn intake. Next, we examined whether the 
associations between baseline iAs exposure and development of T2D varied depending on 
baseline levels of Mg and Zn intake. We tested the significance of baseline dietary Mg and Zn 
status × baseline iAs exposure level (ln-transformed toenail arsenic).  
Potential confounders of iAs-associated T2D identified based on literature include: age, 
sex, drinking status, smoking status, urbanization index, baseline weight status (weight status 
may influence the metabolism and storage of iAs105-107 and it is a well-known risk factor for 
T2D), fish intake (an important source of non-toxic organic arsenic compounds (arsenobetaine 
and arsenosugars)108,109 and is associated with T2D risk110,111), rice intake (an important source of 
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iAs exposure in the study population112 and is also associated with risk of T2D113), and region 
(there is substantial regional variation in exposure sources, diet, cooking method, and lifestyle 
factors across China). We also included daily total energy intake and physical activity level since 
they are associated with risk of T2D. In addition, we included dietary quality index (i.e. tailored 
Alternate Healthy Eating Index) in our model to reduce the impact of other dietary factors in Mg 
and Zn rich foods, such as fibers, on the development of T2D development.  
In our study, we adjusted for the confounders that were identified based on stepwise 
backward selection (p<0.10). The confounders identified in our study include age, sex, weight 
status, drinking status, physical activity level, rice intake, region, daily energy intake, and dietary 
quality index.  
We also stratified models by levels of baseline Mg and Zn intake to compare the 
magnitude of the associations between iAs exposure and development of T2D among 
participants with adequate vs. deficient intake of Mg and Zn, regardless of the significance of the 
interactions. In addition, we stratified the participants based on both iAs exposure (i.e. tertiles) 
and intake of Mg and Zn (i.e. adequate vs. deficient) to generate the joint variable for iAs 
exposure and intake of Mg and Zn. We tested the association between the joint variable and the 
development of T2D. The coefficients from these models estimated the mean differences in each 
measure of T2D development after follow-up among participants with different tertiles of iAs 
exposure and intake of Mg and Zn, relative to participants with lowest tertile of iAs exposure and 
adequate intake of Mg and Zn.  
We conducted several sensitivity analyses. First, we excluded participants with pre-
diagnosed diabetes at follow-up (N=18), who might have medication or adjusted their diet 
pattern after diagnosis. Second, we also excluded participants with extreme self-reported daily 
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energy intake, which was defined as self-reported daily total energy intake <600kcals (N=2) or 
>4,500kcals (N=3)194,195. Third, we examined whether use of Chinese versus US definitions of 
Mg and Zn adequacy differed. We set statistical significance of main effects and interactions at 
p<0.05 with p<0.10 indicating marginal significance. We used complete case analysis for all the 
longitudinal analysis. In addition to complete case analysis, we conducted multiple imputation 
using predictive mean matching (five closest observations was drawn) to take into consideration 
of the impact from missing data. 
Statistical significance of main effects was set at p<0.05 with p<0.10 indicating marginal 
significance. All the statistical analyses were performed in Stata, version 13.1 (StataCorp LP, 
College station, Texas). 
Results:  
Characteristics and deficiency of Mg and Zn in the target population 
Baseline (i.e. 2009) sociodemographic and anthropometric characteristics of the 
participants involved in the complete case analysis (N=1775), as well as biomarkers at baseline 
and follow-up (i.e.2015), baseline arsenic exposure level characterized by toenail arsenic are 
provided in Table 4.1.  
The toenail arsenic ranged from below the LOD to 115.6μg/g, with a median of 0.32μg/g, 
which intersected with ranges reported in the US population (toenail arsenic range=0-
3.26μg/g)77. Though there is no established cut-point for iAs exposure level (high vs. low) based 
on toenail arsenic, the overlapping range of toenail arsenic between US studies and our study 
population suggests that the participants in CHNS are exposed to low-to-moderate levels of 
iAs70,117.  
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Mean intake of Mg and Zn was 298.1mg/day and 10.9mg/day across all participants 
respectively. We categorized participants into adequate vs. deficient intake of Mg and Zn 
according to US Recommended Dietary Allowance (Supplemental Table 4.2)189. There were 
78.9% participants (N=1400) with Mg deficiency and 33.5% participants (N=594) with Zn 
deficiency. Participants from South China had a significantly higher prevalence of Mg deficiency 
(84.1%, N=699) and a lower prevalence of Zn deficiency (28.7%, N=241) compared to 
participants from North or Central China. In addition, the tailored Alternate Healthy Eating 
Index was statistically significantly lower among participants from South. We also found 
statistically significantly lower tailored Alternate Healthy Eating Index among participants with 
higher tertile of toenail arsenic (Supplemental Table 4.1).  
In the complete case analysis, baseline (i.e.2009) FG was significantly lower than follow-
up (i.e.2015) FG (91.9±11.0 vs. 96.8±16.1mg/dL, p<0.05), whereas we found no statistically 
significant difference in HbA1c at baseline vs. follow-up (5.4±0.4 vs. 5.6±0.6%). The mean 2015 
FI was 7.1µU/mL, mean HOMA2-IRs and HOMA2-βs at 2015 were 1.1 and 86.8%. 
Approximately 6.6% and 45.2% of study participants without diabetes at baseline developed 
diabetes and prediabetes during six years of follow-up.  
Comparing indicators of glucose homeostasis across regions, we found participants from 
South and Central China had statistically significantly higher FG at baseline and follow-up 
compared with participants from North China. Individuals from Central China had significantly 
higher HbA1c at baseline, but we found no statistically significant difference in 2015 HbA1c 
among participants from different parts of China. We found FI at 2015 was significantly higher 
among participants from South versus North and Central China (South vs. North vs. Central: 
7.5±4.6 vs. 6.8±3.5 vs. 6.9±3.9 µU/mL), while HOMA2-βs was significantly higher among 
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participants from North versus Central and South China (North vs. Central vs. South: 93.5±34.8 
vs. 84.1±28.9 vs. 85.7±33.9%). In addition, we found no statistically significant difference in 
HOMA2-IRs at 2015 among participants from different parts of China.  
Fasting glucose and pancreatic β-cell function at follow-up differed substantially among 
participants with different levels of baseline Mg and Zn intake.  
We compared indicators of glucose homeostasis (i.e. FG, FI, HbA1c, HOMA2-βs, and 
HOMA2-IRs) at follow-up among participants with different levels of baseline Mg and Zn intake 
(Table 4.2). Participants with adequate intake of Mg at baseline had significantly (p<0.05) lower 
FG (93.6 vs. 95.2mg/dL) but higher HOMA2-βs (82.4 vs. 79.9%) compared with participants 
with deficient Mg intake. Similarly, participants with adequate Zn intake at baseline had 
significantly (P<0.05) lower FG (94.3 vs.96.1mg/dL) and higher HOMA2-βs (80.9 vs. 78.6%) 
compared with participants had deficient intake of Zn at baseline. We found no statistically 
significant difference in Mg and Zn intake among participants with vs. without prediabetes and 
diabetes at follow-up (Supplemental Table 4.3).  
Based on multivariable-adjusted models (Table 4.3), there was an adjusted mean 
difference of -5.18±2.09% in HOMA2-βs among participants with deficient Zn intake at baseline 
compared with participants had adequate Zn intake at baseline. We found positive (though not 
statistically significant) association between baseline Zn deficiency and follow-up FG (0.82±1.04 
mg/dL). In contrast with the descriptive analysis suggesting participants with deficient Mg intake 
at baseline had significantly higher FG and lower HOMA2-βs at follow-up, we did not find 
statistically significant association between baseline Mg intake and development of T2D during 
follow-up in multivariable-adjusted models.  
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Associations between iAs exposure and development of T2D varied by levels of baseline Zn 
intake.  
Among overall participants, we found negative association between iAs exposure (i.e. ln-
transformed toenail arsenic at baseline) and HOMA2-βs at follow up (-1.37±0.67%, p<0.05). In 
addition, there was a positive association between iAs exposure and fasting glucose 
(0.98±0.32mg/dL, p<0.05) after adjusting for identified confounders in our study. 
We found statistically significant interaction (P<0.05) between baseline iAs exposure (i.e. 
ln-transformed toenail arsenic) and deficiency of Zn intake at baseline for HOMA2-βs, 
suggesting that the association between baseline iAs exposure and HOMA2-βs varies depending 
on the level of Zn intake at baseline (Supplemental Table 4.4).  
The adjusted mean differences FG and HOMA2-βs at follow-up associated with baseline 
iAs exposure stratified by levels of baseline Mg and Zn intake are presented in Figure 4.1. We 
found statistically significant positive association between baseline iAs exposure and FG among 
participants with deficient Mg intake at baseline (1.24±0.40mg/dL, p<0.05), and the association 
was significant but weaker among participants with adequate Mg intake at baseline 
(0.91±0.37mg/dL, p<0.10). The positive association between iAs exposure (i.e. ln-transformed 
toenail arsenic) and FG was only significant among participants with adequate Zn intake at 
baseline (1.32±0.42mg/dL, p<0.05), and the magnitude of the association between iAs exposure 
and FG among participants with adequate Zn intake was about twice the magnitude of the 
association among those with deficient Zn intake at baseline (adequate vs. deficient Zn: 
1.32±0.42 vs. 0.75±0.69mg/dL). However, the interaction between iAs exposure and deficiency 
of Zn intake for FG did not reach statistical significance.  
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We found statistically significant negative association between baseline iAs exposure and 
HOMA2-βs among participants with deficient Mg intake (-2.34±0.82mg/dL, P<0.05), while the 
association was null among participants with adequate intake of Mg (-0.46±1.52mg/dL, P>0.10). 
The decline in HOMA2-βs associated with ln-transformed toenail arsenic was considerably as 
well as significantly larger among participants with adequate vs. deficient intake of Zn (-2.32% 
vs. -0.51%, p for interaction<0.05).  
Estimated joint associations of iAs exposure (i.e. tertiles of baseline toenail arsenic) and 
adequacy of Mg and Zn intake on the development of T2D are presented in Table 4.4. Relative 
to participants with lowest tertile of iAs exposure and adequate intake of Mg at baseline, after 
multivariable adjustment, there was a statistically significant increment of 3.72mg/dL in FG 
among individuals exposed to highest tertile of iAs and deficient in Mg intake at baseline, vs. an 
increment of 2.92mg/dL in FG among participants exposed to highest tertile of iAs but with Mg 
intake in the adequate range.  
Consistent with findings in Mg, we found participants with highest tertile of iAs 
exposure, including participants with both adequate and deficient intake of Zn, had statistically 
significantly higher FG compared with participants with lowest tertile of iAs exposure and 
adequate intake of Zn. After multivariable adjustment, there was a significant mean increment of 
3.48mg/dL (p<0.05) in FG among individuals exposed to highest tertile of iAs and with deficient 
Zn intake at baseline, vs. a significant increment of 3.25mg/dL in FG among individuals with 
highest tertile of iAs exposure and adequate Zn intake at baseline.  
In addition, we found statistically significant differences in HOMA2-βs among 
individuals with different levels of iAs exposure and Mg and Zn intake. Comparing with 
participants with adequate intake of Mg and lowest tertile of iAs exposure, there was no 
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significant difference in pancreatic β-cell function among participants with highest tertile of iAs 
exposure and adequate intake of Mg. however, we found a significant lower pancreatic β-cell 
function among those with highest tertile of iAs exposure and deficient intake of Mg (-
5.18±2.43%, p<0.05). Consistent with what was found for Mg, we also found a statistically 
significant adjusted mean difference in pancreatic β-cell function among participants with 
highest tertile of iAs exposure and deficient Zn intake at baseline (-8.50±3.14%, p<0.05), but no 
statistically significant difference was found among those with adequate intake of Zn relative to 
participants with adequate Zn intake and lowest tertile of iAs exposure.  
In models predicting variation in the FI, HbA1c, HOMA2-IRs, odds ratios of incident 
prediabetes and diabetes, we found no statistically significant effect modification by iAs 
exposure and intake of Mg and Zn (data not shown). 
In sensitivity analyses exploring the effects of additionally excluding pre-diagnosed 
diabetes at follow-up, or participants with extreme self-reported daily energy intake (i.e. energy 
intake <600kcals/day or >4,500kcals/day), there was no meaningful difference in results. In 
addition, we also defined adequacy of Mg and Zn intake based on Chinese Recommended 
Nutrient Intake190, the results did not differ meaningfully.  
Discussion:  
Using unique data from China, a population with low-to-moderate level of iAs exposure 
and comparatively low prevalence of obesity, we examined the association between baseline 
(i.e.2009) Mg and Zn intake—alone and in combination with iAs exposure—and the 
development of T2D over six years. Deficiency of Zn intake at baseline was associated with 
decreased pancreatic β-cell function, which was measured by HOMA2-βs, and the association 
remained marginally significant after adjusting for regions. Moreover, we found statistically 
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significant interaction between baseline Zn intake and iAs exposure. The negative association 
between iAs exposure and pancreatic β-cell function was stronger among participants with 
adequate vs. deficient intake of Zn at baseline. These findings suggest that Zn deficiency may be 
associated with development of diabetes through pancreatic β-cell dysfunction, and susceptibility 
of iAs-associated diabetes varies depending on the level of Zn intake at baseline in this 
population. 
Based on literature, major sources of iAs exposure in our study population include iAs 
contaminated air due to coal or charcoal combustion, rice and drinking water contaminated by 
iAs from natural sources, such as mining70-72 118-121. Thus, instead of water iAs, toenail arsenic 
was used as a measurement of individual chronic iAs exposure in our study to better capture the 
iAs exposure from different sources70-72 118,119. A few studies estimate individual iAs exposure 
based on urinary arsenic, which is generally regarded as the most reliable indicator of recent 
exposure to iAs. Nonetheless, a previous rice-feeding trial conducted by Meharg et al.75 found 
considerable variation (up to 13-fold) in an individual’s total iAs urine content throughout the 
day, calling into question the robustness of the routinely used spot urine samples, especially 
among participants low-to-moderately exposed75. Compared to a spot urine sample, the long-
term accumulation of iAs in nails makes the toenail arsenic more reliable as the biomarker of 
chronic iAs exposure74,117. 
A large proportion of our sample was deficient in Mg intake (78.9%), whereas Zn 
deficiency was lower (33.5%) in our sample. The prevalence of Mg and Zn deficiency in our 
study population is consistent with previous studies conducted in China54,65,67. The relatively 
high prevalence of Mg and Zn deficiency provided an outstanding context to examine such 
deficiencies in relation to T2D.  
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We found statistically significant interaction between iAs exposure and Zn intake for 
pancreatic β-cell dysfunction as measured by HOMA2-βs at follow-up (i.e. 2015). Our finding 
suggests that the association between iAs exposure and pancreatic β-cell dysfunction varies 
across population, depending on levels of Zn intake. Very limited studies have examined how 
intake of Mg and Zn is associated with the susceptibility of iAs-associated diabetes. Steinmaus et 
al.26 have stressed the association between Zn intake and iAs metabolism among participants 
from western United States, who are known low-to-moderately exposed to iAs. They found 
participants in the higher quartile of Zn intake had lower urinary percent monomethyl arsenic 
(MMAs%) and higher percent dimethyl arsenic (DMAs%), and the associations remained 
significant in multivariable adjusted regression models. Based on literature, the relevance of a 
high vs. low DMAs% and MMAs% for health risks is uncertain, and may depend on the level of 
iAs exposure. Findings of studies conducted in the population highly exposed to iAs support the 
positive association between MMA% and risk of cancer and other health outcomes, including 
cardiovascular diseases and diabetes39,87,196,197. However, numerous studies in settings with more 
moderate exposure, such as in United States, have suggested a higher DMA% associated with 
increased risk of diabetes and other cardiometabolic outcomes 80-83. Thus, the findings of 
Steinmaus et al.26 support a higher risk of iAs-associated health outcomes among participants 
with higher intake of Zn, which is consistent with our findings. In contrast, Mitra et al.28 found 
no statistically significant association between Zn intake and iAs associated adverse health 
outcomes in the cross-sectional study conducted in West Bengal, where people are known to be 
highly exposed to iAs. Inconsistent with our findings, previous laboratory data supports a lower 
risk of iAs-associated health outcomes among participants with higher intake of Zn, since Milton 
et al.27 found Zn decreased iAs-induced apoptosis from in vitro study.. 
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In contrast with the stronger association between iAs exposure and β-cell dysfunction 
among participants with adequate Zn intake, we found no statistically significant interaction 
between iAs exposure and Mg intake at baseline. However, the association between iAs 
exposure and β-cell dysfunction was only statistically significant among individuals with 
deficient vs. adequate intake of Mg, and the magnitude of the association between iAs exposure 
and HOMA2-βs was about twice among participants with deficient vs. adequate intake of Mg. 
Thus, our study suggests the associations between baseline iAs exposure and pancreatic β-cell 
dysfunction varied among participants with different levels of Mg and Zn intake, and the mixed 
results of the studies on iAs-associated T2D could be due in part to varied susceptibility among 
participants with substantial different Mg and Zn intake21,51,55-60. 
To the extent of our knowledge, others have not formally examined the joint associations 
of essential metals, such as Mg and Zn, and iAs exposure on development of diabetes. However, 
others have suggested that intake of essential metals could be a strategy to reduce the health 
effects of toxic metals, such as iAs24,58. Notably, though iAs had somewhat stronger association 
with β-cell dysfunction among individuals with adequate intake of Zn, the joint associations of 
iAs exposure and adequacy of Zn intake on development of T2D support the idea that adequate 
Zn intake is beneficial for β-cell function.  
Several studies have addressed the associations between Zn level and risks of T2D, but 
findings are inconsistent177-183. The significant negative association between deficiency of 
baseline Zn intake and pancreatic β-cell function in our study is consistent with laboratory data, 
which indicates that adequate Zn intake is associated with lower risk of T2D by exerting insulin-
like effects and reducing the production of cytokines, which leads to pancreatic β-cell 
death167,168,183,198,199. Similarly, in several epidemiological studies researchers found that Zn was 
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positively associated with pancreatic β-cell function167,177-183,198. However, Karamali et al.36 and 
Islam et al.93 have reported that higher Zn was associated with decreased β-cell function. In 
contrast with the null association we found between Zn intake and insulin resistance, Vashum et 
al.42 and Islam et al.93 reported higher Zn level was associated with decreased insulin resistance. 
However, both of these studies were cross-sectional. The statistically significant association 
found between Zn level and insulin resistance in cross-sectional studies could be explained by 
the fact that individuals with T2D may progressively develop insulin resistance over time, even 
if this is not the primary pathway involved in Zn-associated diabetes13,14,144,200. With our 
prospective study design and by excluding participants with diabetes at baseline, we are able to 
capture the early stage change of T2D development that is associated with Zn intake. In line with 
most studies, we did not find statistically significant association between Zn intake and FG, 
HbA1c, as well as the risk of prediabetes and diabetes201-203. The null associations could be 
partially due to the participants who were able to maintain glucose homeostasis at the early 
phase of T2D development13,14,144,200. Additional research is needed to assess the association 
between baseline Zn intake and the development of T2D for a longer follow-up.  
In contrast with a considerable literature indicating lower Mg and Zn levels among 
diabetic individuals174,178,181,182,198,203,204, we found no statistically significant difference in 
baseline Mg and Zn intake among participants with vs. without diabetes. In line with our 
findings, Fernandez-Cao et al.198 also reported no statistically significant difference in Zn intake 
among participants with diabetes vs. non-diabetes based on their systematic literature review, 
while they found significantly lower blood Zn among participants with diabetes. Thus, the 
inconsistent results could be partially due to our use of dietary intake whereas most of others 
have used serum Mg and Zn174,178,181,182,198,203,204. Several studies have addressed the impact of 
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diabetes on the metabolism of metals, posing the risk that altered serum Mg and Zn in diabetic 
individuals may be a consequence rather than a cause of disease17,166,204,205.  
Several epidemiological studies have addressed the association between dietary Mg 
deficiency and increased risk of diabetes, and previous findings also indicate Mg deficiency may 
cause insulin resistance as shown by several studies both in human and in experimental 
animals173,175,176,206. However, we found no statistically significant association between baseline 
Mg intake and risk of T2D in our study population, which has a relatively high prevalence of Mg 
deficiency. Moreover, instead of the association between Mg intake and insulin resistance, we 
found participants with adequate Mg intake had significantly elevated β-cell function. Compared 
with studies conducted in different countries, the heterogenetic results may be related with 
substantial variation in dietary composition according to different geographic 
territory166,173,175,176,206. Moreover, as limited participants in our study with adequate intake of 
Mg, further study is needed to determine the impact of Mg intake in a population with a wide 
range of Mg intake. 
We utilized the unique data from China, a population with relatively high prevalence of 
Mg and Zn deficiency and comparatively low prevalence of obesity, as well as low-to-moderate 
level of iAs exposure, which is more typical than high level of iAs exposure around the 
world55,207. To the best of our knowledge, ours is the first prospective longitudinal study 
designed to examine whether higher intake of Mg and Zn may associate with susceptibility to the 
diabetogenic effects of iAs. Our findings contribute substantially to the current literature as there 
is an urgent need to identify dietary strategies to counter the adverse effects of toxic metals, such 
as iAs, and it has yet been studied by epidemiological studies about how intake of Mg and Zn 
relates to the association between low-to-moderate iAs exposure and development of T2D23,27. 
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Strengths of our study include the standard protocol used to collect data over the follow-
up period, high-quality laboratory methods used for individual and direct measurement of 
chronic iAs exposure. Moreover, few studies on toxic metals, such as iAs, include the high-
quality dietary data. The potential for essential metals to reduce the risk of toxic metals has been 
largely examined using biomarkers of essential metals (e.g. serum and urinary biomarkers). 
However, others have suggested that toxic metals and their related metabolic effects may 
diminish essential metals biomarkers, limiting their utility as markers of intake208,209. Our study 
is one of the few studies that directly examine how intake, rather than biomarkers, of Mg and Zn 
relate to iAs burden. We also excluded participants with diabetes at baseline to better capture the 
early stage changes of glucose homeostasis to reveal the underlying biological mechanism of Zn 
and Mg-associated diabetes.  
Our study has several limitations. First, though the sample size was larger than in many 
previous studies, we had limited cell sizes for stratified analyses. The small cell sizes may have 
reduced our power to detect the interactions. Thus, statistical significance should be interpreted 
with caution, especially for the interactions and stratified analyses. Second, though three-day 24-
hour recall is frequently used in studies to estimate the usual dietary intake, the result of it can be 
affected by several factors, such as over and under report210,211. In our study, we used sensitivity 
analysis to examine differences in model results when we excluded participants with extreme 
self-reported daily energy intake (<600 kcal/d and >4,500 kcals/d) to assess the effects from 
misreporting. We found no statistically significant difference in results before vs. after this 
exclusion. Third, limited information about supplement intake might have altered our estimates 
of daily intake of Mg and Zn. However, since mineral supplements, except calcium, are not 
widely used in this population and none of the participants included in the analysis reported 
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using supplements, it is unlikely that this study limitation influenced our findings212. In addition, 
our study used toenail arsenic as the measurement of iAs exposure. Though toenail arsenic has 
been suggested as a reliable biomarker for iAs exposure over an integrated period of months, 
toenail arsenic cannot separate different forms of iAs, such as trivalent vs. pentavalent, which 
may associate with health outcomes differently90. Therefore, we were unable to examine the 
associations between different forms of iAs exposure and measures of T2D development. 
Moreover, compared with urinary arsenic profiles, toenail arsenic was not able to capture the 
information about iAs metabolism, a more expanded knowledge of the correlations between 
toenail arsenic and existing biomarkers (i.e. urinary arsenic) is needed to better interpret our 
findings. In addition, missing data in our study could be a potential concern. We took into 
account of missing data by conducting multiple imputation, and our multiple imputation results 
are highly consistent with the complete case analysis, which ensures that data analysis samples in 
our study reflect the full population.   
 
  
  
67 
 
Tables and figures 
Table 4.1. Characteristics of Study Participants by Regions 
  Region 
Characteristics All participants North Central South 
Total N 1775 367 580 828 
Baseline (i.e.2009) 
characteristics      
Age, years 49.7±11.3 49.5±10.5 50.4±11.4 49.4±11.6 
Men 747 (42.1) 157 (42.8) 234 (40.3) 356 (43.0) 
Body mass index, kg/m2      
23.0-27.4 787 (44.3) 143 (39.0) ** 214 (36.9) 430 (51.9) 
≥27.5 756 (42.6) 165 (45.0) 272 (46.9) 319 (38.5) 
Smoking     
Current 416 (23.4) 104 (28.3)** 119 (20.5) 193 (23.3) 
Former 50 (2.8) 10 (2.7) 17 (2.9) 23 (2.8) 
Drinking statusa 468 (26.4) 95 (25.9) 165 (28.5) 208 (25.1) 
Total energy intake, 
kcal/day 2186.6±639.2 2128.4±566.7 2201.0±684.5 2202.4±636.0 
Magnesium intake, 
mg/day  
298.1±106.6 313.7±101.8 ** 311.8±112.3 281.7±102.3 
Magnesium deficiency  1400 (78.9) 281 (76.8) ** 420 (72.5) 699 (84.1) 
Zinc intake, mg/day  10.9±3.5 10.8±3.1 ** 10.5±3.7 11.2±3.4 
Zinc deficiency  594 (33.5) 124 (33.9) ** 229 (39.6) 241 (28.7) 
Rice intake, g/day 642.8±423.2 646.0±327.6 ** 390.1±428.8 818.4±363.9 
Fish consumer 710 (40.0) 127 (34.6) ** 206 (35.5) 377 (45.5) 
Urbanization     
Low 599 (33.8) 187 (51.0) ** 184 (31.7) 228 (27.5) 
Medium 677 (38.1) 92 (25.1) 228 (39.3) 357 (43.1) 
High 499 (28.1) 88 (24.0) 168 (29.0) 243 (29.4) 
Total physical activity, 
METS/week 240.4±224.1 319.9±296.6 ** 220.2±201.0 219.3±192.1 
Toenail arsenic, µg/g 0.71±4.71 0.29±0.40 ** 0.33±0.25 1.17±6.86 
Tailored Alternate 
Healthy Eating Index 39.2±10.7 40.9±9.9** 40.7±10.9 37.3±10.7 
Baseline Fasting glucose, 
mg/dL 91.9±11.0 88.9±11.7 ** 93.2±10.2 92.3±10.9 
Baseline Hemoglobin 
A1c, % 5.4±0.5 5.4±0.4 ** 5.7±0.4 5.3±0.5 
Follow-up (i.e. 2015) 
Fasting glucose, mg/dL 96.8±16.1 91.6±14.9 ** 97.0±14.7 98.9±17.1 
Follow-up Fasting insulin, 
µU/mL 7.1±4.1 6.8±3.9 * 6.8±3.5 7.5±4.6 
Follow-up Hemoglobin 
A1c, % 5.6±0.6 5.6±0.5 5.6±0.5 5.6±0.6 
Follow-up HOMA2-βsb, 
% 86.8±32.7 93.5±34.8 ** 84.1±28.9 85.7±33.9 
Follow-up HOMA2-IRsc 1.1±0.6 1.0±0.6 1.0±0.5 1.1±0.7 
Follow-up Dysglycemiad     
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Incident Diabetes 117 (6.6) 19 (5.2) ** 28 (4.8) 70 (8.5) 
Incident Prediabetes 802 (45.2) 136 (37.1) 284 (49.0) 382 (46.1) 
Data are n (%), mean±SD, or median (25th-75th percentile) among individuals involved in the complete case 
analysis (N=1775). a Any alcohol consumption ≥once per month. b HOMA2-βs: Specific β-cell function calculated 
by Homeostasis Model Assessment (HOMA2) calculator updated in 2015 (University of Oxford, 
website; http://www.dtu.ox.ac.uk/homacalculator/index.php) based on fasting glucose and fasting insulin, specific 
HOMA2 is suggested when insulin is measured using a chemiluminescent immunoassay. c HOMA2-IRs: Specific 
insulin resistance calculated by HOMA2. d Diabetes: FG≥126mg/dL, or HbA1c≥6.5%, or self-reported diabetes 
diagnosis or medication use. Prediabetes: FG≥110mg/dL to <126mg/dL, or HbA1c≥5.7% to <6.5%. *p<0.10, 
**p<0.05 for differences across regions using one-way analysis of variance (ANOVA), Pearson's chi-square, or 
Kruskal-Wallis test. 
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Figure 4.1. Adjusted Mean (SE) Difference in Follow-up (i.e.2015) Indicators of Glucose Homeostasis Associated 
with Baseline (i.e.2009) iAs Exposure Stratified by Levels of Magnesium (Mg) and Zinc (Zn) Intake among Non-
diabetic Individuals at Baseline  
 
 
Adjusted mean (SE) difference in follow-up fasting glucose and HOMA2-βs associated with baseline iAs exposure 
(i.e. ln-transformed toenail arsenic) among participants with adequate vs. deficient baseline Mg and Zn intake.  
Estimated from linear regression adjusted for the confounders that were identified based on stepwise backward 
selection (p<0.10). The confounders identified in our study include age, sex, weight status, drinking status, physical 
activity level, rice intake, region, daily energy intake, and dietary quality index. *p<0.10, **p<0.05 for differences 
in indicators of glucose homeostasis associated with ln-transformed baseline toenail arsenic. Ƚp<0.10, ǂp<0.05 for 
interactions between baseline Mg or Zn intake (adequate vs. deficient) × baseline iAs exposure (ln-transformed 
toenail arsenic).  
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Table 4.2. Indicators of  Glucose Homeostasis, Characterized by Fasting Glucose, Fasting Insulin, Glycated Hemoglobin, Pancreatic β-cell Function, and Insulin 
Resistance at Follow-up (i.e. 2015), by Intake of Magnesium (Mg) and Zinc (Zn)a at Baseline (i.e. 2009) (Median, 25th, and 75th Percentiles) 
 N % 
Fasting Glucose,  
mg/dL 
Fasting insulin,  
µU/mL 
Hemoglobin A1c,  
% 
HOMA2-βsb,  
% HOMA2-IRsb 
   p50 (p25, p75) p50 (p25, p75) p50 (p25, p75) p50 (p25, p75) p50 (p25, p75) 
All Participants 1775 100 95.0 (87.5, 102.6) 6.0 (4.5, 8.4) 5.5 (5.3, 5.8) 80.0 (63.4, 103.1) 0.9 (0.7, 1.3) 
By Mg intake:             
Adequate Mg  375 21.1 93.6** (86.4, 101.7) 5.9 (4.4, 8.3) 5.5 (5.3, 5.8) 82.4** (65.2, 106.5) 0.9 (0.6, 1.3) 
Deficient Mg  1400 78.9 95.2 (87.7, 103.1) 6.0 (4.5, 8.4) 5.5 (5.3, 5.8) 79.9 (63.1, 102.1) 0.9 (0.7, 1.3) 
By Zn intake:             
Adequate Zn  1181 66.5 94.3** (86.9, 102.2) 6.0 (4.4, 8.5) 5.5 (5.3, 5.8) 80.9** (64.0, 106.0) 0.9 (0.7, 1.3) 
Deficient Zn  594 33.5 96.1 (88.4, 103.5) 5.8 (4.5, 8.1) 5.5 (5.3, 5.8) 78.6 (62.8, 97.5) 0.9 (0.7, 1.2) 
 
a Intakes of Mg and Zn were categorized as Adequate vs. Deficient based on recommended dietary allowances (RDA), details are presented in Supplemental 
Table 4.2. b Specific pancreatic β-cell function (HOMA2-βs) and specific insulin resistance (HOMA2-IRs) calculated by Homeostasis Model Assessment 
(HOMA2) calculator updated in 2015 (University of Oxford, website; http://www.dtu.ox.ac.uk/homacalculator/index.php) based on fasting glucose and fasting 
insulin. Specific HOMA2 is suggested when insulin is measured using a chemiluminescent immunoassay. *P<0.10, **P<0.05 for Kruskall Wallis test for 
differences in indicators of glucose homeostasis among participants with adequate vs. deficient intake of Mg and Zn. Medians were bolded when the Kruskall 
Wallis test reached significance (P < 0.10). 
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Table 4.3. Associations between Deficiency of Magnesium and Zinc Intakea at baseline (i.e.2009) and T2D 
Incidence and Indicators of Glucose Homeostasis at Follow-up (i.e.2015) 
 
Adjusted for age, sex, weight status, 
drinking status, physical activity level, 
rice intake, region, daily energy intake, 
and dietary quality index 
Associations with Baseline Magnesium Deficiency 
Follow-up Fasting glucose, mg/dL -0.04±1.14 
Follow-up Fasting insulin, µU/mL -0.24±0.29 
Follow-up Hemoglobin A1c, % 0.03±0.04 
Follow-up HOMA2-βsd, % -1.91±2.31 
Follow-up HOMA2-IRsd -0.04±0.04 
Dysglycemia  
Incident Diabetes 1.13 (0.69, 1.86) 
Incident Prediabetes 0.97 (0.58, 1.39) 
Associations with Baseline Zinc Deficiency 
Follow-up Fasting glucose, mg/dL 0.82±1.04 
Follow-up Fasting insulin, µU/mL -0.31±0.27 
Follow-up Hemoglobin A1c, % -0.06±0.04 
Follow-up HOMA2-βsd, % -5.18±2.09** 
Follow-up HOMA2-IRsd -0.04±0.04 
Dysglycemia  
Incident Diabetes 0.83 (0.46, 1.51) 
Incident Prediabetes 0.81 (0.44, 1.46) 
 
Results are derived from multivariable-adjusted linear regression (continuous outcomes) or multinomial logistic 
regression (diabetes, prediabetes, vs. neither) models. Adjusted for the confounders that were identified based on 
stepwise backward selection (p<0.10). The confounders identified in our study include age, sex, weight status, 
drinking status, physical activity level, rice intake, region, daily energy intake, and dietary quality index. a Dietary 
intake of Mg and Zn were categorized into deficient vs. adequate intake based on recommended dietary allowances, 
details are presented in Supplemental Table 4.2. b Diabetes: fasting glucose ≥126mg/dL, or HbA1c≥6.5%, or self-
reported diabetes diagnosis or medication use. Prediabetes: fasting glucose≥110mg/dL to <126mg/dL, or 
HbA1c≥5.7% to <6.5%. c Obesity status defined as Underweight: BMI<18kg/m2; Normal weight: BMI≥23.0 to 
<27.5kg/m2; Obese: BMI≥27.5kg/m2. d Specific pancreatic β-cell function (HOMA2-βs) and specific insulin 
resistance (HOMA2-IRs) calculated by Homeostasis Model Assessment (HOMA2) calculator updated in 2015 
(University of Oxford, website; http://www.dtu.ox.ac.uk/homacalculator/index.php) based on fasting glucose and 
fasting insulin. *p<0.10, **p<0.05 for coefficients of associations between dietary intake of Mg and Zn and 
development of diabetes. Coefficients were bolded when they reached significance (P < 0.10).
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Table 4.4. Estimated Joint Associations of Inorganic Arsenic (iAs) Exposurea at Baseline (i.e.2009) and Dietary 
Intake of Magnesium (Mg) and Zinc (Zn)b at Baseline on Measures of Diabetesc Development at Follow-up 
(i.e.2015) 
  Follow-up Measures 
 N 
Fasting glucose, 
mg/dL 
HOMA2-βs, 
% 
Estimated Joint associations of Baseline Mg intake and iAs exposure  
Adeq Mg+Tertile1 Asc  148 ref ref 
Adeq Mg+Tertile2 As  123 0.51±2.29 -2.18±3.72 
Adeq Mg+Tertile3 As  108 2.92±1.42** -2.52±3.52 
Def Mg+Tertile1 As  444 0.47±1.67 -1.16±3.37 
Def Mg+Tertile2 As  468 1.32±1.58 -2.14±3.42 
Def Mg+Tertile3 As  488 3.72±1.88** -5.18±2.43** 
Estimated Joint associations of Baseline Zn intake and iAs exposure  
Adeq Zn+Tertile1 As  392 ref ref 
Adeq Zn+Tertile2 As  394 0.72±1.33 -2.02±2.69 
Adeq Zn+Tertile3 As  399 3.25±1.62** -3.88±3.37 
Def Zn+Tertile1 As  200 1.81±1.56 -5.64±3.48 
Def Zn+Tertile2 As  197 2.39±1.55 -6.27±3.12** 
Def Zn+Tertile3 As  197 3.48±1.52** -8.50±3.14** 
 
Results (Mean±SE) are derived from multivariable-adjusted linear regression (continuous outcomes) or multinomial 
logistic regression (diabetes, prediabetes, vs. neither) models. Adjusted for the confounders that were identified 
based on stepwise backward selection (p<0.10). The confounders identified in our study include age, sex, weight 
status, drinking status, physical activity level, rice intake, region, daily energy intake, and dietary quality index. a 
Baseline iAs exposure was captured by toenail arsenic and categorized into tertiles. b Dietary intake of Magnesium 
(Mg) and zinc (Zn) were categorized into deficient (Def) vs. adequate (Adeq) based on Recommended Dietary 
Allowances (RDA), details are presented in Supplemental Table 4.2. c Diabetes: FG≥126mg/dL, or HbA1c≥6.5%, or 
self-reported diabetes diagnosis or medication use. Prediabetes: FG≥110mg/dL to <126mg/dL, or HbA1c≥5.7% to 
<6.5%. *p<0.10, **p<0.05 for adjusted means difference in development of diabetes relative to participants with 
lowest tertile of iAs exposure and adequate intake of Mg and Zn at baseline. Coefficients were bolded when they 
reached significance (P < 0.10). 
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Supplemental Table 4.1. Characteristics of Study Participants by Concentrations of Toenail Arsenic, China Health 
and Nutrition Survey 
  Toenail arsenic tertiles (µg/g) at 2009 
Characteristic 
All 
participants <0.23 
≥0.23 and 
<0.44 >0.44 
Total n 1775 589 594 592 
Baseline (i.e.2009) characteristics   
Age, years 49.7±11.3 49.4±11.4 49.7±11.0 50.1±11.5 
Men 747 (42.1) 231 (39.2) 253 (42.6) 263 (44.4) 
Body mass index, kg/m2      
23.0-27.4 787 (44.3) 227 (38.5) ** 257 (43.3) 303 (51.2) 
≥27.5 756 (42.6) 257 (43.6) 271 (45.6) 228 (38.5) 
Smoking     
Current 416 (23.4) 129 (21.9) 156 (26.3) 131 (22.1) 
Former 50 (2.8) 15 (2.5) 17 (2.9) 18 (3.0) 
Drinking statusa 468 (26.4) 157 (26.7) 163 (27.4) 148 (25.0) 
Total energy intake, 
kcal/day 2186.6±639.2 2170.5±641.8 2199.8±629.8 2189.4±646.8 
Magnesium intake, mg/day 298.1±106.6 309.2±114.8 ** 295.8±99.4 289.5±104.3 
Magnesium deficiency 1400 (78.9) 444 (75.5) ** 468 (79.2) 488 (81.8) 
Zinc intake, mg/day 10.9±3.5 10.8±3.6 11.0±3.4 11.0±3.4 
Zinc deficiency 594 (33.5) 200 (34.0) 197 (33.3) 197 (32.6) 
Rice intake, g/day 642.8±423.2 517.1±381.1 ** 678.4±428.1 732.1±429.3 
Recent fish consumer 710 (40.0) 225 (38.2) * 260 (43.8) 225 (38.0) 
Urbanization     
Low 599 (33.8) 147 (25.0) ** 233 (39.2) 219 (37.0) 
Medium 677 (38.1) 227 (38.5) 193 (32.5) 257 (43.4) 
High 499 (28.1) 215 (36.5) 168 (28.3) 116 (19.6) 
Total physical activity, 
METS/week 240.4±224.1 215.9±215.2 ** 241.9±222.8 263.2±231.7 
Region     
North 367 (20.7) 204 (34.6) ** 106 (17.9) 57 (9.6) 
Central 580 (32.7) 263 (44.7) 200 (33.7) 117 (19.8) 
South 828 (46.7) 122 (20.7) 288 (48.5) 418 (70.6) 
Toenail arsenic, µg/g 0.71±4.71 0.14±0.07 ** 0.33±0.06 1.68±8.07 
Tailored Alternate Healthy 
Eating Index 39.2±10.7 40.3±10.8** 39.4±10.6 38.0±10.7 
Baseline Fasting glucose, 
mg/dL 91.9±11.0 91.4±11.0 91.7±10.9 92.5±10.9 
Baseline Hemoglobin A1c, 
% 5.4±0.5 5.5±0.4 ** 5.4±0.5 5.3±0.5 
Follow-up (i.e.2015) Fasting 
glucose, mg/dL  96.8±16.1 95.1±16.0 ** 96.5±14.5 98.6±17.5 
Follow-up Fasting insulin, 
µU/mL 7.1±4.1 7.1±3.8 7.1±4.1 7.2±4.4 
Follow-up Hemoglobin 
A1c, % 5.6±0.6 5.6±0.5 5.6±0.6 5.6±0.6 
Follow-up HOMA2-βs, %b 86.8±32.7 89.8±32.5 ** 86.7±32.8 83.8±32.7 
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Follow-up HOMA2-IRsc 1.1±0.6 1.1±0.6 1.1±0.6 1.1±0.7 
Follow-up Dysglycemiad     
Incident Diabetes 117 (6.6) 31 (5.3) 46 (7.7) 40 (6.8) 
Incident Prediabetes 802 (45.2) 253 (43.0) 260 (43.8) 289 (48.8) 
Data are n (%), mean±SD, or median (25th-75th percentile) among individuals involved in the complete case 
analysis (N=1775). a Any alcohol consumption ≥once per month. b HOMA2-βs: Specific β-cell function calculated 
by Homeostasis Model Assessment (HOMA2) calculator updated in 2015 (University of Oxford, 
website; http://www.dtu.ox.ac.uk/homacalculator/index.php) based on fasting glucose and fasting insulin, specific 
HOMA2 is suggested when insulin is measured using a chemiluminescent immunoassay. c HOMA2-IRs: Specific 
insulin resistance calculated by HOMA2. d Diabetes: FG≥126mg/dL, or HbA1c≥6.5%, or self-reported diabetes 
diagnosis or medication use. Prediabetes: FG≥110mg/dL to <126mg/dL, or HbA1c≥5.7% to <6.5%. *p<0.10, 
**p<0.05 for differences across tertiles of toenail arsenic using one-way analysis of variance (ANOVA), Pearson's 
chi-square, or Kruskal-Wallis test.
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Supplemental Table 4.2. Recommended Daily Allowances (RDA) for Magnesium (Mg) and Zinc (Zn) 
Age Men Women 
 Mg Zn Mg Zn 
19–30 years 400mg 11mg 310mg 8mg 
≥31 years  420mg 11mg 320mg 8mg 
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Supplemental Table 4.3. Comparison of Baseline (i.e.2009) Magnesium (Mg) and Zinc (Zn) Intake among Participants with vs. without Prediabetes and Diabetes 
at Follow-up (i.e. 2015) 
 Follow-up Measures 
 Non-diabetic individuals Pre-diabetes Diabetes 
 Median p25, p75 Median p25, p75 Median p25, p75 
2009 Mg intake 283.1 234.2, 353.4 279.7 225.4, 348.5 289.7 226.1, 345.5 
2009 Zn intake 10.4 8.6, 12.9 10.4 8.4, 12.9 11 8.9, 13.3 
*P<0.10, **P<0.05 for differences in baseline Mg and Zn intake among participants with vs. without prediabetes and diabetes at follow-up based on Kruskal-
Wallis test.  
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Supplemental Table 4.4. Interactions between ln-transformed Toenail Arsenic at Baseline (i.e.2009) and Deficiency of Magnesium (Mg) and Zinc (Zn) Intakea at 
Baseline for Measures of Diabetes Development at Follow-up (i.e.2015) Based on Multivariable-adjusted Linear Regression or Multinomial Logistic Regression 
Models 
 
 Follow-up Measures 
 Fasting 
Glucose 
Fasting Insulin HbA1c HOMA2-βs HOMA2-IRs Prediabetes Diabetes 
Baseline Mg -0.24±0.83 -0.30±0.21 0.02±0.03 -1.87±1.68 -0.05±0.03 0.06±0.12 0.03±0.24 
Baseline Zn -0.37±0.71 0.20±0.18 0.03±0.02 2.86±1.44** 0.03±0.03 0.08±0.10 0.05±0.20 
 
Results are derived from multivariable-adjusted linear regression (continuous outcomes) or multinomial logistic regression (diabetes, prediabetes, vs. neither) 
models. Adjusted for the confounders that were identified based on stepwise backward selection (p<0.10). The confounders identified in our study include age, 
sex, weight status, drinking status, physical activity level, rice intake, region, daily energy intake, and dietary quality index. a Deficiency of baseline Mg and Zn 
intake was defined based on US Recommended Dietary Allowances (Supplemental Table 4.2). *p<0.10, **p<0.05 for significance of interaction between ln-
transformed toenail arsenic× deficiency of baseline Mg and Zn intake.  
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CHAPTER 5. ASSOCIATION BETWEEN VARIANTS IN ARSENIC (+3 OXIDATION 
STATE) METHYLTRANSFERASE (AS3MT) AND URINARY METABOLITES OF 
INORGANIC ARSENIC: ROLE OF EXPOSURE LEVEL60 
 
Overview 
Variants in AS3MT, the gene encoding arsenic (+3 oxidation state) methyltranserase, 
have been shown to influence patterns of inorganic arsenic (iAs) metabolism. Several studies 
have suggested that capacity to metabolize iAs may vary depending on levels of iAs exposure, 
with shifts in the proportions of different iAs metabolites in urine reported when levels of 
inorganic As in drinking water exceed 50 ppb. However, it is not known whether the influence of 
variants in AS3MT on iAs metabolism may also vary by level of exposure. We investigated, in a 
population of Mexican adults exposed to drinking water As, whether associations between seven 
candidate variants in AS3MT and urinary iAs metabolites were consistent with prior studies, and 
whether these associations varied depending on the level of exposure. Overall, associations 
between urinary measures of iAs metabolism and AS3MT variants were consistent with the 
literature. Referent genotypes, defined as the genotype previously associated with a higher 
percentage of urinary dimethylated As (DMAs%), were associated with significant increases in 
the DMAs% and in the ratio of DMAs to monomethylated As (MAs), and significant reductions 
in MAs% and iAs%. For three variants, associations with between genotypes and measures of 
iAs metabolism were significantly stronger among subjects exposed to water As >50 vs. ≤50 ppb 
(water As X genotype interaction P<0.05). For example, for rs10748835, the multivariable-
adjusted mean (SE) reduction in DMAs/MAs associated with having polymorphisms other than 
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the referent genotype was -2.2 (0.8) vs. -0.4 (0.4) among highly vs. less exposed participants.  In 
contrast, for one variant (rs17881215), associations were significantly stronger at exposures ≤50 
ppb. Results suggest that iAs exposure may influence the extent to which several AS3MT 
variants affect iAs metabolism. The variants most strongly associated with iAs metabolism—and 
perhaps with susceptibility to iAs-associated disease—may vary in settings with lower vs. higher 
exposure.   
Introduction:  
Chronic exposure to inorganic arsenic (iAs) has been associated with increased risk of 
several types of cancer, with a substantial literature suggesting iAs exposure may also be 
associated with other health outcomes, including cardiovascular diseases and diabetes16,57,90,207. 
There are multiple sources of exposure to iAs, including contaminated drinking water, food, soil, 
and air, as well as occupational settings16. Contaminated drinking water is a common source of 
high exposure, and is a widespread public health problem, estimated to affect around 140 million 
people worldwide16,213. There is growing evidence that, along with levels of exposure to iAs, 
inter-individual variation in the capacity to metabolize iAs is an important determinant of 
toxicity, and thus of health risks related to this exposure89,214. Using measures of proportions of 
iAs metabolites in urine, which have been postulated to reflect capacity to metabolize iAs, 
numerous studies suggest that individual variation in patterns of iAs metabolism may influence 
susceptibility to adverse health outcomes among subjects exposed to iAs in drinking water81,82, 
or may be directly associated with health risks51,80,87,214,215.  Although the indicators of iAs 
metabolism most strongly related to risk have varied, associations between measures of iAs 
metabolism and health risks have been reported in settings with widely varying levels of iAs 
exposure80-82,87,196,216.   
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In humans, the primary pathway for metabolism of iAs involves sequential methylation 
to form monomethylated As (MAs) and dimethylated As (DMAs) metabolites, which are 
excreted in the urine31. Higher percentages of total urinary As represented by DMAs (DMAs%), 
and lower percentages of MAs or the unmethylated iAs (MAs% and iAs%, respectively) in urine 
have been hypothesized to be indicators of higher capacity to metabolize iAs31,78,79. The ratios of 
MAs to iAs (MAs/iAs) and of DMAs to MAs (DMAs/MAs) in urine have also been widely used 
as indicators of capacity for the first and second methylation steps. However, the measures of 
iAs metabolism most predictive of increased health risks remain to be established, given the 
conflicting associations reported in recent studies 31,80-83. 
Arsenic (+3 oxidation state) methyltrasferase (AS3MT) is a key enzyme in the pathway 
for the methylation of iAs, and variants in the AS3MT have been shown to be associated with 
inter-individual differences in iAs metabolism 32-35,84,85. Previous studies have linked 
polymorphic sites in this gene to significant differences in urinary measures of iAs metabolism in 
various populations 32-35,84,86. It has been suggested that iAs exposure level may modify iAs 
metabolism, as reflected by changes in urinary As methylation profiles, with a shift in the 
proportions of urinary metabolites among persons exposed to levels approximately >50ppb vs. 
≤50ppb 85,87-89. We have previously reported based on laboratory experiments that levels and 
proportions of the methylated products, including DMAs/MAs ratio, differ between recombinant 
variants of human AS3MT and depend on the substrate concentration 36. However, to our 
knowledge, no population study has formally explored to what extent associations between 
AS3MT variants and measures of iAs metabolism may vary depending on levels of iAs exposure. 
Such heterogeneity, if present, could lead to inconsistencies across populations with varying iAs 
  
81 
 
exposure in the extent to which genetic variants either relate to measures of iAs metabolism, or 
modify health risks associated with environmental iAs exposure.  
The aims of this study were to examine the consistency of previously established 
associations between multiple AS3MT variants and the profiles of urinary iAs metabolites in a 
population with substantial variability in exposure, and to assess evidence of heterogeneity in the 
magnitude of these associations depending on the extent to which subjects are exposed to iAs in 
drinking water. 
Method 
Study population. Participants were originally recruited for a cross-sectional study on the 
association of iAs exposure with prevalence of diabetes mellitus in Chihuahua, Mexico, which 
has been described previously 81. Briefly, in the parent study, a total of 1160 adults were 
recruited with a minimum of five year uninterrupted residency in the area. Pregnant women, 
subjects with urinary tract infection, and individuals with potential occupational exposure to iAs 
(e.g. those working with pesticides or in mines or smelters) were excluded since these conditions 
affect the urinary profiles of iAs metabolites. Participants provided samples of household 
drinking water and spot urine samples in which As metabolites were measured, and interviewer-
administered questionnaires were used to collect a wide array of information on factors including 
health status (including diagnosed diabetes), use of medications, smoking, use of alcohol. 
Physical exams included an oral glucose tolerance test (OGTT) for detecting undiagnosed 
diabetes, as well as measures of weight, height, body mass index (BMI), waist and hip 
circumferences, blood pressure, and skin lesions associated with iAs exposure. For use in 
sensitivity analyses exploring effects of diabetes, subjects were classified as having diabetes 
based on fasting plasma glucose (FPG≥126mg/dL) or two-hour post OGTT glucose 
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(2HPG≥200mg/dL), or on self-reported diagnosis or use of diabetes medication 217,218. All 
subjects provided signed informed consent, and the study was approved by the Institutional 
Review Boards of UNC-Chapel Hill and the Centro de Investigación y de Estudios Avanzados of 
the Instituto Politécnico Nacional in Mexico City.  
Measurements of water and urinary As. The analyses of As in water and urines were 
described in detail in the parent study 81. Drinking water was collected in subjects’ homes, and 
the concentration of iAs in these water samples was measured by hydride generation (HG)-
cryotrapping (CT)-atomic absorption spectrometry (AAS) 219. Spot urine samples were collected 
during morning medical exams as described previously 220. Concentrations of iAs, MAs and 
DMAs in spot urine were measured by HG-CT-AAS. Certified standard reference materials 
(SRMs) from the inter-laboratory comparison program in Quebec and the SRM 2669 (Arsenic 
Species in Frozen Human Urine) from National Institute of Standards & Technology were used 
as quality controls.  
The limit of detection (LOD) for iAs in water as well As species in urine was 0.01 μg 
As/L. Concentrations of water iAs and urinary As species which were below LOD (1.9% for 
water iAs, 1.6% for urinary iAs) were imputed at LOD/2. Total speciated As in urine (tAs) was 
calculated as sum of the inorganic arsenic species iAs, MAs and DMAs. iAs metabolism was 
characterized using measures recommended in the literature 221,222, namely percentages of each 
iAs metabolite (DMAs%, MAs%, iAs%), as well as the ratios of MAs/iAs (also known as the 
primary methylation index) and DMAs/MAs (the secondary methylation index) in urine.  
Genotyping. DNA was isolated from venous blood collected in the OGTT using the 
QIAamp DNA Blood Mini Kit (Qiagen) according to the manufacturer’s protocol. We reviewed 
the available literature to look for candidate AS3MT variants associated with urinary As profiles. 
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Nine AS3MT variants linked to differences in iAs metabolism or susceptibility to iAs toxicity 
were identified for analysis in this study based on literature published through April 2011 37-
39,84,197,219,222-227. These AS3MT variants included eight single nucleotide polymorphisms (SNPs), 
rs35232887 (Arg173Trp), rs34556438 (Thr306lle), rs11191439 (Met287Thr), rs17881215 
(G4965C), rs3740393 (G12390C), rs3740390 (C14215T), rs11191453 (T35587C), rs10748835 
(G35991A), and three variable number of tandem repeats (VNTR) variants, AB, A2B, and A3B. 
The AS3MT variants were analyzed either in the Mammalian Genotyping Core (UNC, Chapel 
Hill, NC, USA) or in our laboratory, using predesigned or custom TaqMan assays (Applied 
Biosystems, Carlsbad, CA, USA). The ABI Dual 384-Well GeneAmp PCR System 9700 and 
ABI PRISM 7900HT Sequence Detection System from Applied Biosystems was used for 
genotyping and the ABI SDS software for data analysis. VNTR variants and rs17881215 were 
identified by sequencing a PCR-amplified promoter region.  
Due to funding constraints, samples for a random subset of approximately half the 
subjects in the full sample were sent to the Mammalian Genotyping Core (N=543). 
Subsequently, an additional random sample was analyzed for rs17881215 and VNTR in our 
laboratory. Due to genotyping failure, the analysis sample available for each variant measured in 
the core facility varied in size from N=500 (for rs10748835) to N=506 (for rs3740393), with 
N=715 available for rs17881215 and VNTR. 772 subjects had data on at least one candidate 
genetic marker along with measures of water As, iAs metabolism, age and gender.  In addition to 
our primary analyses in the maximum sample with available data for each variant, we analyzed 
associations in a sample limited to subjects with data available for all candidate variants (N=483) 
to confirm that effects were not affected by varied sample size; results were not meaningfully 
different (Supplemental Tables 5.1). 
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Statistical analysis. We estimated associations between candidate variants in AS3MT and 
each measure of iAs metabolism described above. In all analyses, we defined the variant 
previously reported to be associated with a higher DMAs% as the referent genotype in order to 
facilitate comparisons with existing literature. Genotype frequencies were estimated and tested 
for departure from Hardy-Weinberg equilibrium (HWE) by calculating pairwise r2 coefficients 
between variants.  
To determine whether candidate AS3MT variants were related to biomarker estimates of 
overall iAs exposure vs. to measures of iAs metabolism, we first compared median (25th, 75th 
percentile) tAs, as well as each indicator of iAs metabolism, across allelic variants. Medians 
were used rather than means given the highly non-normal distribution of tAs (Shapiro-Wilk 
P<0.01). The non-parametric Kruskall-Wallis test was used to identify statistically significant 
differences in each As measure across genotypes for each polymorphism. For all analyses, P 
<0.10 was used a priori to define marginal significance and P<0.05 to define significance, given 
the moderate sample size. We further evaluated associations between AS3MT genotypes and 
indicators of metabolism using multiple linear regression models adjusting for age and gender, 
which are known to influence iAs metabolism 223,228-230. Coefficients from these models 
estimated the mean differences in each measure of iAs metabolism among different genotypes of 
each variant, adjusting for age and sex.  
Next, we explored whether associations between AS3MT variants and iAs metabolism 
appeared to vary depending on levels of exposure. To identify AS3MT variants for which 
associations with measures of iAs metabolism differed significantly with changes in the 
concentration of drinking water As, we tested the significance of polymorphism x water As 
interactions in age- and sex-adjusted linear regression models using global F tests. Based on 
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previous literature, interactions were tested defining high vs. low water As exposure with a 
cutoff of 50ppb, close to the sample median of 48.64 ppb.  Age- and sex-adjusted models were 
also run stratified by higher vs. lower water As to compare the magnitude of associations 
between AS3MT variants and measures of iAs metabolism among individuals more vs. less 
exposed, regardless of the significance of interactions.   
In addition to sensitivity analyses to evaluate the influence of varying sample size 
described above, we compared the associations between urinary As profiles and AS3MT variants 
before and after adjusting for or excluding persons with diabetes; results did not differ 
meaningfully (Supplemental Tables 5.2). Additionally, because numerous epidemiological 
studies have shown that BMI may influence the metabolism of iAs 105-107,153, we evaluated the 
impact of adjusting for BMI; again, results did not differ meaningfully (data not shown). 
Similarly, additionally adjusting for either total water As or urinary tAs had no meaningful effect 
(data not shown).  Statistical analysis was performed using STATA version 13 (Stata 
Corporation, College Station, TX) except Global F test for the polymorphism x water As 
interactions, which was performed with PROC GLM in SAS, version 9.4 (SAS Institute, Inc., 
Cary, North Carolina). 
Results:  
Characteristics of the population and AS3MT genotype frequencies.   
After excluding subjects with missing data on urinary As species, age, or gender (N=42), 
there were 772 individuals (520 females, 252 males) with available information on at least one 
candidate variant. Exposure to water As varied substantially, with a median (25th – 75th 
percentile) of 48.6 (37.1 – 74.1) ppb and range of 0.01ppb to 419.77ppb. Of the 9 initial 
candidate AS3MT variants, two SNPs (rs35232887 and rs34556438) had a very low frequency 
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(N<5) for the non-wildtype genotypes and were not used for further analysis. Genotype 
frequencies varied substantially for all other variants (Table 5.1). Three pairs of SNPs—
rs11191439 and rs17881215, rs3740393 and rs3740390, rs3740390 and rs11191453—were in 
linkage disequilibrium with r2>0.8. The referent genotype—which we defined as the genotype 
associated with a higher DMAs% in previously published studies—corresponded to the wildtype 
(based on global genotype frequency reports from National Center for Biotechnology 
Information) for only two SNPs (rs11191439 and rs17881215, highly correlated with each other) 
(Table 5.1). For rs11191453, since there was no observation in our sample with the homozygous 
variant (CC) previously associated with the highest DMAs%, we used the heterozygous variant 
(TC) as the referent. For VNTR, as only N=1 subject had the true referent genotype A3B, we 
defined A2B, which was also associated with a higher DMAs% 33,84, as the referent. A3B was 
excluded from further analyses due to low frequency (N=1).   
Urinary measures of arsenic metabolism varied substantially with variants. 
Table 5.1 also shows the median (25th, 75th percentile) of each measure of iAs 
metabolism—DMAs%, MAs%, iAs%, DMAs/MAs, and MAs/iAs—overall and stratified by 
genotypes of each AS3MT variant. Values for the percentages and ratios of urinary metabolites 
were consistent with the full study population81. The median (25th, 75th percentiles) for tAs, 
DMAs%, MAs%, iAs%, DMAs/MAs, and MAs/iAs were 62.9µg/L (34.2µg/L, 108.4µg/L), 
76.9% (71.3%, 81.4%), 13.9% (10.9%, 17.4%), 8.8% (6.3%, 12.2%), 5.5 (4.2, 7.4), and 1.6 (1.2, 
2.1), respectively. Water As was significantly positively correlated with urinary tAs (Spearman's 
R =0.23, P<0.01).  
In descriptive analysis, no significant difference in tAs was observed across genotypes 
for any of the seven candidate variants (P>0.10; Table 5.1). Descriptive analyses also showed 
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that consistent with prior literature, the referent genotype was associated with increases in the 
DMAs% for all seven candidate markers. These differences were significant (P<0.05) for five 
variants, and marginally significant for two (VNTR and rs10748835, P<0.10).  The five variants 
associated with significant increases in the DMAs% were also associated with significant 
reductions in the MAs% (P<0.05); VNTR and rs10748835 were associated with small but non-
significant reductions in this measure. Similarly, the DMAs/MAs ratio was significantly higher 
among participants with the referent genotype for six variants, the exception being VNTR. There 
was a reduction in iAs% observed for the referent genotypes for six of the candidate markers 
examined, although differences were at least of marginally significance for only three variants. 
The exception to this pattern, rs3740393, showed lower iAs% for the heterozygous (GC) instead 
of referent homozygous (CC) genotype. In contrast to the patterns observed for all other 
measures of iAs metabolism, there were no clear pattern and no significant differences in the 
MAs/iAs ratio across genotypes in any of the candidate variants.  
Adjusted mean differences in urinary measures of iAs metabolism associated with having 
polymorphisms other than the referent genotypes are shown in Table 5.2, based on multivariable 
linear models adjusted for age and gender. Results were similar to descriptive analyses. Having 
non-referent genotypes was associated with significant (P<0.05) decreases in the DMAs% for at 
least one genotype in all seven variants, significant increases in the MAs% for five variants, and 
marginally significant increases (P<0.10) in the MAs% for rs10748835 and VNTR. Excluding 
some genotypes with very small cell sizes (N<5), the five SNPs significantly associated with 
these measures of iAs metabolism (rs3740390 and two correlated SNPs rs3740393 and 
rs11191453; rs17881215 and the correlated SNP rs11191439) were associated with the largest 
adjusted mean differences in both DMAs% (from 3.3±0.7% to 4.6±2.2%) and MAs% (from 
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1.8±0.5% to 3.9±1.4%), with smaller differences associated with polymorphisms in rs10748835 
and VNTR.  
Significant differences in measures of iAs metabolism associated with genetic 
polymorphisms were most notable for the DMAs/MAs ratio. Compared to the referent genotype, 
all other genotypes in each variant were associated with at least marginally significant (P<0.10) 
differences in DMAs/MAs with only two exceptions: the homozygous variant of rs11191439, for 
which the cell size was small (N=3), and polymorphisms in VNTR, for which the association 
was null. The magnitude of association with DMAs/MAs was strongest—a >2-unit change—for 
variants in rs3740393 and the correlated SNP rs3740390, with the weakest associations—of 
about half this magnitude—for rs10748835.  Like the descriptive analyses, few variants (n=3) 
were significantly associated with the iAs%, and none with the MAs/iAs ratio, after 
multivariable adjustment.  
Associations between AS3MT variants and urinary measures of iAs metabolism among 
subjects with higher versus lower exposure to drinking water As.  
There were interactions between elevated (>50ppb) exposure to water As and several 
genetic variants, suggesting that the degree to which genotype in these variants influence patterns 
of iAs metabolism may vary with increasing exposure. Interactions were significant primarily for 
the DMAs/MAs ratio (P<0.05 for three variants: the correlated SNPS rs3740390 and rs3740393, 
as well as rs10748835; Figures 5.1c, Supplemental Table 5.3). There were also marginal 
significant (P<0.10) interactions between exposure level and one variant (rs17881215) for the 
DMAs% and MAs%.  
As shown in Figure 5.1c, the decline in the DMAs/MAs ratio associated with having 
genotypes other than the referent was considerably as well as significantly larger among more vs. 
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less highly exposed individuals for three SNPs:  rs3740390, the correlated SNP rs3740393, and 
rs10748835 (see also Supplemental Table 5.4). In the sample as a whole, the magnitude of 
associations with the DMA/MAs ratio were strongest for the first two SNPs. However, except for 
the null relationship with VNTR, this last SNP—rs10748835—was the variant most weakly 
associated with the DMAs/MAs in the overall sample. Though interactions did not reach 
significance, the magnitude of associations with polymorphisms in rs10748835 and both the 
DMAs% and MAs% were more than two times larger among highly vs. more moderately 
exposed individuals (Figures 5.1a and 1b, Supplemental Table 5.4).   
In contrast to the stronger associations seen at higher levels of exposure for these three 
variants, for polymorphisms in rs17881215 the magnitude of association with both the DMAs% 
and MAs% was marginally significantly weaker at higher exposure (P<0.10; Figures 5.1a and 
1b, Supplemental Tables 5.3 and 5.4). There was, however, no difference in the magnitude of 
association between polymorphisms in this SNP and the DMAs/MAs ratio at high vs. low levels 
of exposure.  
In models predicting variation in the iAs% and the MAs/iAs ratio, no significant effect 
modification by water As was observed. However, for both outcomes, the magnitude of 
associations appeared to vary depending on the level of water As exposure for polymorphisms 
that included both rs10748835 and rs17881215, for which interactions reached significance for 
other measures (Supplemental Table 5.4, Figure 5.1d and 1e).  
In sensitivity analyses exploring the effects of additionally adjusting for diabetes 
(Supplemental Table 5.2), or for BMI, urinary tAs and water As (not shown), there were no 
meaningful differences in results.  
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Discussion  
Inter-individual variation in urinary measures of iAs metabolism has been associated with 
the risk of adverse health outcomes associated with iAs exposure 51,81,89,214, indicating that factors 
influencing metabolism may affect susceptibility to disease. There is growing evidence—
including a recent review—that a number of candidate variants in AS3MT affect iAs metabolism 
32-35,84,85. At present, evidence on the consistency with which these variants relate to markers of 
metabolism across populations is limited and mixed, perhaps in part due to the small sample size 
and modest power in most previous studies (N<300)33,40. Moreover, although it has been 
suggested that the extent to which some variants influence iAs metabolism might be stronger 
among subjects more highly exposed to iAs 89, to our knowledge, studies have yet to formally 
explore such heterogeneity. In this study, we aimed to confirm relationships between seven 
candidate AS3MT variants and urinary markers of iAs metabolism 32,37,40,84,216,219,223-226,231,232, and 
examine the extent to which these associations may vary depending on the level of exposure to 
drinking water As.  
In this study, genotypes associated with a higher DMAs% in previous studies were 
consistently associated with significantly higher DMAs%, DMAs/MAs and lower MAs%; 
almost all associations were at least marginally significant at P<0.10. Reference genotypes also 
tended to be associated with a lower iAs%, though these relationships were largely not 
significant. However, associations with the ratio of MAs to iAs, which has been used as an 
indicator of the efficiency of the first methylation step, were consistently non-significant, and 
varied considerably in terms of direction and magnitude. 
We found significant interactions between four of the seven candidate AS3MT variants 
and concentrations of As in drinking water. Three SNPs (rs3740393, rs3740390, and 
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rs10748835) had somewhat stronger associations with indicators of iAs metabolism among 
individuals exposed to higher vs. lower levels of As in drinking water, with significant 
differences in the magnitude of association for the  DMAs/MAs ratio. In contrast, one SNP 
(rs17881215) was more strongly associated with two markers of iAs metabolism—the DMAs% 
and MAs%—among participants with lower rather than with higher exposure. This suggests that 
the genetic variants most influential for aspects of iAs metabolism may vary across populations, 
depending on prevailing levels of exposure. This finding also suggests the possibility that the 
variants most influential for modifying health risks may differ in more highly exposed 
populations than in settings with low exposure. Though earlier studies, to the best of our 
knowledge, have not formally examined whether the degree of exposure to iAs may modify the 
influence of AS3MT variants on iAs metabolism, prior literature has suggested that patterns of 
metabolism may vary by level of exposure 88,228,230,233,234. Several studies have suggested that at 
exposures exceeding 50 ppb, there may be an increase in the MAs% in urine and decrease in 
DMAs%, perhaps due to saturated capacity for the secondary methylation step or the inhibition 
of AS3MT activity by high levels of iAs 88,228. At these higher exposures, genetic variants may 
be either more, or less, influential on iAs metabolism. However, in our sample, we did not 
observe meaningful differences in urinary As profiles between groups exposed to higher (≥50 
ppb) vs. lower concentrations of water As in our study. The median (25th, 75th percentile) for 
more vs. less exposed groups were 77.2% (71.4%, 81.8%) vs. 76.5% (70.9%, 81.2%), 14.0% 
(11.1%, 17.4%) vs. 13.6% (10.9%. 17.4%), and 5.4 (4.2, 7.3) vs. 5.6 (4.2, 7.4) for DMAs%, 
MAs% and DMAs/MAs accordingly (Kruskall-Wallis P>0.10 for all pairwise comparisons). 
Interactions between AS3MT variants and levels of exposure (i.e. water iAs) did not 
depend on the magnitude of the association between those variants and urinary iAs profiles in the 
  
92 
 
overall population. For example, in the population as a whole, polymorphisms in rs10748835 
were much more weakly associated with urinary iAs metabolites than those in rs3740393. 
However, there were significant differences in the magnitude of association with the 
DMAs/MAs ratio among participants with high vs. low exposure for both variants.  
In our analyses, the referent genotype, defined as the one previously associated with a 
higher DMAs%--and postulated to be associated as well with a higher DMAs/MAs, lower 
MAs% and lower iAs%-- was not always the major (i.e. most frequent) genotypes in our sample.  
Indeed, the postulated beneficial referent genotype was the major genotype for only rs11191439 
and rs17881215. However, defining the referent genotype based on the hypothesized direction of 
association facilitated comparisons with previous literature.  
It is unclear what the implications of the AS3MT variant-iAs metabolism associations are 
for health of iAs-exposed individuals. Based on previous literature, the relevance of a high vs. 
low DMAs%, MAs% or DMAs/MAs ratio for health risks is uncertain, and may depend on the 
level of exposure. Several studies in high exposure settings have found a high MAs% to be 
associated with increased risk of cancer and other health outcomes, including cardiovascular 
diseases and diabetes 39,87,196,197. However, numerous studies in settings with more moderate 
exposure have reported a higher DMAs% to be associated with increased risk of diabetes and 
other cardiometabolic outcomes 80-83. The conflicting results for the associations between urinary 
iAs methylation profiles and health outcomes may be due to differences in the distribution of 
trivalent and pentavalent methylated metabolites (MAsIII vs. MAsV; DMAsIII vs. DMAsV) 
which exhibit different toxicities in laboratory models 39,79,80,83,235-238. However, differentiating 
between the trivalent and pentavalent As species in urine is technically challenging and is rarely 
implemented in population studies 239. Therefore, analyses performed in most population studies, 
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including the present study, are typically limited to measurements of total iAs, MAs and DMAs, 
and the percentages and ratios of these metabolites in urine.  
This study was conducted in the Chihuahua area of Mexico, with moderately elevated 
levels of iAs in drinking water (median concentration of 48.6 ppb). Many previous studies have 
been conducted in areas with substantially higher exposure 90 (e.g. water iAs exposure level for 
studies done in Bangladesh is likely to be between 100 and 200 ppb 82,87,233,240). Thus there is 
uncertainty regarding the health effects of more moderate levels of iAs exposure, and the 
influence of genetic polymorphisms on iAs metabolism and toxicity, in areas with moderate 
exposure, which are more typical population exposures around the world. The range of exposure 
in this Chihuahua cohort—with nearly 50% of subjects at levels below 50 ppb—enabled us to 
analyze interactions between AS3MT variants in the moderate range of water As exposure at 
which some studies have suggested iAs metabolism may shift 88,228.  
 A limitation of this study is that, although the sample size was larger than in many 
previous studies33,37,40,223,224, we had small cell sizes for genotypes of several candidate AS3MT 
variants, particularly in analyses stratified by water As. The small cell sizes may have reduced 
our power to detect interactions between level of exposure and methylation profiles for those 
variants.  
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Tables and figures 
Table 5.1. Urinary As profiles of arsenic metabolites overall and by AS3MT variants (median and 25th, 75th percentiles) 
 N % 
Total Speciated 
Urine Arsenic 
(tAs) 
Dimethylated 
Arsenic % 
(DMAs%) 
Monomethylated 
Arsenic % 
(MAs%) 
Unmethylated 
Inorganic 
Arsenic % 
(iAs%) 
DMAs/MAs 
Ratio 
MAs/iAs 
Ratio 
  
 
 p50 (p25, p75) p50 (p25, p75) p50 (p25, p75) p50 (p25, p75) p50 (p25, p75) p5
0 
(p25, p75) 
All subjects 772  62.9 (34.2, 108.4) 76.9 (71.3. 81.4) 13.9 (10.9,17.4) 8.8 (6.3, 12.2) 5.5 (4.2, 7.4) 1.6 (1.2, 2.1) 
By AS3MT variant:              
rs111914391 
 
*TT 412 82 59.5 (31.3, 105.5) 77.3‡ (71.7, 81.8) 13.5‡ (10.8, 16.7) 8.9 (6.1, 12.4) 5.7‡ (4.4, 7.6) 1.5 (1.1, 2.1) 
TC 86 17 52.5 (30.4, 99.7) 74.9 (66.5, 79.0) 15.8 (13.0, 20.0) 9.8 (6.3, 14.5) 4.7 (3.3, 6.0) 1.8 (1.2, 2.5) 
CC 3 1 64.8 (26.6, 151.0) 65.6 (59.2, 73.8) 19.7 (13.9, 27.8) 13.0 (12.2, 14.7) 3.3 (2.1, 5.3) 1.3 (1.1, 2.1) 
rs178812151 
*GG 579 81 61.4 (33.1, 107.4) 77.6‡ (72.8, 82.5) 13.4‡ (10.7, 16.6) 8.6 (6.1, 11.6) 5.8‡ (4.4, 7.6) 1.6 (1.2, 2.1) 
GC 124 17 67.5 (38.0, 112.8) 74.9 (69.0, 80.5) 15.1 (12.8, 19.2) 8.8 (6.7, 13.9) 4.9 (3.6, 6.3) 1.6 (1.2, 2.3) 
CC 12 2 45.2 (34.3, 82.4) 73.9 (65.3, 78.7) 19.8 (12.6, 21.6) 11.2 (5.0, 13.1) 3.7 (3.0, 6.2) 1.8 (1.3, 3.0) 
rs37403932 
GG 280 55 59.0 (30.9, 97.4) 75.3‡ (69.3, 79.6) 14.7‡ (11.7, 18.9) 9.9‡ (7.1, 13.1) 5.1‡ (3.8, 6.8) 1.6 (1.2, 2.1) 
GC 200 40 57.2 (30.6, 107.6) 78.6 (72.9, 83.3) 13.0 (10.8, 16.0) 8.3 (5.4, 12.0) 5.8 (4.6, 7.6) 1.6 (1.1, 2.3) 
*CC 26 5 72.6 (46.5, 125.0) 80.7 (74.0, 84.4) 12.0 (9.4, 15.0) 9.2 (4.3, 12.0) 6.7 (5.3, 9.0) 1.2 (1.0, 1.8) 
rs37403902, 3 
 
CC 293 58 59.9 (32.4, 99.5) 75.5‡ (69.4, 79.7) 14.5‡ (11.8, 18.8) 10.0‡ (7.1, 13.3) 5.3‡ (3.8, 6.8) 1.6 (1.1, 2.1) 
CT 192 38 56.6 (30.1, 105.6) 78.7 (73.5, 83.4) 12.8 (10.5, 15.9) 8.1 (5.4, 11.9) 6.2 (4.7, 7.8) 1.6 (1.1, 2.3) 
*TT 20 4 71.3 (36.9, 119.2) 80.3 (70.2, 86.0) 12.6 (9.0, 15.3) 7.9 (4.4, 14.8) 6.3 (4.7, 9.5) 1.2 (0.9, 1.7) 
rs111914533 
TT 290 58 59.7 (32.4, 99.5) 75.3‡ (69.2, 79.7) 14.6‡ (11.8, 18.9) 10.0‡ (7.1, 13.4) 5.2‡ (3.7, 6.8) 1.6 (1.2, 2.1) 
*TC 212 42 57.9 (30.1, 107.6) 78.8 (73.4, 83.5) 12.8 (10.3, 15.9) 8.1 (5.3, 12.0) 6.2 (4.7, 8.0) 1.6 (1.1, 2.3) 
rs10748835 
GG 151 30 60.5 (33.1, 99.5) 76.0† (70.1, 80.2) 14.5 (12.0,18.1) 9.5 (7.1, 12.9) 5.4† (3.9, 6.6) 1.5 (1.1, 2.1) 
GA 251 50 57.2 (29.4, 104.3) 76.7 (70.3, 81.3) 13.7 (10.8, 17.4) 9.0 (6.1, 12.9) 5.5 (4.1, 7.6) 1.6 (1.1, 2.1) 
*AA 98 20 64.8 (32.0, 112.6) 78.5 (73.8, 83.5) 13.7 (10.3, 15.9) 8.3 (5.1, 11.7) 5.7 (4.6, 7.7) 1.6 (1.1, 2.2) 
VNTR AB 587 82 61.5 (33.2, 112.0) 76.9† (70.9, 81.5) 13.9 (11.0, 17.4) 8.7 (6.2, 12.3) 5.5 (4.1, 7.3) 1.6 (1.2, 2.1) 
 *A2B 127 18 60.5 (34.2, 92.6) 77.9 (73.8, 82.1) 13.6 (10.6, 16.1) 8.3 (6.3, 10.5) 5.6 (4.6, 7.9) 1.6 (1.2, 2.2) 
* Identifies the referent genotype, defined as the genotype associated in previous literature with a higher DMAs%. † P<0.10 ‡P<0.05 for Kruskall wallis test for 
differences in urinary As metabolites among different genotypes of the AS3MT variants. Medians bolded when the Kruskall Wallis test reached significance 
(P<0.10). 1, 2, 3 The pairs of variants shown were in linkage disequilibrium with r2>0.80.   
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Figure 5.1. Associations between AS3MT variants and urinary arsenic profiles among subjects with higher vs. lower 
water arsenic (As) 
 
† P<0.10 ‡ P<0.05 for differences in urinary As profiles associated with having non-referent AS3MT variants 
genotypes compared with referent genotypes, where referent genotypes were defined as those associated with a  
higher DMAs% in previous studies. * Indicates interaction (P<0. 10) for variant X categorical water iAs (>50 vs. 
≤50ppb). Results come from multiple linear regression models adjusted for age and gender.  
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Table 5.2. Adjusted associations between AS3MT variants and urinary profiles of arsenic metabolitesa 
   Dimethylated  
Arsenic % 
(DMAs%) 
Monomethylated  
Arsenic % 
(MAs%) 
Unmethylated 
Inorganic Arsenic % 
(iAs%) 
DMAs/MAs Ratio MAs/iAs Ratio 
Polymorphism  N 
Coeff (SE) P Coeff (SE) P Coeff (SE) P Coeff (SE) P Coeff (SE) P 
rs111914391 
[ref TT, N=412] 
TC 86 -3.5 (1.0) 0.00‡ 2.3 (0.6) 0.00‡ 1.2 (0.6) 0.04‡ -1.2 (0.4) 0.00‡ -1.4 (1.2) 0.23 
CC 3 -9.1 (4.7) 0.05† 6.5 (3.1) 0.04‡ 2.7 (2.9) 0.36 -2.6 (1.8) 0.15 -1.6 (5.8) 0.79 
             
rs178812151 
 [ref GG, N=579] 
GC 124 -3.3 (0.8) 0.00‡ 1.9 (0.5) 0.00‡ 1.4 (0.5) 0.00‡ -1.1 (0.3) 0.00‡ -0.2 (1.5) 0.92 
CC 12 -4.6 (2.2) 0.04‡ 3.9 (1.4) 0.01‡ 0.7 (1.4) 0.63 -1.6 (0.9) 0.06† -1.5 (4.3) 0.72 
             
rs37403932 
 [ref CC, N =26] 
GC 200 -1.4 (1.7) 0.41 1.8 (1.1) 0.10 -0.4 (1.0) 0.68 -2.1 (0.6) 0.00‡ 1.4 (2.1) 0.50 
GG 280 -4.2 (1.7) 0.01‡ 3.3 (1.1) 0.00‡ 0.9 (1.0) 0.36 -3.1 (0.6) 0.00‡ -0.5 (2.0) 0.80 
             
rs37403902, 3 
 [ref TT, N=20] 
CT 192 -0.6 (1.9) 0.73 1.4 (1.3) 0.27 -0.7 (1.2) 0.53 -2.3 (0.7) 0.00‡ 0.2 (2.3) 0.93 
CC 293 -3.8 (1.9) 0.05‡ 3.0 (1.2) 0.02‡ 0.8 (1.2) 0.50 -3.4 (0.7) 0.00‡ -0.5 (2.3) 0.82 
             
rs111914533 
 [ref TC, N=212] 
TT 290 -3.3 (0.7) 0.00‡ 1.8 (0.5) 0.00‡ 1.5 (0.5) 0.00‡ -1.3 (0.3) 0.00‡ -0.7 (0.9) 0.43 
             
rs10748835 
[ref AA, N=98] 
GA 251 -1.5 (1.0) 0.12 0.7 (0.6) 0.27 0.8 (0.6) 0.19 -0.6 (0.4) 0.10† 0.7 (1.2) 0.59 
GG 151 -2.2 (1.1) 0.04‡ 1.3 (.7) 0.07† 0.9 (0.7) 0.16 -1.1 (0.4) 0.01‡ 0.1 (1.3) 0.95 
             
VNTR 
[ref A2B, N =127] 
AB 587 -1.6 (0.8) 0.04‡ 0.9 (0.5) 0.09† 0.7 (0.5) 0.14 -0.2 (0.3) 0.45 0.2 (1.4) 0.88 
a Linear regression model adjusted for age and gender; referent genotype defined as the genotype associated in previous literature with a higher DMAs%.  
† P<0.10 ‡ P<0.05 for coefficients of associations between AS3MT variants and urinary As profiles, results come from multiple linear regression model adjusted for 
age and gender. Coefficients (SE) were bolded when they reached significance (P<0.10). 1, 2, 3 The pairs of variants shown were in linkage disequilibrium with 
r2>0.80.   
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Supplemental Table 5.1a. Population characteristics and genotype frequencies among subjects with complete data 
available for all AS3MT variants and covariates  
 
N % 
Water As (ppb) 
p50 (p25, p75) 
All subjects  483 100% 46.0 (33.1, 58.8) 
Gender    
  Male 157 33% 45.4 (28.9, 60.7) 
  Female 326 67% 46.6 (35.9, 58.0) 
Age (years)    
  18-24 60 12% 43.9 (31.9, 50.0) 
  25-34 107 22% 43.9 (28.7, 51.3) 
  35-39 64 13% 48.1 (36.8, 64.3) 
  40-44 44 9% 48.0 (32.1, 69.9)  
  ≥45 208 43% 47.5 (35.4, 68.1) 
rs11191439    
  TT 398 82% 45.8 (32.4, 62.5) 
  TC 82 17% 48.1 (39.1, 55.5) 
  CC 3 1% 42.1 (0.7, 50.4) 
rs17881215    
  GG 392 81% 45.7 (32.5, 61.2) 
  GC 82 17% 48.1 (36.9, 54.2) 
  CC 9 2% 50.4 (41.5, 61.0) 
rs3740393    
  GG 262 54% 46.7 (30.3, 58.8) 
  GC 195 40% 45.5 (35.7, 53.8) 
  CC 26 5% 46.5 (35.9, 78.6) 
rs3740390    
  CC 275 57% 46.6 (30.3, 62.3) 
  CT 188 39% 45.6 (35.8, 52.5) 
  TT 20 4% 46.5 (34.4, 88.8) 
rs11191453    
  TT 275 57% 46.6 (30.3, 62.3) 
  TC 208 43% 45.8 (35.8, 52.8) 
  CC 0 0% -- 
rs10748835    
  GG 143 30% 45.2 (28.2, 58.3) 
  GA 245 51% 46.0 (32.5, 55.0) 
  AA 95 19% 47.0 (36.4, 67.2) 
VNTR    
  AB 396 82% 46.3 (32.5, 55.5) 
  A2B 86 18% 45.4 (37.6, 69.7) 
  A3B 1 0% 1.24 (--) 
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Supplemental Table 5.1b. Urinary profiles of As metabolites overall and by AS3MT variants among subjects with complete data available for all AS3MT variants 
and covariates: median and 25th, 75th percentiles 
  
N 
Dimethylated 
As % (DMAs%) 
Monomethylated As % 
(MAs%) 
Unmethylated 
Inorganic As % 
(iAs%) 
DMAs/MAs Ratio MAs/iAs Ratio 
p50 (p25, p75) p50 (p25, p75) p50 (p25, p75) p50 (p25, p75) p50 (p25, p75) 
All subjects  483 76.8 (70.1, 81.3) 13.9 (10.9, 17.4) 9.0 (6.1, 12.7) 5.5 (4.1, 7.4) 1.6 (1.1, 2.2) 
             By AS3MT variant:            
rs111914391  *TT 398 77.4‡ (71.7, 81.8) 13.5‡ (10.8, 16.5) 8.9 (6.1, 12.3) 5.7‡ (4.4, 7.6) 1.5 (1.1, 2.1) 
TC 82 74.7 (66.2, 78.5) 15.8 (13.0, 20.0) 10.1 (6.5, 14.6) 4.7 (3.3, 6.0) 1.7 (1.2, 2.5) 
CC 3 65.6 (59.2, 73.8) 19.7 (13.9, 27.8) 13.0 (12.2, 14.7) 3.3 (2.1, 5.3) 1.3 (1.1, 2.1) 
             rs178812151 *GG 392 77.5‡ (71.8, 81.8) 13.4‡ (10.8, 16.5) 8.9‡ (6.1, 12.3) 5.7‡ (4.4, 7.6) 1.5 (1.1, 2.1) 
GC 82 74.4 (66.0, 78.5) 15.6 (13.0, 19.6) 10.2 (6.7, 15.0) 4.8 (3.3, 6.0) 1.6 (1.0, 2.3) 
CC 9 66.2 (65.0, 75.6) 19.8 (19.6, 22.7) 12.2 (4.6, 13.2) 3.3 (2.8, 4.0) 1.9 (1.4, 2.2) 
rs37403932 GG 262 75.5‡ (69.6, 79.6) 14.7‡ (11.7, 18.9) 9.8‡ (7.0, 13.4) 5.2‡ (3.8, 6.9) 1.6 (1.1, 2.1) 
GC 195 78.6 (72.8, 83.4) 13.0 (10.8, 15.9) 8.3 (5.3, 12.0) 5.9 (4.6, 7.6) 1.6 (1.1, 2.3) 
*CC 26 80.7 (74.0, 84.4) 12.0 (9.4, 15.0) 9.2 (4.3, 12.0) 6.7 (5.3, 9.0) 1.2 (1.0, 1.8) 
             rs37403902, 3 CC 275 75.5‡ (69.4, 79.6) 14.5‡ (11.6, 18.8) 10.0‡ (7.0, 13.4) 5.3‡ (3.8, 6.9) 1.6 (1.1, 2.1) 
CT 188 78.7 (73.4, 83.4) 12.8 (10.5, 15.9) 8.1 (5.4, 11.9) 6.2 (4.7, 7.8) 1.6 (1.1, 2.3) 
*TT 20 80.3 (70.2, 86.0) 12.6 (9.0, 15.3) 7.9 (4.4, 14.8) 6.3 (4.7, 9.5) 1.2 (0.9, 1.7) 
             rs111914533 TT 275 75.5‡ (69.4, 79.6) 14.5‡ (11.6, 18.8) 10.0‡ (7.0, 13.4) 5.3‡ (3.8, 6.9) 1.6 (1.1, 2.1) 
*TC 208 78.8 (73.3, 83.5) 12.8 (10.3, 15.9) 8.1 (5.3, 12.0) 6.2 (4.7, 7.9) 1.6 (1.1, 2.3) 
             
rs10748835 GG 143 76.2† (70.1, 80.2) 14.4 (12.0,18.1) 9.5 (7.1, 13.0) 5.4† (3.9, 6.8) 1.5 (1.1, 2.1) 
GA 245 76.7 (70.3, 81.2) 13.7 (10.9, 17.4) 9.0 (6.1, 12.8) 5.5 (4.1, 7.4) 1.6 (1.1, 2.1) 
*AA 95 78.6 (73.8, 83.5) 13.7 (10.3, 15.9) 8.2 (5.0, 12.0) 5.7 (4.6, 7.8) 1.6 (1.1, 2.3) 
             VNTR AB 396 76.6† (69.9, 81.3) 14.0 (10.9, 17.7) 9.4† (6.1, 13.2) 5.4 (4.0, 7.3) 1.6 (1.1, 2.1) 
 *A2
B 
86 77.9 (73.9, 81.4) 13.6 (10.8, 15.9) 8.3 (6.4, 10.5) 5.6 (4.6, 7.1) 1.6 (1.2, 2.4) 
* Identifies the referent genotype, defined as the genotype associated in previous literature with a higher DMAs%. † P<0.10 ‡P<0.05 for significant differences 
in urinary As measures across genotypes for each AS3MT variant based on global test adjusted for age and gender. Medians bolded when the global test 
reached significance (P<0.10). 1, 2, 3 The pairs of variants shown were in linkage disequilibrium with r2>0.80.   
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Supplemental Table 5.1c. Adjusted associations between AS3MT variants and urinary profiles of As metabolites among subjects with complete data available for 
all AS3MT variants and covariatesa 
Polymorphism  N 
Dimethylated 
As % 
(DMAs%) 
Monomethylated 
As % 
(MAs%) 
Unmethylated 
Inorganic As % 
(iAs%) 
DMAs/MAs ratio MAs/iAs ratio 
β (SE) P β (SE) P β (SE) P β (SE) P β (SE) P 
rs111914391 
[ref TT, N=398] 
TC 82 -3.8 (1.0) 0.00‡ 2.3 (0.7) 0.00‡ 1.5 (0.6) 0.02‡ -1.2 (0.4) 0.00‡ -1.5 (1.2) 0.21 
CC 3 -9.1 (4.7) 0.06† 6.5 (3.1) 0.04‡ 2.7 (3.0) 0.37 -2.6 (1.8) 0.15 -1.6 (5.9) 0.79 
             
rs178812151 
[ref GG, N=392] 
GC 82 -3.9 (1.0) 0.00‡ 2.1 (0.7) 0.00‡ 1.8 (0.6) 0.00‡ -1.1 (0.4) 0.00‡ -1.7 (1.2) 0.17 
CC 9 -6.9 (2.2) 0.01‡ 5.4 (1.8) 0.00‡ 1.5 (1.7) 0.39 -2.4 (1.1) 0.03‡ -0.9 (3.4) 0.80 
             
rs37403932 
[ref CC, N=26] 
GC 195 -1.4 (1.7) 0.42 1.8 (1.1) 0.10 -0.5 (1.0) 0.67 -2.1 (0.6) 0.00‡ 1.4 (2.1) 0.50 
GG 262 -4.2 (1.7) 0.01‡ 3.3 (1.1) 0.00‡ 1.0 (1.0) 0.35 -3.1 (0.6) 0.00‡ -0.5 (2.1) 0.82 
             
rs37403902, 3 
[ref TT, N=20] 
CT 188 -0.7 (1.9) 0.72 1.4 (1.3) 0.26 -0.7 (1.2) 0.54 -2.4 (0.7) 0.00‡ 0.2 (2.4) 0.92 
CC 275 -3.8 (1.9) 0.04‡ 3.0 (1.3) 0.02‡ 0.8 (1.2) 0.47 -3.4 (0.7) 0.00‡ -0.5 (2.4) 0.85 
             
rs111914533 
[ref TC, N=208] 
TT 275 -3.2 (0.8) 0.00‡ 1.7 (0.5) 0.00‡ 1.5 (0.5) 0.00‡ -1.2 (0.3) 0.00‡ -0.7 (0.9) 0.47 
             
rs10748835  
[ref AA, N=95] 
GA 245 -1.6 (1.0) 0.12 0.8 (0.7) 0.26 0.8 (0.6) 0.20 -0.6 (0.4) 0.10† 0.6 (1.2) 0.60 
GG 143 -2.3 (1.1) 0.04‡ 1.3 (0.7) 0.07† 0.9 (0.7) 0.17 -1.1 (0.4) 0.01‡ 0.1 (1.4) 0.92 
             
VNTR 
[ref A2B, N =86] 
AB 396 -2.0 (1.0) 0.04‡ 0.7 (0.6) 0.26§ 1.3 (0.6) 0.04† -0.1 (0.4) 0.77 -0.3 (1.2) 0.77 
a Linear regression model adjusted for age and gender; referent genotype defined as the genotype associated in previous literature with a higher DMAs%. 
†P<0.10 ‡ P<0.05 for coefficients of associations between AS3MT variants and urinary As profiles, results come from multiple linear regression model adjusted 
for age and gender. Coefficients (SE) were bolded when they reached significance (P<0.10). 1, 2, 3 The pairs of variants shown were in linkage disequilibrium 
with r2>0.80.   
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Supplemental Table 5.2a. Urinary profiles of As metabolites overall and by AS3MT variants: median and 25th, 75th percentiles excluding subjects miss 
information for diabetes 
  N Dimethylated  
As % (DMAs%) 
Monomethylated  
As % (MAs%) 
Unmethylated  
Inorganic As % 
(iAs%) 
DMAs/MAs Ratio MAs/iAs  
Ratio 
p50 (p25,p75) p50 (p25,p75) p50 (p25,p75) p50 (p25,p75) p50 (p25,p75) 
All subjects 771 76.9 (71.3. 81.4) 13.9 (10.9,17.4) 8.8 (6.3, 12.2) 5.5 (4.2, 7.4) 1.6 (1.2, 2.1) 
             By AS3MT variant:             
rs111914391 
 
*TT 412 77.3‡ (71.7, 81.8) 13.5‡ (10.8, 16.7) 8.9 (6.1, 12.4) 5.7‡ (4.4, 7.6) 1.5 (1.1, 2.1) 
TC 86 74.9 (66.5, 79.0) 15.8 (13.0, 20.0) 9.8 (6.3, 14.5) 4.7 (3.3, 6.0) 1.8 (1.2, 2.5) 
CC 3 65.6 (59.2, 73.8) 19.7 (13.9, 27.8) 13.0 (12.2, 14.7) 3.3 (2.1, 5.3) 1.3 (1.1, 2.1) 
             rs178812151 *GG 578 77.6‡ (72.9, 82.5) 13.4‡ (10.7, 16.6) 8.6‡ (6.1, 11.6) 5.8‡ (4.4, 7.6) 1.6 (1.2, 2.1) 
GC 124 74.9 (69.0, 80.5) 15.1 (12.8, 19.2) 8.8 (6.7, 13.9) 4.9 (3.6, 6.3) 1.6 (1.2, 2.3) 
CC 12 73.9 (65.3, 78.7) 19.8 (12.6, 21.6) 11.2 (5.0, 13.1) 3.7 (3.0, 6.2) 1.8 (1.3, 3.0) 
rs37403932 GG 280 75.3‡ (69.3, 75.3) 14.7‡ (11.7, 18.9) 9.9‡ (7.1, 13.1) 5.1‡ (3.8, 6.8) 1.6† (1.2, 2.1) 
GC 200 78.6 (72.9, 83.3) 13.0 (10.8, 16.0) 8.3 (5.4, 12.0) 5.8 (4.6, 7.6) 1.6 (1.1, 2.3) 
*CC 26 80.7 (74.0, 84.4) 12.0 (9.4, 15.0) 9.2 (4.3, 13.0) 6.7 (5.3, 9.0) 1.2 (1.0, 1.8) 
             rs37403902, 3 CC 293 75.5‡ (69.4, 79.7) 14.5‡ (11.8, 18.8) 10.0‡ (7.1, 13.3) 5.3‡ (3.8, 6.8) 1.6 (1.1, 2.1) 
CT 192 78.7 (73.5, 83.4) 12.8 (10.5, 15.9) 8.1 (5.4, 11.9) 6.2 (4.7, 7.8) 1.6 (1.1, 2.3) 
*TT 20 80.3 (70.2, 86.0) 12.6 (9.0, 15.3) 7.9 (4.4, 14.8) 6.3 (4.7, 9.5) 1.2 (0.9, 1.7) 
             rs111914533 TT 290 75.3‡ (69.2, 79.7) 14.6‡ (11.9, 18.9) 10.0‡ (7.1, 13.4) 5.2‡ (3.7, 6.8) 1.6 (1.2, 2.1) 
*TC 212 78.8 (73.4, 83.5) 12.8 (10.3, 15.9) 8.1 (5.3, 12.0) 6.2 (4.7, 8.0) 1.6 (1.1, 2.3) 
             rs10748835 GG 151 76.0† (70.1, 80.2) 14.5 (12.0,18.1) 9.5 (7.1, 12.9) 5.4‡ (3.9, 6.6) 1.5 (1.1, 2.1) 
GA 251 76.7 (70.3, 81.3) 13.7 (10.8, 17.4) 9.0 (6.1, 12.9) 5.5 (4.1, 7.6) 1.6 (1.1, 2.1) 
*AA 98 78.5 (73.8, 83.5) 13.7 (10.3, 15.9) 8.3 (5.1, 11.7) 5.7 (4.6, 7.7) 1.6 (1.1, 2.2) 
             VNTR AB 587 76.9† (70.9, 81.5) 13.9 (11.0, 17.4) 8.7 (6.2, 12.3) 5.5 (4.1, 7.3) 1.6 (1.2, 2.1) 
 *A2B 126 78.0 (73.9, 82.1) 13.6 (10.6, 16.1) 8.2 (6.3, 10.4) 5.7 (4.6, 7.9) 1.6 (1.2, 2.2) 
* Identifies the referent genotype, defined as the genotype associated in previous literature with a higher DMAs%. † P<0.10 ‡P<0.05 for significant differences 
in urinary As measures across genotypes for each AS3MT variant based on global test adjusted for age and gender. Medians bolded when the global test 
reached significance (P<0.10). 1, 2, 3 The pairs of variants shown were in linkage disequilibrium with r2>0.80.   
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Supplemental Table 5.2b. Adjusted associations between AS3MT variants and urinary profiles of As metabolites a 
  N Dimethylated  
As % (DMAs%) 
Mono-methylated 
As % (MAs%) 
Unmethylated 
Inorganic As % 
(iAs%) 
DMAs/MAs ratio MAs/iAs ratio 
Polymorphism   
Coeff 
(SE) 
P Coeff 
(SE) 
P Coeff 
(SE) 
P Coeff 
(SE) 
P Coeff 
(SE) 
P 
rs111914391 
 [ref TT, N=412] 
TC 86 -3.5 (1.0) 0.00‡ 2.3 (0.6) 0.00‡ 1.2 (0.6) 0.04‡ -1.2 (0.4) 0.00‡ -1.4 (1.2) 0.23 
CC 3 -9.2 (4.7) 0.05† 6.5 (3.1) 0.04‡ 2.7 (2.9) 0.36 -2.6 (1.8) 0.14 -1.6 (5.8) 0.79 
             
rs178812151  
[ref GG, N=579] 
GC 124 -3.4 (0.8) 0.00‡ 1.9 (0.5) 0.00‡ 1.4 (0.5) 0.00‡ -1.2 (0.3) 0.00‡ -0.2 (1.5) 0.91 
CC 12 -4.5 (2.2) 0.04‡ 3.8 (1.4) 0.01‡ 0.7 (1.4) 0.62 -1.5 (0.9) 0.08† -1.5 (4.3) 0.73 
             
rs37403932 
[ref CC, N=26] 
GC 200 -1.1 (1.7) 0.50 1.6 (1.1) 0.14 -0.5 (1.0) 0.64 -1.9 (0.6) 0.00‡ 1.3 (2.1) 0.52 
GG 280 -4.1 (1.7) 0.02‡ 3.2 (1.1) 0.00‡ 0.9 (1.0) 0.39 -2.9 (0.6) 0.00‡ -0.6 (2.0) 0.78 
             
rs37403902, 3 
[ref TT, N=20] 
CT 192 -0.3 (1.9) 0.89 1.1 (1.3) 0.39 -0.8 (1.2) 0.49 -2.0 (0.7) 0.01‡ 0.1 (2.4) 0.97 
CC 293 -3.5 (1.9) 0.06† 2.8 (1.2) 0.03‡ 0.7 (1.2) 0.54 -3.1 (0.7) 0.00‡ -0.6 (2.3) 0.79 
             
rs111914533 
[ref TC, N=212] 
TT 290 -3.4 (0.7) 0.00‡ 1.8 (0.5) 0.00‡ 1.5 (0.5) 0.00‡ -1.3 (0.3) 0.00‡ -0.7 (0.9) 0.44 
             
rs10748835 
[ref AA, N=98] 
GA 251 -1.4 (1.0) 0.16 0.6 (0.6) 0.34 0.8 (0.6) 0.20 -0.5 (0.4) 0.16 0.6 (1.2) 0.61 
GG 151 -2.2 (1.1) 0.04‡ 1.3 (0.7) 0.07† 0.9 (0.7) 0.16 -1.1 (0.4) 0.01‡ 0.1 (1.3) 0.95 
             
VNTR 
[ref A2B, N =127] 
AB 587 -1.6 (0.8) 0.04‡ 0.8 (0.5) 0.13 0.8 (0.5) 0.10 -0.2 (0.3) 0.61 0.3 (1.4) 0.85 
a Linear regression model adjusted for age, gender, and diabetes; referent genotype defined as the genotype associated in previous literature with a higher 
DMAs%. †P<0.10 ‡ P<0.05 for coefficients of associations between AS3MT variants and urinary As profiles, results come from multiple linear regression model 
adjusted for age, gender, and diabetes. Coefficients (SE) were bolded when they reached significance (P<0.10). 1, 2, 3 The pairs of variants shown were in 
linkage disequilibrium with r2>0.80.   
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Supplemental Table 5.3. Global test statistics for interactions between variants with categorical water iAs concentrationa  
Polymorphism Dimethylated  
Arsenic % (DMAs%) 
Monomethylated  
Arsenic % (MAs%) 
Unmethylated Inorganic 
Arsenic % (iAs%) 
DMAs/MAs Ratio MAs/iAs Ratio 
F P F P F P F P F P 
rs111914391 
 
0.07 0.79 0.09 0.76 0.57 0.45 0.10 0.75 0.04 0.84 
rs178812151 
 
3.18 0.08 3.39 0.07 0.86 0.35 1.50 0.22 2.58 0.11 
rs37403932 
 
0.40 0.67 0.38 0.68 0.14 0.87 5.79 0.01 0.44 0.65 
rs37403902, 3 
 
0.14 0.87 0.03 0.97 0.20 0.82 5.31 0.01 0.35 0.70 
rs111914533 
 
0.23 0.63 0.02 0.88 0.37 0.54 0.64 0.43 0.10 0.75 
rs10748835 
 
0.66 0.52 1.24 0.29 0.68 0.51 4.64 0.01 0.66 0.52 
VNTR 
 
1.02 0.31 1.17 0.28 0.24 0.62 0.51 0.47 0.21 0.64 
a Categorical water iAs concentration was defined as higher (>50ppb) vs. lower (≤50ppb). 1, 2, 3 The pairs of variants shown were in linkage disequilibrium with 
r2>0.80.   
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Supplemental Table 5.4. Associations between AS3MT variants and urinary profiles of As metabolites among subjects with higher (>50ppb) vs. lower (≤50ppb) 
drinking water Asa 
Variant: 
Water iAs level 
 N Dimethylated  
As % (DMAs%) 
Monomethylated  
As % (MAs%) 
Unmethylated 
Inorganic As% 
(iAs%) 
DMAs/MAs 
Ratio 
MAs/iAs  
Ratio 
Coeff (SE) P Coeff (SE) P Coeff (SE) P Coeff (SE) P Coeff 
(SE) 
P 
rs111914391 [ref TT]:            
Low [ref N=263] TC 51 -3.9 (1.3) 0.00‡ 2.2 (0.9) 0.02‡ 1.7 (0.8) 0.03‡ -1.1 (0.4) 0.01‡ -1.2 (1.4) 0.39 
CC 2 -12.5 (5.9) 0.04‡ 9.3 (4.1) 0.03‡ 3.2 (3.7) 0.40 -3.2 (1.9) 0.09† -1.3 (6.6) 0.85 
High [ref N=149] TC 35 -2.9 (1.5) 0.05‡ 2.3 (0.8) 0.01‡ 0.6 (0.9) 0.50 -1.3 (0.7) 0.08† -2.0 (2.1) 0.34 
CC 1 -3.3 (7.8) 0.67 0.7 (4.5) 0.87 2.6 (4.7) 0.59 -1.3 (3.9) 0.74 -1.1 (11.4) 0.93 
rs178812151 [ref GG]: 
 
           
Low [ref N=322] GC 69 -4.5 (1.1) 0.00‡* 2.7 (0.7) 0.00‡* 1.8 (0.7) 0.01‡ -1.4 (0.4) 0.00‡ 1.9 (1.7) 0.2
4 CC 5 -5.0 (3.6) 0.17 5.3 (2.5) 0.04‡ -0.3 (2.3) 0.89 -1.9 (1.2) 0.12 -1.2 (5.7) 0.8
3 High [ref N=257] GC 55 -1.9 (1.1) 0.08† 0.9 (0.6) 0.14 1.0 (0.6) 0.13 -0.7 (0.5) 0.15 -2.9 (2.6) 0.2
6 CC 7 -4.4 (2.7) 0.11 2.9 (1.6) 0.07† 1.5 (1.6) 0.36 -1.4 (1.3) 0.27 -2.2 (6.6) 0.7
4 rs37403932 [ref CC]:            
Low [ref N=16] GC 133 -1.3 (2.2) 0.57 1.6 (1.6) 0.29 -0.4 (1.4) 0.79 -0.5 (0.7) 0.50* 0.0 (2.4) 0.99 
GG 170 -3.7 (2.2) 0.09† 2.8 (1.5) 0.07† 0.9 (1.4) 0.52 -1.4 (0.7) 0.05‡* -1.5 (2.4) 0.53 
High [ref N=10] GC 67 -1.2 (2.6) 0.63 2.0 (1.5) 0.19 -0.7 (1.6) 0.65 -4.6 (1.2) 0.00‡ 3.6 (3.8) 0.34 
GG 110 -5.1 (2.5) 0.04‡ 4.0 (1.5) 0.01‡ 1.0 (1.5) 0.50 -5.7 (1.2) 0.00‡ 1.1 (3.7) 0.77 
rs37403902 [ref TT]: 
 
           
Low [ref N=12] CT 128 -0.6 (2.5) 0.81 1.3 (1.8) 0.48 -0.6 (1.6) 0.69 -0.5 (0.8) 
4 
0.54* -1.3 (2.8) 0.64 
CC 178 -3.5 (2.5) 0.16 2.9 (1.7) 0.10 0.7 (1.6) 0.67 -1.5 (0.8) 0.06†* -2.1 (2.8) 0.46 
High [ref N=8] CT 64 -0.2 (2.9) 0.95 1.4 (1.7) 0.40 -1.2 (1.7) 0.48 -5.1 (1.4) 0.00‡ 2.2 (4.2) 0.60 
CC 115 -3.9 (2.8) 0.17 3.2 (1.6) 0.05† 0.7 (1.7) 0.67 -6.2 (1.3) 0.00‡ 1.5 (4.1) 0.71 
rs11191453 [ref TC]: 
 
           
Low [ref N=140] 
 
TT 178 -3.1 (1.0) 0.00‡ 1.8 (0.7) 0.01‡ 1.3 (0.6) 0.03‡ -1.1 (0.3) 0.00‡ -0.9 (1.1) 0.41 
High [ref N=72] TT 112 -3.9 (1.1) 0.00‡ 2.0 (0.7) 0.00‡ 1.9 (0.7) 0.01‡ -1.7 (0.6) 0.00‡ -0.4 (1.7) 0.80 
rs10748835 [ref AA]: 
 
           
Low [ref N=59] GA 161 -0.7 (1.3) 0.58 -0.0 (0.9) 0.98 0.7 (0.8) 0.36 0.3 (0.4) 0.54* -0.4 (1.4) 0.79 
  
 
1
0
4
 
GG 96 -1.3 (1.4) 0.35 0.8 (1.0) 0.39 0.5 (0.9) 0.59 -0.4 (0.4) 0.35* -0.8 (1.5) 0.61 
High [ref N=39] GA 90 -2.7 (1.5) 0.07† 2.0 (0.9) 0.02‡ 0.7 (0.9) 0.46 -2.1 (0.7) 0.01‡ 2.4 (2.2) 0.27 
GG 55 -3.7 (1.6) 0.02‡ 2.1 (0.9) 0.03‡ 1.6 (1.0) 0.10 -2.2 (0.8) 0.01‡ 1.7 (2.4) 0.47 
VNTR [ref A2B] 
 
           
Low [ref N=66] 
 
AB 329 -1.1 (1.1) 0.33 0.6 (0.8) 0.45 0.4 (0.7) 0.55 -0.1 (0.4) 0.80 0.8 (1.6) 0.65 
High [ref N=61] AB 258 -2.0 (1.0) 0.04‡ 1.2 (0.6) 0.04‡ 0.8 (0.6) 0.17 -0.4 (0.5) 0.40 -0.4 (2.5) 0.88 
a Linear regression model adjusted for age and gender; referent genotype defined as the genotype associated in previous literature with a higher DMAs%. 
†P<0.10 ‡ P<0.05 for coefficients of associations between AS3MT variants and urinary As profiles stratified by water As: higher (>50ppb) vs. lower (≤50ppb) 
drinking water As, results come from multiple linear regression model adjusted for age and gender. Coefficients (SE) were bolded when they reached 
significance (P<0.10). *Significant (P<0.10) Interaction with categorical drinking water As (higher vs. lower) based on global F test.  
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ENDNOTES 
 
60This chapter previously appeared as an article in Toxicological Sciences. The original citation 
is as follows: Xu, X., et al., “Association between Variants in Arsenic (+3 Oxidation State) 
Methyltransferase (AS3MT) and Urinary Metabolites of Inorganic Arsenic: Role of Exposure 
Level” Toxicological Sciences, 2016.  
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CHAPTER 6. SYNTHESIS 
 
Overview of findings 
Though literature indicates that low-to-moderate level of iAs exposure may contribute to 
the current epidemic of T2D, the results of the few studies are inconsistent and most of them are 
cross-sectional51,55-57. In this research, we sought to examine the association between iAs 
exposure at baseline (i.e.2009) and development of T2D over 6-years follow-up in a population 
low-to-moderately exposed to iAs. In addition, we also aim to determine effective strategy to 
counter the diabetogenic effects of iAs and identify genetic susceptible group of iAs-associated 
adverse health outcomes due to impairment of iAs metabolism. 
We used data from CHNS, which is an ongoing household-based cohort study designed 
to examine a series of economic, sociological, demographic, and health questions in the Chinese 
population, who are known to be low-to-moderately exposed to iAs. We are able to answer our 
study questions capitalizing on the rich CHNS data, which includes: concentration of toenail 
arsenic at baseline that reflects iAs exposure level in recent months; baseline dietary Mg and Zn 
intake assessed using three consecutive days 24-hour; indicators of glucose homeostasis at 
follow-up (i.e. 2015) including fasting glucose and insulin. Moreover, we took the different 
measures of T2D (insulin resistance vs. pancreatic β-cell dysfunction) into account: associations 
with both iAs and intake of Mg and Zn may be most apparent for measures of specific 
mechanism through which the iAs exposure and intake of Mg and Zn influence the development 
of T2D. Rather than only testing the associations using the measure of fasting glucose, we 
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examined the associations using measures of pancreatic β-cell function and insulin resistance, 
which were calculated by Homeostasis Model Assessment (HOMA2) calculator updated in 2015 
(University of Oxford, website; http://www.dtu.ox.ac.uk/homacalculator/index.php) to better 
understand the study question41,42.  
Answering these questions is important as it improves the understanding of the role of 
low-to-moderate level of iAs exposure, which is the exposure level common worldwide, in the 
current epidemic of T2D. Findings can also inform efforts to combat the diabetogenic effects of 
iAs by maximizing the effectiveness of Mg and Zn intake. It is extremely important as it is 
challenging to eliminate iAs exposure from our daily life. Our findings can also identify 
genetically susceptible subgroups in which there are augmented impaired iAs metabolism 
correlated with iAs exposure. Below we present a brief review of our findings, limitations and 
strengths of our research, its significance and public health impact, as well as future directions. 
Whether iAs exposure at low-to-moderate level contribute to the current epidemic of T2D? 
To understand how low-to-moderate level of iAs exposure at baseline is related to the 
T2D development over time, we examined the association between baseline iAs exposure and 
T2D development over 6 years in a population with low-to-moderate level of iAs exposure. 
Using multinomial logistic regression models and multivariable-adjusted linear regression 
models, we determined how baseline iAs exposure, which was captured by toenail arsenic, 
associated with T2D incidence and indicators of glucose homeostasis, which was characterized 
by fasting glucose, fasting insulin, HbA1c, pancreatic β-cell function, and insulin resistance at 
follow-up.  
Our findings further confirm the diabetogenic effects of low-to-moderate iAs exposure, 
which may contribute greatly to the current epidemic of T2D, especially in the populations with 
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low prevalence of obesity. Moreover, our findings also suggest that instead of insulin resistance, 
pancreatic β-cell dysfunction is primarily involved in iAs-associated diabetes.  
How the diabetogenic effects of low-to-moderate iAs exposure varied by population 
characteristics?  
To evaluate the consistency of the associations between iAs exposure and development of 
T2D by participant characteristics, we tested the interactions between toenail arsenic at baseline 
and the participants characteristics that were suggested to modify the iAs-associated adverse 
health outcomes114. We conducted additional analyses stratified by age (<55, 55-64, or ≥65 
years), sex, body mass index (<18, 23.0-27.4, or ≥27.5kg/m2), smoking status (current, former, 
or never), drinking status (<, or ≥once/month), and region (North, Central, or South) to better 
inform how the characteristics of the participants relate to iAs-associated diabetes.  
We found that men and participants who consumed alcohol were more susceptible to the 
diabetogenic effects of iAs than women and those who did not consume alcohol. Our findings 
inform that intervention strategies to reduce the iAs exposure or counter the diabetogenic effects 
of iAs are extremely important for men and alcohol consumers. In addition, though Fatmi et 
al.160 suggests reduced susceptibility of iAs-associated adverse health outcomes among obese 
individuals, we found that low-to-moderate iAs exposure at baseline promoted rapid progression 
to more severe diabetes for obese individuals. Thus, instead of thinking obesity as a preventive 
factor for iAs-associated adverse health outcomes, our study stresses the adverse effects of low-
to-moderate level of iAs exposure among obese individuals.  
What are the potential reasons for the inconsistent results of iAs-associated diabetes from 
previous studies?  
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The results of the researches exploring the associations between low-to-moderate level of 
iAs exposure and risk of T2D are highly inconsistent54,58-60. In our study, we determined the 
potential reasons for the inconsistent results by 1) comparing the analyses using the cross-
sectional vs. longitudinal data; 2) using different measures of T2D development (i.e. HbA1c vs. 
fasting glucose); 3) comparing the associations between iAs exposure and development of T2D 
among participants with different characteristics that thought to modify iAs-associated health 
outcomes, such as age, sex, weight status, drinking and smoking status.  
There have been growing concerns that cross-sectional study design cannot capture the 
temporal relationship between iAs exposure and development of diabetes, and diabetes might 
affect iAs excretion and metabolism53,17. In line with this concern, we found different results for 
the associations between baseline iAs exposure and risk of diabetes using longitudinal vs. cross-
sectional analysis. The longitudinal analysis suggests positive association between baseline iAs 
exposure and fasting glucose, β-cell dysfunction, odds of incident diabetes and prediabetes, 
whereas the cross-sectional analysis suggests lower odds of diabetes associated with iAs 
exposure. Our findings further indicate that the inconsistent results for the associations between 
iAs exposure and risk of diabetes reported in previous studies could be partially explained by the 
different study designs. 
We also found significant differences in the associations between baseline iAs exposure 
and development of T2D while using different measures of T2D (i.e. fasting glucose vs. HbA1c). 
Our findings further confirm the concern about using HbA1c to diagnose diabetes among 
subjects exposed to iAs as laboratory data suggests iAs exposure is correlated with hemoglobin 
concentration61,62. Thus, our findings further support the idea that FG is more feasible to capture 
the change in glucose hemostasis induced by iAs exposure, and the real association between iAs 
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exposure and development of diabetes could be ignored if only HbA1c is used to define 
diabetes139.  
Moreover, as mentioned above, the associations between iAs exposure and T2D 
development varied by characteristics of the participants, such as sex, drinking status, and weight 
status. Thus, the different characteristics of the study populations may also partially explain the 
inconsistent results across studies.  
Whether the diabetogenic effects of iAs is modified by dietary Mg and Zn intake at baseline? 
The inconsistent results in previous studies on the associations between low-to-moderate 
iAs exposure and development of T2D further stress the importance of exploring factors that 
may be associated with the diabetogenic effects of iAs. To determine whether the diabetogenic 
effects of low-to-moderate iAs exposure are associated with intake of Mg and Zn, which are the 
macronutrients involved in glucose metabolism, we first determined the associations between 
Mg and Zn intake at baseline and T2D development over 6 years follow-up. We found 
deficiency of Zn intake at baseline might contribute to development of T2D through inducing 
pancreatic β-cell dysfunction. And our findings indicate that improvement of Zn intake could be 
a potential strategy to reduce T2D risk.  
Second, we examined whether the diabetogenic effects of low-to-moderate iAs exposure 
varied depending on levels of Mg and Zn intake at baseline by testing the significance of the 
interactions between dietary Mg and Zn status × iAs exposure level at baseline. We found the 
susceptibility of iAs-associated diabetes varied depending on levels of Zn intake at baseline, and 
participants with adequate intake of Zn are more susceptible to iAs-associated β-cell dysfunction. 
Our results further suggest that the mixed results between low-to-moderate level of iAs exposure 
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and development of T2D among studies could be partially correlated with different levels of 
essential metals intake, such as Zn, across studies. 
Does promoting Zn intake an effective strategy to counter the diabetogenic effects of low-to-
moderate iAs exposure? 
The positive association between low-to-moderate iAs exposure and T2D development 
observed in our study further stresses the need of identifying strategies to reduce the 
diabetogenic effects of iAs. We stratified participants based on both iAs exposure (i.e. tertiles) 
and intake of Mg and Zn (i.e. adequate vs. deficient) to generate the joint variable for iAs 
exposure and intake of Mg and Zn. We tested the association between the joint variable and the 
development of T2D.  
We found comparing with the participants with the same level of iAs exposure, those 
with adequate intake of Mg or Zn were always with lower fasting glucose and better pancreatic 
β-cell function comparing with those with deficient Mg or Zn intake. Overall, the findings 
support the idea that promoting intake of Mg and Zn may potentially be an effective strategy to 
counter the diabetogenic effects of iAs. 
Whether the associations between genetic variants of AS3MT and iAs metabolism varied by 
exposure level? 
In this study, seven AS3MT variants which may play a role in iAs metabolism were 
examined based on results of previous studies. The patterns of association between markers of 
iAs metabolism and these variants were highly consistent with those reported in previous studies, 
confirming that these variants are in part responsible for the inter-individual differences in 
urinary profiles of iAs metabolites. We found that specific genotypes in five SNPs, rs17881215, 
rs3740393, rs3740390, rs11191439, and rs11191453, were associated with significantly higher 
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DMAs% and lower MAs% in urine. Polymorphisms in these SNPs, along with rs10748835, were 
also associated with the DMAs/MAs ratio.  
Our results also suggested that the role of several of these AS3MT variants in iAs 
metabolism may differ among populations with different levels of iAs exposure. Three SNPs, 
rs3740393, rs3740390, and rs10748835, appeared to have significantly more potent effects, 
based on associations with larger decreases in the DMAs/MAs ratio, among subjects highly 
exposed to As in drinking water (> 50ppb). In contrast, rs17881215 had significantly more 
potent effects among subjects with lower water As levels. Since measures of iAs metabolism 
have been associated with risk of adverse health outcomes, these findings suggest that variants in 
AS3MT may influence susceptibility to health effects of iAs exposure, and that the role of these 
variants may depend on the level of iAs exposure. However, given that toxicity of iAs 
metabolites varies by oxidation status 79,80,83,235-238, further research focusing on whether and how 
these variants relate to the distribution of trivalent and pentavalent metabolites is needed to better 
clarify the influence of AS3MT polymorphism on iAs methylation profiles, and on health 
outcomes.  
Limitations  
Our study has several limitations. First, our study used toenail arsenic as the 
measurement of iAs exposure, and it has been suggested as a more reliable biomarker of chronic 
iAs exposure comparing with urinary arsenic74,117. However, a more expanded knowledge of 
toxicokinetic data and information on the correlations with existing biomarkers (i.e. urinary 
arsenic) is needed to better interpret our findings.  
Second, though our sample size was larger than many previous studies, we had limited 
cell sizes for stratified analyses. The small cell sizes may have reduced our power to detect the 
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interactions, and the statistical significance should be interpreted with caution, especially for the 
interactions and stratified analyses. 
 Third, though three-day 24-hour recall is frequently used in studies to estimate the usual 
dietary intake, the result of it can be affected by several factors, such as over and under 
report210,211. In our study, we used sensitivity analysis to examine differences in model results 
when we excluded participants with extreme self-reported daily energy intake (<600 kcal/d and 
>4,500 kcals/d) to assess the effects from misreporting. We found no statistically significant 
difference in results before vs. after this exclusion.  
Fourth, limited information about supplement intake might have altered our estimates of 
daily intake of Mg and Zn. However, since mineral supplements, except calcium, are not widely 
used in this population and none of the participants included in the analysis reported using 
supplements, it is unlikely that this study limitation influenced our findings212.  
Strengths 
Despite the limitations, our study has several key strengths. First, the prospective, 
longitudinal design and the size of the CHNS cohort provide an outstanding opportunity to 
understand how, in a population with low-to-moderate iAs exposure, baseline (i.e.2009) iAs 
exposure relates to the development of T2D during follow-up, and potential effect modification 
by Mg and Zn intake. The CHNS with rich longitudinal data, especially high-quality dietary 
data, toenail concentration of arsenic that reflects iAs exposure level in recent months at 
baseline, provides a special opportunity for us to conduct this study 
Second, we took accounted for different measures of T2D (insulin resistance vs. 
pancreatic β-cell dysfunction) to better inform the understanding of underlying biological 
mechanism of iAs-associated T2D. We also excluded participants with diabetes at baseline to 
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better capture the early stage changes of glucose homeostasis to reveal the underlying biological 
mechanism of Zn and Mg-associated diabetes 
Third, few studies on toxic metals, such as iAs, include the high-quality dietary data. The 
potential for essential metals to reduce the risk of toxic metals has been largely examined using 
biomarkers of essential metals (e.g. serum and urinary biomarkers). However, others have 
suggested that toxic metals and their related metabolic effects may diminish essential metals 
biomarkers, limiting their utility as markers of intake208,209. Our study is one of the few studies 
that directly examine how intake, rather than biomarkers, of Mg and Zn relate to iAs burden. In 
addition, we accounted for potential confounders with progressive degrees of adjustment in our 
models.  
Significance and public health impact 
Our research has significant public health implications. First, our findings show 
significant and positive association between baseline iAs exposure and development of T2D over 
6 years of follow-up. Our findings further confirm the diabetogenic effects of low-to-moderate 
level of iAs exposure, which is the exposure level very common worldwide 51,55-57, and indicate 
that the low-to-moderate level of iAs exposure may contribute substantially to the current 
epidemic of T2D. Moreover, our study highlights the needs for interventions to decrease iAs 
exposure from our daily life or strategies to counter the diabetogenic effects of iAs even in the 
regions with low-to-moderate iAs exposure.  
Second, our research takes into account the different measures of T2D, such as fasting 
glucose, HbA1c, pancreatic β-cell dysfunction, and insulin resistance. We found positive 
association between iAs exposure and fasting glucose, whereas found null association between 
iAs exposure and HbA1c. Our finding further confirms the concern of using HbA1c to diagnose 
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diabetes among population exposed to iAs, as previous laboratory studies have indicated the 
association between iAs exposure on hemoglobin concentration61,62. Moreover, our study is the 
first to describe the association between iAs exposure and insulin resistance vs. pancreatic β-cell 
dysfunction. Our research strengthens the limited understanding of iAs-associated T2D and 
suggests that instead of insulin resistance, pancreatic β-cell dysfunction is primarily involved in 
iAs-associated T2D. 
Our research is the first to describe and document the associations between baseline Mg 
and Zn intake and iAs-associated diabetes. Our findings support the idea that the susceptibility of 
iAs-associated diabetes varies depending on levels of Zn intake at baseline, and participants with 
adequate intake of Zn are more susceptible to iAs-associated β-cell dysfunction. Our findings 
contribute to better understanding of the mixed results between low-to-moderate iAs exposure 
and development of T2D, which could be partially due to the varied susceptibility among 
participants with different intake of essential metals, such as Zn. The estimated joint associations 
of Mg and Zn intake with iAs exposure in association with T2D stress the importance of having 
adequate Mg and Zn intake to reduce the risk of T2D. Overall, our findings suggest potential 
benefits of promoting intake of Mg and Zn to counter the diabetogenic effects of iAs, and 
emphasize the importance of intervention efforts on increasing intake of Mg and Zn for 
participants with different levels of iAs exposure.  
Future directions 
This study provides a foundation for further study of several important questions, 
including future research examining: (i) if dietary factors besides Mg and Zn may mitigate 
adverse effects of iAs (e.g. antioxidant vitamins); (ii) how a wider array of toxic and essential 
metals affect multiple cardio-metabolic outcomes (e.g. dyslipidemias); and (iii) how toxic and 
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essential metals relate to cardiometabolic risk after accounting for genetic susceptibility. In 
addition, a more expanded knowledge of toxicokinetic data and information on the correlations 
with existing biomarkers (i.e. urinary arsenic) is needed to better interpret our findings
  
117 
 
REFERENCES 
1 Rathmann, W. & Giani, G. Global prevalence of diabetes: estimates for the year 2000 and 
projections for 2030. Diabetes care 27, 2568-2569; author reply 2569 (2004). 
2 Ma, R. C. & Chan, J. C. Type 2 diabetes in East Asians: similarities and differences with 
populations in Europe and the United States. Annals of the New York Academy of 
Sciences 1281, 64-91, doi:10.1111/nyas.12098 (2013). 
3 Alwan, A. Global status report on noncommunicable diseases 2010.  (World Health 
Organization, 2011). 
4 Guariguata, L. et al. Global estimates of diabetes prevalence for 2013 and projections for 
2035. Diabetes Res Clin Pract 103, 137-149, doi:10.1016/j.diabres.2013.11.002 (2014). 
5 Yang, S. H., Dou, K. F. & Song, W. J. Prevalence of diabetes among men and women in 
China. The New England journal of medicine 362, 2425-2426; author reply 2426 (2010). 
6 Cerf, M. E. Beta cell dysfunction and insulin resistance. Frontiers in endocrinology 4, 37 
(2013). 
7 Ashcroft, F. M. & Rorsman, P. Diabetes mellitus and the beta cell: the last ten years. Cell 
148, 1160-1171, doi:10.1016/j.cell.2012.02.010 (2012). 
8 Chan, J. C. Diabetes and noncommunicable disease: prevent the preventables. JAMA : the 
journal of the American Medical Association 310, 916-917, 
doi:10.1001/jama.2013.168099 (2013). 
9 Kahn, S. E. Clinical review 135: The importance of beta-cell failure in the development 
and progression of type 2 diabetes. The Journal of clinical endocrinology and metabolism 
86, 4047-4058, doi:10.1210/jcem.86.9.7713 (2001). 
10 Perley, M. & Kipnis, D. M. Plasma insulin responses to glucose and tolbutamide of 
normal weight and obese diabetic and nondiabetic subjects. Diabetes 15, 867-874 (1966). 
11 Polonsky, K. S., Given, B. D. & Van Cauter, E. Twenty-four-hour profiles and pulsatile 
patterns of insulin secretion in normal and obese subjects. The Journal of clinical 
investigation 81, 442-448, doi:10.1172/JCI113339 (1988). 
12 Brereton, M. F., Rohm, M. & Ashcroft, F. M. beta-Cell dysfunction in diabetes: a crisis 
of identity? Diabetes Obes Metab 18 Suppl 1, 102-109, doi:10.1111/dom.12732 (2016). 
13 Relimpio, F. "The relative contributions of insulin resistance and beta-cell dysfunction to 
the pathophysiology of Type 2 diabetes", by Kahn SE. Diabetologia 46, 1707, 
doi:10.1007/s00125-003-1237-y (2003). 
  
118 
 
14 Kim, C. H., Kim, H. K., Kim, E. H., Bae, S. J. & Park, J. Y. Relative contributions of 
insulin resistance and beta-cell dysfunction to the development of Type 2 diabetes in 
Koreans. Diabet Med 30, 1075-1079, doi:10.1111/dme.12201 (2013). 
15 Yabe, D., Seino, Y., Fukushima, M. & Seino, S. beta cell dysfunction versus insulin 
resistance in the pathogenesis of type 2 diabetes in East Asians. Current diabetes reports 
15, 602, doi:10.1007/s11892-015-0602-9 (2015). 
16 Iarc Working Group on the Evaluation of Carcinogenic Risks to Humans. Arsenic, 
metals, fibres, and dusts. IARC Monogr Eval Carcinog Risks Hum 100, 11-465 (2012). 
17 Khan, A. R. & Awan, F. R. Metals in the pathogenesis of type 2 diabetes. J Diabetes 
Metab Disord 13, 16, doi:10.1186/2251-6581-13-16 (2014). 
18 Gilbert-Diamond, D. et al. Rice consumption contributes to arsenic exposure in US 
women. Proceedings of the National Academy of Sciences of the United States of 
America 108, 20656-20660, doi:10.1073/pnas.1109127108 (2011). 
19 Naujokas, M. F. et al. The broad scope of health effects from chronic arsenic exposure: 
update on a worldwide public health problem. Environmental health perspectives 121, 
295-302, doi:10.1289/ehp.1205875 (2013). 
20 Petriello, M. C. et al. Modulation of persistent organic pollutant toxicity through 
nutritional intervention: emerging opportunities in biomedicine and environmental 
remediation. Sci Total Environ 491-492, 11-16, doi:10.1016/j.scitotenv.2014.01.109 
(2014). 
21 Zhai, Q., Narbad, A. & Chen, W. Dietary strategies for the treatment of cadmium and 
lead toxicity. Nutrients 7, 552-571, doi:10.3390/nu7010552 (2015). 
22 Skalny, A. A. et al. Zinc asparaginate supplementation induces redistribution of toxic 
trace elements in rat tissues and organs. Interdiscip Toxicol 8, 131-138, 
doi:10.1515/intox-2015-0020 (2015). 
23 Srivastava, D., Subramanian, R. B., Madamwar, D. & Flora, S. J. Protective effects of 
selenium, calcium, and magnesium against arsenic-induced oxidative stress in male rats. 
Arh Hig Rada Toksikol 61, 153-159, doi:10.2478/10004-1254-61-2010-1993 (2010). 
24 Kosnett, M. J. Chelation for heavy metals (arsenic, lead, and mercury): protective or 
perilous? Clin Pharmacol Ther 88, 412-415, doi:10.1038/clpt.2010.132 (2010). 
25 Hambidge, M. Human zinc deficiency. The Journal of nutrition 130, 1344S-1349S 
(2000). 
26 Steinmaus, C. et al. Dietary intake and arsenic methylation in a U.S. population. 
Environmental health perspectives 113, 1153-1159, doi:10.1289/ehp.7907 (2005). 
  
119 
 
27 Milton, A. G., Zalewski, P. D. & Ratnaike, R. N. Zinc protects against arsenic-induced 
apoptosis in a neuronal cell line, measured by DEVD-caspase activity. Biometals : an 
international journal on the role of metal ions in biology, biochemistry, and medicine 17, 
707-713 (2004). 
28 Mitra, S. R. et al. Nutritional factors and susceptibility to arsenic-caused skin lesions in 
West Bengal, India. Environmental health perspectives 112, 1104-1109, 
doi:10.1289/ehp.6841 (2004). 
29 Wang, C. T. Concentration of arsenic, selenium, zinc, iron and copper in the urine of 
blackfoot disease patients at different clinical stages. European journal of clinical 
chemistry and clinical biochemistry : journal of the Forum of European Clinical 
Chemistry Societies 34, 493-497 (1996). 
30 Carlson-Lynch, H., Beck, B. D. & Boardman, P. D. Arsenic risk assessment. 
Environmental health perspectives 102, 354-356, doi:10.1289/ehp.94102354 (1994). 
31 Thomas, D. J. et al. Arsenic (+3 oxidation state) methyltransferase and the methylation of 
arsenicals. Exp Biol Med (Maywood) 232, 3-13 (2007). 
32 Antonelli, R., Shao, K., Thomas, D. J., Sams, R., 2nd & Cowden, J. AS3MT, GSTO, and 
PNP polymorphisms: impact on arsenic methylation and implications for disease 
susceptibility. Environ Res 132, 156-167, doi:10.1016/j.envres.2014.03.012 (2014). 
33 Fu, S. et al. Urinary arsenic metabolism in a Western Chinese population exposed to 
high-dose inorganic arsenic in drinking water: influence of ethnicity and genetic 
polymorphisms. Toxicology and applied pharmacology 274, 117-123, 
doi:10.1016/j.taap.2013.11.004 (2014). 
34 Gribble, M. O. et al. Linkage Analysis of Urine Arsenic Species Patterns in the Strong 
Heart Family Study. Toxicological sciences : an official journal of the Society of 
Toxicology, doi:10.1093/toxsci/kfv164 (2015). 
35 Pierce, B. L. et al. Genome-wide association study identifies chromosome 10q24.32 
variants associated with arsenic metabolism and toxicity phenotypes in Bangladesh. PLoS 
Genet 8, e1002522, doi:10.1371/journal.pgen.1002522 (2012). 
36 Ding, L. et al. Methylation of arsenic by recombinant human wild-type arsenic (+3 
oxidation state) methyltransferase and its methionine 287 threonine (M287T) polymorph: 
Role of glutathione. Toxicol Appl Pharmacol 264, 121-130, 
doi:10.1016/j.taap.2012.07.024 (2012). 
37 Engstrom, K. et al. Polymorphisms in arsenic(+III oxidation state) methyltransferase 
(AS3MT) predict gene expression of AS3MT as well as arsenic metabolism. 
Environmental health perspectives 119, 182-188, doi:10.1289/ehp.1002471 (2011). 
  
120 
 
38 Agusa, T. et al. Genetic polymorphisms in AS3MT and arsenic metabolism in residents 
of the Red River Delta, Vietnam. Toxicology and applied pharmacology 236, 131-141, 
doi:10.1016/j.taap.2009.01.015 (2009). 
39 Chung, C. J. et al. Polymorphisms in arsenic metabolism genes, urinary arsenic 
methylation profile and cancer. Cancer Causes Control 20, 1653-1661, 
doi:10.1007/s10552-009-9413-0 (2009). 
40 Drobna, Z. et al. Environmental exposure to arsenic, AS3MT polymorphism and 
prevalence of diabetes in Mexico. Journal of exposure science & environmental 
epidemiology 23, 151-155, doi:10.1038/jes.2012.103 (2013). 
41 Wallace, T. M., Levy, J. C. & Matthews, D. R. Use and abuse of HOMA modeling. 
Diabetes care 27, 1487-1495 (2004). 
42 Levy, J. C., Matthews, D. R. & Hermans, M. P. Correct homeostasis model assessment 
(HOMA) evaluation uses the computer program. Diabetes care 21, 2191 (1998). 
43 Matthews, D. R. et al. Homeostasis model assessment: insulin resistance and beta-cell 
function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28, 
412-419 (1985). 
44 Salas-Salvado, J., Martinez-Gonzalez, M. A., Bullo, M. & Ros, E. The role of diet in the 
prevention of type 2 diabetes. Nutrition, metabolism, and cardiovascular diseases : 
NMCD 21 Suppl 2, B32-48, doi:10.1016/j.numecd.2011.03.009 (2011). 
45 Psaltopoulou, T., Ilias, I. & Alevizaki, M. The role of diet and lifestyle in primary, 
secondary, and tertiary diabetes prevention: a review of meta-analyses. The review of 
diabetic studies : RDS 7, 26-35, doi:10.1900/RDS.2010.7.26 (2010). 
46 Zeggini, E. et al. Meta-analysis of genome-wide association data and large-scale 
replication identifies additional susceptibility loci for type 2 diabetes. Nature genetics 40, 
638-645, doi:10.1038/ng.120 (2008). 
47 Kong, X., Xing, X., Hong, J., Zhang, X. & Yang, W. Genetic variants associated with 
lean and obese type 2 diabetes in a Han Chinese population: A case-control study. 
Medicine (Baltimore) 95, e3841, doi:10.1097/MD.0000000000003841 (2016). 
48 Replication, D. I. G. et al. Genome-wide trans-ancestry meta-analysis provides insight 
into the genetic architecture of type 2 diabetes susceptibility. Nature genetics 46, 234-
244, doi:10.1038/ng.2897 (2014). 
49 Thayer, K. A., Heindel, J. J., Bucher, J. R. & Gallo, M. A. Role of environmental 
chemicals in diabetes and obesity: a National Toxicology Program workshop review. 
Environmental health perspectives 120, 779-789, doi:10.1289/ehp.1104597 (2012). 
  
121 
 
50 Mendez, M. A. et al. Chronic Exposure to Arsenic and Markers of Cardiometabolic Risk: 
A Cross-Sectional Study in Chihuahua, Mexico. Environmental health perspectives 124, 
104-111, doi:10.1289/ehp.1408742 (2016). 
51 Kuo, C. C. et al. Arsenic exposure, arsenic metabolism, and incident diabetes in the 
strong heart study. Diabetes care 38, 620-627, doi:10.2337/dc14-1641 (2015). 
52 Feng, W. et al. Association of urinary metal profiles with altered glucose levels and 
diabetes risk: a population-based study in China. PloS one 10, e0123742, 
doi:10.1371/journal.pone.0123742 (2015). 
53 Liu, S. et al. Arsenic induces diabetic effects through beta-cell dysfunction and increased 
gluconeogenesis in mice. Sci Rep 4, 6894, doi:10.1038/srep06894 (2014). 
54 Ma, G. et al. Assessment of intake inadequacy and food sources of zinc of people in 
China. Public health nutrition 10, 848-854, doi:10.1017/S136898000744143X (2007). 
55 Navas-Acien, A. et al. Arsenic exposure and type 2 diabetes: a systematic review of the 
experimental and epidemiological evidence. Environmental health perspectives 114, 641-
648 (2006). 
56 Brauner, E. V. et al. Long-term exposure to low-level arsenic in drinking water and 
diabetes incidence: a prospective study of the diet, cancer and health cohort. 
Environmental health perspectives 122, 1059-1065, doi:10.1289/ehp.1408198 (2014). 
57 Sung, T. C., Huang, J. W. & Guo, H. R. Association between Arsenic Exposure and 
Diabetes: A Meta-Analysis. Biomed Res Int 2015, 368087, doi:10.1155/2015/368087 
(2015). 
58 Goyer, R. A. Nutrition and metal toxicity. The American journal of clinical nutrition 61, 
646S-650S (1995). 
59 Sun, H. J. et al. Arsenic and selenium toxicity and their interactive effects in humans. 
Environment international 69, 148-158, doi:10.1016/j.envint.2014.04.019 (2014). 
60 Xu, X. et al. Association Between Variants in Arsenic (+3 Oxidation State) 
Methyltranserase (AS3MT) and Urinary Metabolites of Inorganic Arsenic: Role of 
Exposure Level. Toxicological sciences : an official journal of the Society of Toxicology 
153, 112-123, doi:10.1093/toxsci/kfw112 (2016). 
61 Antonio Garcia, M. T., Herrera Duenas, A. & Pineda Pampliega, J. Hematological effects 
of arsenic in rats after subchronical exposure during pregnancy and lactation: the 
protective role of antioxidants. Experimental and toxicologic pathology : official journal 
of the Gesellschaft fur Toxikologische Pathologie 65, 609-614, 
doi:10.1016/j.etp.2012.06.004 (2013). 
  
122 
 
62 Biswas, D. et al. Mechanism of erythrocyte death in human population exposed to arsenic 
through drinking water. Toxicol Appl Pharmacol 230, 57-66, 
doi:10.1016/j.taap.2008.02.003 (2008). 
63 Menke, A., Casagrande, S., Geiss, L. & Cowie, C. C. Prevalence of and Trends in 
Diabetes Among Adults in the United States, 1988-2012. JAMA 314, 1021-1029, 
doi:10.1001/jama.2015.10029 (2015). 
64 Xu, Y. et al. Prevalence and control of diabetes in Chinese adults. JAMA 310, 948-959, 
doi:10.1001/jama.2013.168118 (2013). 
65 Qin, Y. et al. Dietary intake of zinc in the population of Jiangsu Province, China. Asia 
Pacific journal of clinical nutrition 18, 193-199 (2009). 
66 Xu, B. et al. Low serum magnesium level is associated with microalbuminuria in chinese 
diabetic patients. International journal of endocrinology 2013, 580685, 
doi:10.1155/2013/580685 (2013). 
67 Li, Y. et al. Magnesium status and dietary intake of mid-old people in a rural area of 
China. Magnes Res 22, 66-71 (2009). 
68 Galan, P. et al. Dietary magnesium intake in a French adult population. Magnes Res 10, 
321-328 (1997). 
69 Joy, E. J. M. et al. Risk of dietary magnesium deficiency is low in most African countries 
based on food supply data. Plant and Soil 368, 129-137, doi:10.1007/s11104-012-1388-z 
(2013). 
70 Ab Razak, N. H., Praveena, S. M. & Hashim, Z. Toenail as a biomarker of heavy metal 
exposure via drinking water: a systematic review. Rev Environ Health 30, 1-7, 
doi:10.1515/reveh-2014-0063 (2015). 
71 Adair, B. M., Hudgens, E. E., Schmitt, M. T., Calderon, R. L. & Thomas, D. J. Total 
arsenic concentrations in toenails quantified by two techniques provide a useful 
biomarker of chronic arsenic exposure in drinking water. Environmental research 101, 
213-220, doi:10.1016/j.envres.2005.08.004 (2006). 
72 Button, M., Jenkin, G. R., Harrington, C. F. & Watts, M. J. Human toenails as a 
biomarker of exposure to elevated environmental arsenic. J Environ Monit 11, 610-617, 
doi:10.1039/b817097e (2009). 
73 Wilhelm, M. et al. Comparison of arsenic levels in fingernails with urinary As species as 
biomarkers of arsenic exposure in residents living close to a coal-burning power plant in 
Prievidza District, Slovakia. J Expo Anal Environ Epidemiol 15, 89-98, 
doi:10.1038/sj.jea.7500350 (2005). 
74 Slotnick, M. J. & Nriagu, J. O. Validity of human nails as a biomarker of arsenic and 
selenium exposure: a review. Environmental research 102, 125-139 (2006). 
  
123 
 
75 Meharg, A. A. et al. Urinary excretion of arsenic following rice consumption. Environ 
Pollut 194, 181-187, doi:10.1016/j.envpol.2014.07.031 (2014). 
76 Pan, X. R., Yang, W. Y., Li, G. W. & Liu, J. Prevalence of diabetes and its risk factors in 
China, 1994. National Diabetes Prevention and Control Cooperative Group. Diabetes 
care 20, 1664-1669 (1997). 
77 Farzan, S. F., Chen, Y., Rees, J. R., Zens, M. S. & Karagas, M. R. Risk of death from 
cardiovascular disease associated with low-level arsenic exposure among long-term 
smokers in a US population-based study. Toxicol Appl Pharmacol 287, 93-97, 
doi:10.1016/j.taap.2015.05.013 (2015). 
78 Vahter, M. Mechanisms of arsenic biotransformation. Toxicology 181-182, 211-217 
(2002). 
79 Tseng, C. H. Arsenic methylation, urinary arsenic metabolites and human diseases: 
current perspective. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 25, 1-22, 
doi:10.1080/10590500701201695 (2007). 
80 Del Razo, L. M. et al. Exposure to arsenic in drinking water is associated with increased 
prevalence of diabetes: a cross-sectional study in the Zimapan and Lagunera regions in 
Mexico. Environ Health 10, 73, doi:10.1186/1476-069X-10-73 (2011). 
81 Mendez, M. A. et al. Chronic Exposure to Arsenic and Markers of Cardiometabolic Risk-
A Cross-Sectional Study in Chihuahua, Mexico. Environ Health Perspect, 
doi:10.1289/ehp.1408742 (2015). 
82 Chen, Y. et al. A prospective study of arsenic exposure, arsenic methylation capacity, and 
risk of cardiovascular disease in Bangladesh. Environmental health perspectives 121, 
832-838, doi:10.1289/ehp.1205797 (2013). 
83 Nizam, S. et al. Differences in urinary arsenic metabolites between diabetic and non-
diabetic subjects in Bangladesh. International journal of environmental research and 
public health 10, 1006-1019, doi:10.3390/ijerph10031006 (2013). 
84 Wood, T. C. et al. Human arsenic methyltransferase (AS3MT) pharmacogenetics: gene 
resequencing and functional genomics studies. J Biol Chem 281, 7364-7373, 
doi:10.1074/jbc.M512227200 (2006). 
85 Schlebusch, C. M. et al. Human adaptation to arsenic-rich environments. Molecular 
biology and evolution 32, 1544-1555, doi:10.1093/molbev/msv046 (2015). 
86 Gao, J. et al. The Genetic Architecture of Arsenic Metabolism Efficiency: A SNP-Based 
Heritability Study of Bangladeshi Adults. Environmental health perspectives, 
doi:10.1289/ehp.1408909 (2015). 
 
  
124 
 
87 Lindberg, A. L., Rahman, M., Persson, L. A. & Vahter, M. The risk of arsenic induced 
skin lesions in Bangladeshi men and women is affected by arsenic metabolism and the 
age at first exposure. Toxicology and applied pharmacology 230, 9-16, 
doi:10.1016/j.taap.2008.02.001 (2008). 
88 Kile, M. L. et al. Variability in biomarkers of arsenic exposure and metabolism in adults 
over time. Environmental health perspectives 117, 455-460, doi:10.1289/ehp.11251 
(2009). 
89 Pierce, B. L. et al. Arsenic metabolism efficiency has a causal role in arsenic toxicity: 
Mendelian randomization and gene-environment interaction. International journal of 
epidemiology 42, 1862-1871, doi:10.1093/ije/dyt182 (2013). 
90 Maull, E. A. et al. Evaluation of the association between arsenic and diabetes: a National 
Toxicology Program workshop review. Environmental health perspectives 120, 1658-
1670, doi:10.1289/ehp.1104579 (2012). 
91 Walton, F. S. et al. Inhibition of insulin-dependent glucose uptake by trivalent arsenicals: 
possible mechanism of arsenic-induced diabetes. Toxicol Appl Pharmacol 198, 424-433, 
doi:10.1016/j.taap.2003.10.026 (2004). 
92 Paul, D. S., Harmon, A. W., Devesa, V., Thomas, D. J. & Styblo, M. Molecular 
mechanisms of the diabetogenic effects of arsenic: inhibition of insulin signaling by 
arsenite and methylarsonous acid. Environmental health perspectives 115, 734-742, 
doi:10.1289/ehp.9867 (2007). 
93 Fu, J. et al. Low-level arsenic impairs glucose-stimulated insulin secretion in pancreatic 
beta cells: involvement of cellular adaptive response to oxidative stress. Environmental 
health perspectives 118, 864-870, doi:10.1289/ehp.0901608 (2010). 
94 Xue, P. et al. Prolonged inorganic arsenite exposure suppresses insulin-stimulated AKT 
S473 phosphorylation and glucose uptake in 3T3-L1 adipocytes: involvement of the 
adaptive antioxidant response. Biochemical and biophysical research communications 
407, 360-365, doi:10.1016/j.bbrc.2011.03.024 (2011). 
95 Douillet, C. et al. Methylated trivalent arsenicals are potent inhibitors of glucose 
stimulated insulin secretion by murine pancreatic islets. Toxicol Appl Pharmacol 267, 11-
15, doi:10.1016/j.taap.2012.12.007 (2013). 
96 Paul, D. S., Walton, F. S., Saunders, R. J. & Styblo, M. Characterization of the impaired 
glucose homeostasis produced in C57BL/6 mice by chronic exposure to arsenic and high-
fat diet. Environmental health perspectives 119, 1104-1109, doi:10.1289/ehp.1003324 
(2011). 
97 Zhang, B., Zhai, F. Y., Du, S. F. & Popkin, B. M. The China Health and Nutrition 
Survey, 1989-2011. Obesity reviews : an official journal of the International Association 
for the Study of Obesity 15 Suppl 1, 2-7, doi:10.1111/obr.12119 (2014). 
  
125 
 
98 Popkin, B. M. The implications of the nutrition transition for obesity in the developing 
world. Obesity epidemiology: from aetiology to public health, 136-142 (2010). 
99 Kile, M. L. et al. Association between total ingested arsenic and toenail arsenic 
concentrations. J Environ Sci Health A Tox Hazard Subst Environ Eng 42, 1827-1834, 
doi:10.1080/10934520701566819 (2007). 
100 Yang, Y., Wang, G. & Pan, X. C. China food composition. Peking University Medical 
Press, Beijing 329 (2002). 
101 Yao, M. et al. Relative influence of diet and physical activity on cardiovascular risk 
factors in urban Chinese adults. International journal of obesity and related metabolic 
disorders : journal of the International Association for the Study of Obesity 27, 920-932, 
doi:10.1038/sj.ijo.0802308 (2003). 
102 Consultation, W. H. O. E. Appropriate body-mass index for Asian populations and its 
implications for policy and intervention strategies. Lancet 363, 157-163, 
doi:10.1016/S0140-6736(03)15268-3 (2004). 
103 Niu, J. & Seo, D. C. Central obesity and hypertension in Chinese adults: a 12-year 
longitudinal examination. Preventive medicine 62, 113-118, 
doi:10.1016/j.ypmed.2014.02.012 (2014). 
104 Jones-Smith, J. C. & Popkin, B. M. Understanding community context and adult health 
changes in China: development of an urbanicity scale. Social science & medicine 71, 
1436-1446 (2010). 
105 Grashow, R. et al. Inverse association between toenail arsenic and body mass index in a 
population of welders. Environ Res 131, 131-133, doi:10.1016/j.envres.2014.03.010 
(2014). 
106 Gomez-Rubio, P. et al. Association between body mass index and arsenic methylation 
efficiency in adult women from southwest U.S. and northwest Mexico. Toxicol Appl 
Pharmacol 252, 176-182, doi:10.1016/j.taap.2011.02.007 (2011). 
107 Su, C. T. et al. The relationship between obesity, insulin and arsenic methylation 
capability in Taiwan adolescents. The Science of the total environment 414, 152-158, 
doi:10.1016/j.scitotenv.2011.10.023 (2012). 
108 Navas-Acien, A., Francesconi, K. A., Silbergeld, E. K. & Guallar, E. Seafood intake and 
urine concentrations of total arsenic, dimethylarsinate and arsenobetaine in the US 
population. Environ Res 111, 110-118, doi:10.1016/j.envres.2010.10.009 (2011). 
109 Taylor, V. et al. Human exposure to organic arsenic species from seafood. Sci Total 
Environ 580, 266-282, doi:10.1016/j.scitotenv.2016.12.113 (2017). 
  
126 
 
110 Kaushik, M. et al. Long-chain omega-3 fatty acids, fish intake, and the risk of type 2 
diabetes mellitus. The American journal of clinical nutrition 90, 613-620, 
doi:10.3945/ajcn.2008.27424 (2009). 
111 Patel, P. S. et al. Association between type of dietary fish and seafood intake and the risk 
of incident type 2 diabetes: the European prospective investigation of cancer (EPIC)-
Norfolk cohort study. Diabetes care 32, 1857-1863, doi:10.2337/dc09-0116 (2009). 
112 Zhu, Y. G. et al. High percentage inorganic arsenic content of mining impacted and 
nonimpacted Chinese rice. Environmental science & technology 42, 5008-5013 (2008). 
113 Hu, E. A., Pan, A., Malik, V. & Sun, Q. White rice consumption and risk of type 2 
diabetes: meta-analysis and systematic review. BMJ 344, e1454, doi:10.1136/bmj.e1454 
(2012). 
114 Gribble, M. O. et al. Arsenic exposure, diabetes prevalence, and diabetes control in the 
Strong Heart Study. Am J Epidemiol 176, 865-874, doi:10.1093/aje/kws153 (2012). 
115 Wang, W., Xie, Z., Lin, Y. & Zhang, D. Association of inorganic arsenic exposure with 
type 2 diabetes mellitus: a meta-analysis. J Epidemiol Community Health 68, 176-184, 
doi:10.1136/jech-2013-203114 (2014). 
116 Kuo, C. C., Moon, K. A., Wang, S. L., Silbergeld, E. & Navas-Acien, A. The Association 
of Arsenic Metabolism with Cancer, Cardiovascular Disease, and Diabetes: A Systematic 
Review of the Epidemiological Evidence. Environmental health perspectives 125, 
087001, doi:10.1289/EHP577 (2017). 
117 Karagas, M. R. et al. Measurement of low levels of arsenic exposure: a comparison of 
water and toenail concentrations. American journal of epidemiology 152, 84-90 (2000). 
118 Awata, H., Linder, S., Mitchell, L. E. & Delclos, G. L. Association of Dietary Intake and 
Biomarker Levels of Arsenic, Cadmium, Lead, and Mercury among Asian Populations in 
the United States: NHANES 2011-2012. Environmental health perspectives 125, 314-
323, doi:10.1289/EHP28 (2017). 
119 Ma, L., Wang, L., Jia, Y. & Yang, Z. Arsenic speciation in locally grown rice grains from 
Hunan Province, China: Spatial distribution and potential health risk. Sci Total Environ 
557-558, 438-444, doi:10.1016/j.scitotenv.2016.03.051 (2016). 
120 Guo, H., Wen, D., Liu, Z., Jia, Y. & Guo, Q. A review of high arsenic groundwater in 
Mainland and Taiwan, China: distribution, characteristics and geochemical processes. 
Applied Geochemistry 41, 196-217 (2014). 
121 Yu, G., Sun, D. & Zheng, Y. Health effects of exposure to natural arsenic in groundwater 
and coal in China: an overview of occurrence. Environmental health perspectives 115, 
636-642, doi:10.1289/ehp.9268 (2007). 
  
127 
 
122 Belkin, H., Zheng, B. & Finkelman, R. Geochemistry of coal and endemic arsenism in 
Southwest Guizhou, China. US Geological survey open file report (1997). 
123 Zheng, B. et al. Issues of health and disease relating to coal use in southwestern China. 
International Journal of Coal Geology 40, 119-132 (1999). 
124 Ma, L., Wang, L., Tang, J. & Yang, Z. Arsenic speciation and heavy metal distribution in 
polished rice grown in Guangdong Province, Southern China. Food chemistry 233, 110-
116, doi:10.1016/j.foodchem.2017.04.097 (2017). 
125 Liu, C. P. et al. Arsenic contamination and potential health risk implications at an 
abandoned tungsten mine, southern China. Environ Pollut 158, 820-826, 
doi:10.1016/j.envpol.2009.09.029 (2010). 
126 Williams, P. N. et al. Occurrence and partitioning of cadmium, arsenic and lead in mine 
impacted paddy rice: Hunan, China. Environmental science & technology 43, 637-642 
(2009). 
127 Liao, X. Y., Chen, T. B., Xie, H. & Liu, Y. R. Soil As contamination and its risk 
assessment in areas near the industrial districts of Chenzhou City, Southern China. 
Environ Int 31, 791-798, doi:10.1016/j.envint.2005.05.030 (2005). 
128 Liu, H., Probst, A. & Liao, B. Metal contamination of soils and crops affected by the 
Chenzhou lead/zinc mine spill (Hunan, China). Sci Total Environ 339, 153-166, 
doi:10.1016/j.scitotenv.2004.07.030 (2005). 
129 Chen, Y. et al. Arsenic Transport in Rice and Biological Solutions to Reduce Arsenic 
Risk from Rice. Frontiers in plant science 8, 268, doi:10.3389/fpls.2017.00268 (2017). 
130 Bakhat, H. F. et al. Arsenic uptake, accumulation and toxicity in rice plants: Possible 
remedies for its detoxification: A review. Environmental science and pollution research 
international 24, 9142-9158, doi:10.1007/s11356-017-8462-2 (2017). 
131 Yu, H. Y. et al. The availabilities of arsenic and cadmium in rice paddy fields from a 
mining area: The role of soil extractable and plant silicon. Environ Pollut 215, 258-265, 
doi:10.1016/j.envpol.2016.04.008 (2016). 
132 Xue, S. et al. Cadmium, lead, and arsenic contamination in paddy soils of a mining area 
and their exposure effects on human HEPG2 and keratinocyte cell-lines. Environ Res 
156, 23-30, doi:10.1016/j.envres.2017.03.014 (2017). 
133 Shao, Y., Wang, J., Chen, X. & Wu, Y. The consolidation of food contaminants standards 
in China. Food Control 43, 213-216 (2014). 
134 Lorenzo, C. et al. A1C between 5.7 and 6.4% as a marker for identifying pre-diabetes, 
insulin sensitivity and secretion, and cardiovascular risk factors: the Insulin Resistance 
Atherosclerosis Study (IRAS). Diabetes care 33, 2104-2109, doi:10.2337/dc10-0679 
(2010). 
  
128 
 
135 Committee of the Japan Diabetes Society on the Diagnostic Criteria of Diabetes, M. et al. 
Report of the committee on the classification and diagnostic criteria of diabetes mellitus. 
Journal of diabetes investigation 1, 212-228, doi:10.1111/j.2040-1124.2010.00074.x 
(2010). 
136 Hinzmann, R., Schlaeger, C. & Tran, C. T. What do we need beyond hemoglobin A1c to 
get the complete picture of glycemia in people with diabetes? Int J Med Sci 9, 665-681, 
doi:10.7150/ijms.4520 (2012). 
137 Association, A. D. Diagnosis and classification of diabetes mellitus. Diabetes care 33, 
S62-S69 (2010). 
138 Navas-Acien, A., Silbergeld, E. K., Pastor-Barriuso, R. & Guallar, E. Arsenic exposure 
and prevalence of type 2 diabetes in US adults. JAMA 300, 814-822, 
doi:10.1001/jama.300.7.814 (2008). 
139 Chen, Y. et al. No association between arsenic exposure from drinking water and 
diabetes mellitus: a cross-sectional study in Bangladesh. Environmental health 
perspectives 118, 1299-1305, doi:10.1289/ehp.0901559 (2010). 
140 Mudaliar, S. & Edelman, S. V. Insulin therapy in type 2 diabetes. Endocrinology and 
Metabolism Clinics 30, 935-982 (2001). 
141 Rotter, I. et al. Relationship between the concentrations of heavy metals and bioelements 
in aging men with metabolic syndrome. International journal of environmental research 
and public health 12, 3944-3961 (2015). 
142 Baek, K., Lee, N. & Chung, I. Association of arsenobetaine with beta-cell function 
assessed by homeostasis model assessment (HOMA) in nondiabetic Koreans: data from 
the fourth Korea National Health and Nutrition Examination Survey (KNHANES) 2008-
2009. Annals of occupational and environmental medicine 29, 31 (2017). 
143 Lin, H. C. et al. Arsenic methylation capacity and obesity are associated with insulin 
resistance in obese children and adolescents. Food and chemical toxicology : an 
international journal published for the British Industrial Biological Research Association 
74, 60-67, doi:10.1016/j.fct.2014.08.018 (2014). 
144 Kahn, S. E. The relative contributions of insulin resistance and beta-cell dysfunction to 
the pathophysiology of Type 2 diabetes. Diabetologia 46, 3-19, doi:10.1007/s00125-002-
1009-0 (2003). 
145 Diaz-Villasenor, A. et al. Arsenic exposure and calpain-10 polymorphisms impair the 
function of pancreatic beta-cells in humans: a pilot study of risk factors for T2DM. PloS 
one 8, e51642, doi:10.1371/journal.pone.0051642 (2013). 
146 Singh, A. P., Goel, R. K. & Kaur, T. Mechanisms pertaining to arsenic toxicity. 
Toxicology international 18, 87-93, doi:10.4103/0971-6580.84258 (2011). 
  
129 
 
147 Izquierdo-Vega, J. A., Soto, C. A., Sanchez-Pena, L. C., De Vizcaya-Ruiz, A. & Del 
Razo, L. M. Diabetogenic effects and pancreatic oxidative damage in rats subchronically 
exposed to arsenite. Toxicology letters 160, 135-142, doi:10.1016/j.toxlet.2005.06.018 
(2006). 
148 Bonini, M. G. & Sargis, R. M. Environmental Toxicant Exposures and Type 2 Diabetes 
Mellitus: Two Interrelated Public Health Problems on the Rise. Current opinion in 
toxicology 7, 52-59, doi:10.1016/j.cotox.2017.09.003 (2018). 
149 Hill, D. S., Wlodarczyk, B. J., Mitchell, L. E. & Finnell, R. H. Arsenate-induced maternal 
glucose intolerance and neural tube defects in a mouse model. Toxicol Appl Pharmacol 
239, 29-36, doi:10.1016/j.taap.2009.05.009 (2009). 
150 Coronado-Gonzalez, J. A., Del Razo, L. M., Garcia-Vargas, G., Sanmiguel-Salazar, F. & 
Escobedo-de la Pena, J. Inorganic arsenic exposure and type 2 diabetes mellitus in 
Mexico. Environmental research 104, 383-389, doi:10.1016/j.envres.2007.03.004 (2007). 
151 Watanabe, C. et al. Males in rural Bangladeshi communities are more susceptible to 
chronic arsenic poisoning than females: analyses based on urinary arsenic. Environmental 
health perspectives 109, 1265-1270 (2001). 
152 Fischer, L. M. et al. Sex and menopausal status influence human dietary requirements for 
the nutrient choline. Am J Clin Nutr 85, 1275-1285, doi:10.1093/ajcn/85.5.1275 (2007). 
153 Gribble, M. O. et al. Body composition and arsenic metabolism: a cross-sectional 
analysis in the Strong Heart Study. Environ Health 12, 107, doi:10.1186/1476-069X-12-
107 (2013). 
154 Garciafigueroa, D. Y., Klei, L. R., Ambrosio, F. & Barchowsky, A. Arsenic-stimulated 
lipolysis and adipose remodeling is mediated by G-protein-coupled receptors. 
Toxicological sciences : an official journal of the Society of Toxicology 134, 335-344, 
doi:10.1093/toxsci/kft108 (2013). 
155 Hou, Y. et al. Association between arsenic suppression of adipogenesis and induction of 
CHOP10 via the endoplasmic reticulum stress response. Environmental health 
perspectives 121, 237-243, doi:10.1289/ehp.1205731 (2013). 
156 Klei, L. R., Garciafigueroa, D. Y. & Barchowsky, A. Arsenic activates endothelin-1 Gi 
protein-coupled receptor signaling to inhibit stem cell differentiation in adipogenesis. 
Toxicological sciences : an official journal of the Society of Toxicology 131, 512-520, 
doi:10.1093/toxsci/kfs323 (2013). 
157 Milton, A. H. et al. Association between nutritional status and arsenicosis due to chronic 
arsenic exposure in Bangladesh. International journal of environmental health research 
14, 99-108, doi:10.1080/0960312042000209516 (2004). 
  
130 
 
158 Salazard, B. et al. Low-level arsenite activates the transcription of genes involved in 
adipose differentiation. Cell biology and toxicology 20, 375-385, doi:10.1007/s10565-
004-1471-1 (2004). 
159 Wauson, E. M., Langan, A. S. & Vorce, R. L. Sodium arsenite inhibits and reverses 
expression of adipogenic and fat cell-specific genes during in vitro adipogenesis. 
Toxicological sciences : an official journal of the Society of Toxicology 65, 211-219 
(2002). 
160 Fatmi, Z. et al. Health burden of skin lesions at low arsenic exposure through 
groundwater in Pakistan. Is river the source? Environmental research 109, 575-581, 
doi:10.1016/j.envres.2009.04.002 (2009). 
161 Tseng, C. H. et al. Long-term arsenic exposure and incidence of non-insulin-dependent 
diabetes mellitus: a cohort study in arseniasis-hyperendemic villages in Taiwan. 
Environmental health perspectives 108, 847-851 (2000). 
162 Lin, W. Y. et al. Body mass index and all-cause mortality in a large Chinese cohort. 
CMAJ 183, E329-336, doi:10.1503/cmaj.101303 (2011). 
163 Wang, D. et al. Ethnic differences in body composition and obesity related risk factors: 
study in Chinese and white males living in China. PloS one 6, e19835, 
doi:10.1371/journal.pone.0019835 (2011). 
164 Wang, J. et al. Asians have lower body mass index (BMI) but higher percent body fat 
than do whites: comparisons of anthropometric measurements. The American journal of 
clinical nutrition 60, 23-28, doi:10.1093/ajcn/60.1.23 (1994). 
165 Quilliot, D. et al. Evidence that diabetes mellitus favors impaired metabolism of zinc, 
copper, and selenium in chronic pancreatitis. Pancreas 22, 299-306 (2001). 
166 Xu, J., Zhou, Q., Liu, G., Tan, Y. & Cai, L. Analysis of serum and urinal copper and zinc 
in Chinese northeast population with the prediabetes or diabetes with and without 
complications. Oxidative medicine and cellular longevity 2013, 635214, 
doi:10.1155/2013/635214 (2013). 
167 Karamouzis, M. V., Gorgoulis, V. G. & Papavassiliou, A. G. Transcription factors and 
neoplasia: vistas in novel drug design. Clinical cancer research : an official journal of 
the American Association for Cancer Research 8, 949-961 (2002). 
168 Jansen, J., Karges, W. & Rink, L. Zinc and diabetes--clinical links and molecular 
mechanisms. The Journal of nutritional biochemistry 20, 399-417, 
doi:10.1016/j.jnutbio.2009.01.009 (2009). 
169 Mooren, F. C. Magnesium and disturbances in carbohydrate metabolism. Diabetes Obes 
Metab 17, 813-823, doi:10.1111/dom.12492 (2015). 
  
131 
 
170 Lin, C. C. & Huang, Y. L. Chromium, zinc and magnesium status in type 1 diabetes. 
Current opinion in clinical nutrition and metabolic care 18, 588-592, 
doi:10.1097/MCO.0000000000000225 (2015). 
171 Wells, I. C. Evidence that the etiology of the syndrome containing type 2 diabetes 
mellitus results from abnormal magnesium metabolism. Canadian journal of physiology 
and pharmacology 86, 16-24, doi:10.1139/y07-122 (2008). 
172 Afridi, H. I. et al. Potassium, calcium, magnesium, and sodium levels in biological 
samples of hypertensive and nonhypertensive diabetes mellitus patients. Biol Trace Elem 
Res 124, 206-224, doi:10.1007/s12011-008-8142-7 (2008). 
173 Akter, S. et al. Association of dietary and serum magnesium with glucose metabolism 
markers: The Furukawa Nutrition and Health Study. Clin Nutr ESPEN 24, 71-77, 
doi:10.1016/j.clnesp.2018.01.011 (2018). 
174 Karamali, M. et al. Zinc supplementation and the effects on metabolic status in 
gestational diabetes: A randomized, double-blind, placebo-controlled trial. J Diabetes 
Complications 29, 1314-1319, doi:10.1016/j.jdiacomp.2015.07.001 (2015). 
175 Xu, T., Chen, G. C., Zhai, L. & Ke, K. F. Nonlinear Reduction in Risk for Type 2 
Diabetes by Magnesium Intake: An Updated Meta-Analysis of Prospective Cohort 
Studies. Biomedical and environmental sciences : BES 28, 527-534, 
doi:10.3967/bes2015.075 (2015). 
176 Barbagallo, M. & Dominguez, L. J. Magnesium and type 2 diabetes. World journal of 
diabetes 6, 1152-1157, doi:10.4239/wjd.v6.i10.1152 (2015). 
177 Yary, T., Virtanen, J. K., Ruusunen, A., Tuomainen, T. P. & Voutilainen, S. Serum zinc 
and risk of type 2 diabetes incidence in men: The Kuopio Ischaemic Heart Disease Risk 
Factor Study. J Trace Elem Med Biol 33, 120-124, doi:10.1016/j.jtemb.2015.11.001 
(2016). 
178 Kazi, T. G. et al. Copper, chromium, manganese, iron, nickel, and zinc levels in 
biological samples of diabetes mellitus patients. Biol Trace Elem Res 122, 1-18, 
doi:10.1007/s12011-007-8062-y (2008). 
179 Vashum, K. P. et al. Is dietary zinc protective for type 2 diabetes? Results from the 
Australian longitudinal study on women's health. BMC Endocr Disord 13, 40, 
doi:10.1186/1472-6823-13-40 (2013). 
180 Vashum, K. P. et al. Is serum zinc associated with pancreatic beta cell function and 
insulin sensitivity in pre-diabetic and normal individuals? Findings from the Hunter 
Community Study. PloS one 9, e83944, doi:10.1371/journal.pone.0083944 (2014). 
181 Basaki, M., Saeb, M., Nazifi, S. & Shamsaei, H. A. Zinc, copper, iron, and chromium 
concentrations in young patients with type 2 diabetes mellitus. Biol Trace Elem Res 148, 
161-164, doi:10.1007/s12011-012-9360-6 (2012). 
  
132 
 
182 Al-Maroof, R. A. & Al-Sharbatti, S. S. Serum zinc levels in diabetic patients and effect 
of zinc supplementation on glycemic control of type 2 diabetics. Saudi medical journal 
27, 344-350 (2006). 
183 Perez, A. et al. Association between zinc nutritional status and glycemic control in 
individuals with well-controlled type-2 diabetes. J Trace Elem Med Biol, 
doi:10.1016/j.jtemb.2018.03.019 (2018). 
184 Martini, L. A., Catania, A. S. & Ferreira, S. R. Role of vitamins and minerals in 
prevention and management of type 2 diabetes mellitus. Nutrition reviews 68, 341-354, 
doi:10.1111/j.1753-4887.2010.00296.x (2010). 
185 El Dib, R. et al. Zinc supplementation for the prevention of type 2 diabetes mellitus in 
adults with insulin resistance. The Cochrane database of systematic reviews, CD005525, 
doi:10.1002/14651858.CD005525.pub3 (2015). 
186 Vaquero, M. P. Magnesium and trace elements in the elderly: intake, status and 
recommendations. J Nutr Health Aging 6, 147-153 (2002). 
187 Doets, E. L., Cavelaars, A. E., Dhonukshe-Rutten, R. A., van 't Veer, P. & de Groot, L. 
C. Explaining the variability in recommended intakes of folate, vitamin B12, iron and 
zinc for adults and elderly people. Public health nutrition 15, 906-915, 
doi:10.1017/S1368980011002643 (2012). 
188 Durlach, J. Recommended dietary amounts of magnesium: Mg RDA. Magnesium 
research 2, 195-203 (1989). 
189 Council, N. R. Recommended dietary allowances.  (National Academies Press, 1989). 
190 Wang, S. S., Lay, S., Yu, H. N. & Shen, S. R. Dietary Guidelines for Chinese Residents 
(2016): comments and comparisons. J Zhejiang Univ Sci B 17, 649-656, 
doi:10.1631/jzus.B1600341 (2016). 
191 Wang, Z. et al. Diet quality and its association with type 2 diabetes and major 
cardiometabolic risk factors among adults in China. Nutrition, metabolism, and 
cardiovascular diseases : NMCD 28, 987-1001, doi:10.1016/j.numecd.2018.06.012 
(2018). 
192 Ford, E. S. & Mokdad, A. H. Dietary magnesium intake in a national sample of US 
adults. The Journal of nutrition 133, 2879-2882 (2003). 
193 Briefel, R. R. et al. Zinc intake of the U.S. population: findings from the third National 
Health and Nutrition Examination Survey, 1988-1994. The Journal of nutrition 130, 
1367S-1373S (2000). 
194 Rosenbaum, D. L. et al. Energy intake highs and lows: how much does consistency 
matter in weight control? Clin Obes 6, 193-201, doi:10.1111/cob.12142 (2016). 
  
133 
 
195 Carrera, P. M., Gao, X. & Tucker, K. L. A study of dietary patterns in the Mexican-
American population and their association with obesity. Journal of the American Dietetic 
Association 107, 1735-1742, doi:10.1016/j.jada.2007.07.016 (2007). 
196 Chen, C. J. et al. Biomarkers of exposure, effect, and susceptibility of arsenic-induced 
health hazards in Taiwan. Toxicology and applied pharmacology 206, 198-206, 
doi:10.1016/j.taap.2004.10.023 (2005). 
197 Chung, W. H., Sung, B. H., Kim, S. S., Rhim, H. & Kuh, H. J. Synergistic interaction 
between tetra-arsenic oxide and paclitaxel in human cancer cells in vitro. International 
journal of oncology 34, 1669-1679 (2009). 
198 Fernandez-Cao, J. C. et al. Dietary zinc intake and whole blood zinc concentration in 
subjects with type 2 diabetes versus healthy subjects: A systematic review, meta-analysis 
and meta-regression. J Trace Elem Med Biol 49, 241-251, 
doi:10.1016/j.jtemb.2018.02.008 (2018). 
199 Zheng, Y., Li, X. K., Wang, Y. & Cai, L. The role of zinc, copper and iron in the 
pathogenesis of diabetes and diabetic complications: therapeutic effects by chelators. 
Hemoglobin 32, 135-145, doi:10.1080/03630260701727077 (2008). 
200 Matveyenko, A. V. & Butler, P. C. Relationship between beta-cell mass and diabetes 
onset. Diabetes Obes Metab 10 Suppl 4, 23-31, doi:10.1111/j.1463-1326.2008.00939.x 
(2008). 
201 Yin, Y. et al. Identification of Risk Factors Affecting Impaired Fasting Glucose and 
Diabetes in Adult Patients from Northeast China. International journal of environmental 
research and public health 12, 12662-12678, doi:10.3390/ijerph121012662 (2015). 
202 Park, J. S. et al. Longitudinal association between toenail zinc levels and the incidence of 
diabetes among American young adults: The CARDIA Trace Element Study. Sci Rep 6, 
23155, doi:10.1038/srep23155 (2016). 
203 Anetor, J., Senjobi, A., Agbedana, E. & Ajose, O. Decreased serum magnesium and zinc 
levels: atherogenic implications in type-2 diabetes mellitus in Nigerians. Nutrition and 
health 16, 291-300 (2002). 
204 Zhang, H. et al. Alterations of serum trace elements in patients with type 2 diabetes. J 
Trace Elem Med Biol 40, 91-96, doi:10.1016/j.jtemb.2016.12.017 (2017). 
205 Kaur, B. & Henry, J. Micronutrient status in type 2 diabetes: a review. Adv Food Nutr 
Res 71, 55-100, doi:10.1016/B978-0-12-800270-4.00002-X (2014). 
206 Eibl, N. L. et al. Hypomagnesemia in type II diabetes: effect of a 3-month replacement 
therapy. Diabetes care 18, 188-192 (1995). 
  
134 
 
207 Moon, K., Guallar, E. & Navas-Acien, A. Arsenic exposure and cardiovascular disease: 
an updated systematic review. Curr Atheroscler Rep 14, 542-555, doi:10.1007/s11883-
012-0280-x (2012). 
208 Hussein Were, F., Njue, W., Murungi, J. & Wanjau, R. Use of human nails as bio-
indicators of heavy metals environmental exposure among school age children in Kenya. 
Sci Total Environ 393, 376-384, doi:10.1016/j.scitotenv.2007.12.035 (2008). 
209 Dehghan, M., Akhtar-Danesh, N., McMillan, C. R. & Thabane, L. Is plasma vitamin C an 
appropriate biomarker of vitamin C intake? A systematic review and meta-analysis. 
Nutrition journal 6, 41, doi:10.1186/1475-2891-6-41 (2007). 
210 Poslusna, K., Ruprich, J., de Vries, J. H., Jakubikova, M. & van't Veer, P. Misreporting 
of energy and micronutrient intake estimated by food records and 24 hour recalls, control 
and adjustment methods in practice. The British journal of nutrition 101 Suppl 2, S73-85, 
doi:10.1017/S0007114509990602 (2009). 
211 Black, A. E. & Cole, T. J. Biased over- or under-reporting is characteristic of individuals 
whether over time or by different assessment methods. Journal of the American Dietetic 
Association 101, 70-80, doi:10.1016/S0002-8223(01)00018-9 (2001). 
212 Xie, D. X. et al. Association between low dietary zinc and hyperuricaemia in middle-
aged and older males in China: a cross-sectional study. BMJ open 5, e008637, 
doi:10.1136/bmjopen-2015-008637 (2015). 
213 Smith, A. H., Lingas, E. O. & Rahman, M. Contamination of drinking-water by arsenic in 
Bangladesh: a public health emergency. Bull World Health Organ 78, 1093-1103 (2000). 
214 Sun, G. et al. Urinary arsenic metabolites in children and adults exposed to arsenic in 
drinking water in Inner Mongolia, China. Environmental health perspectives 115, 648-
652, doi:10.1289/ehp.9271 (2007). 
215 Huang, Y. K. et al. Arsenic methylation capability and hypertension risk in subjects 
living in arseniasis-hyperendemic areas in southwestern Taiwan. Toxicology and applied 
pharmacology 218, 135-142, doi:10.1016/j.taap.2006.10.022 (2007). 
216 Engstrom, K. S. et al. Genetic variation in arsenic (+3 oxidation state) methyltransferase 
(AS3MT), arsenic metabolism and risk of basal cell carcinoma in a European population. 
Environ Mol Mutagen 56, 60-69, doi:10.1002/em.21896 (2015). 
217 Kerner, W., Bruckel, J. & German Diabetes, A. Definition, classification and diagnosis of 
diabetes mellitus. Experimental and clinical endocrinology & diabetes : official journal, 
German Society of Endocrinology [and] German Diabetes Association 122, 384-386, 
doi:10.1055/s-0034-1366278 (2014). 
218 World Health Organization. Definition and diagnosis of diabetes mellitus and 
intermediate hyperglycaemia: report of a WHO/IDF consultation. (2006). 
  
135 
 
219 Hernandez-Zavala, A. et al. Speciation of arsenic in exfoliated urinary bladder epithelial 
cells from individuals exposed to arsenic in drinking water. Environmental health 
perspectives 116, 1656-1660, doi:10.1289/ehp.11503 (2008). 
220 Currier, J. M. et al. Associations between arsenic species in exfoliated urothelial cells and 
prevalence of diabetes among residents of Chihuahua, Mexico. Environ Health Perspect 
122, 1088-1094, doi:10.1289/ehp.1307756 (2014). 
221 Vahter, M. & Concha, G. Role of metabolism in arsenic toxicity. Pharmacol Toxicol 89, 
1-5 (2001). 
222 Thomas, D. J., Styblo, M. & Lin, S. The cellular metabolism and systemic toxicity of 
arsenic. Toxicol Appl Pharmacol 176, 127-144, doi:10.1006/taap.2001.9258 (2001). 
223 Lindberg, A. L. et al. Metabolism of low-dose inorganic arsenic in a central European 
population: influence of sex and genetic polymorphisms. Environmental health 
perspectives 115, 1081-1086, doi:10.1289/ehp.10026 (2007). 
224 Valenzuela, O. L. et al. Association of AS3MT polymorphisms and the risk of 
premalignant arsenic skin lesions. Toxicology and applied pharmacology 239, 200-207, 
doi:10.1016/j.taap.2009.06.007 (2009). 
225 Sampayo-Reyes, A. et al. Arsenic induces DNA damage in environmentally exposed 
Mexican children and adults. Influence of GSTO1 and AS3MT polymorphisms. 
Toxicological sciences : an official journal of the Society of Toxicology 117, 63-71, 
doi:10.1093/toxsci/kfq173 (2010). 
226 Hwang, Y. H. et al. Genetic polymorphism of As3MT and delayed urinary DMA 
excretion after organic arsenic intake from oyster ingestion. J Environ Monit 12, 1247-
1254, doi:10.1039/c000844c (2010). 
227 Schlawicke Engstrom, K. et al. Genetic polymorphisms influencing arsenic metabolism: 
evidence from Argentina. Environ Health Perspect 115, 599-605, doi:10.1289/ehp.9734 
(2007). 
228 Lindberg, A. L. et al. Gender and age differences in the metabolism of inorganic arsenic 
in a highly exposed population in Bangladesh. Environmental research 106, 110-120, 
doi:10.1016/j.envres.2007.08.011 (2008). 
229 Loffredo, C. A., Aposhian, H. V., Cebrian, M. E., Yamauchi, H. & Silbergeld, E. K. 
Variability in human metabolism of arsenic. Environmental research 92, 85-91 (2003). 
230 Tseng, C. H. A review on environmental factors regulating arsenic methylation in 
humans. Toxicology and applied pharmacology 235, 338-350, 
doi:10.1016/j.taap.2008.12.016 (2009). 
 
  
136 
 
231 Beebe-Dimmer, J. L. et al. Genetic variation in glutathione S-transferase omega-1, 
arsenic methyltransferase and methylene-tetrahydrofolate reductase, arsenic exposure and 
bladder cancer: a case-control study. Environmental health : a global access science 
source 11, 43, doi:10.1186/1476-069X-11-43 (2012). 
232 Hernandez, A., Paiva, L., Creus, A., Quinteros, D. & Marcos, R. Micronucleus frequency 
in copper-mine workers exposed to arsenic is modulated by the AS3MT Met287Thr 
polymorphism. Mutat Res Genet Toxicol Environ Mutagen 759, 51-55, 
doi:10.1016/j.mrgentox.2013.09.010 (2014). 
233 Ahsan, H. et al. Arsenic metabolism, genetic susceptibility, and risk of premalignant skin 
lesions in Bangladesh. Cancer epidemiology, biomarkers & prevention : a publication of 
the American Association for Cancer Research, cosponsored by the American Society of 
Preventive Oncology 16, 1270-1278, doi:10.1158/1055-9965.EPI-06-0676 (2007). 
234 Styblo, M. et al. Metabolism of arsenic in primary cultures of human and rat hepatocytes. 
Chemical research in toxicology 12, 560-565, doi:10.1021/tx990050l (1999). 
235 Kligerman, A. D. & Tennant, A. H. Insights into the carcinogenic mode of action of 
arsenic. Toxicology and applied pharmacology 222, 281-288, 
doi:10.1016/j.taap.2006.10.006 (2007). 
236 Petrick, J. S., Ayala-Fierro, F., Cullen, W. R., Carter, D. E. & Vasken Aposhian, H. 
Monomethylarsonous acid (MMA(III)) is more toxic than arsenite in Chang human 
hepatocytes. Toxicology and applied pharmacology 163, 203-207, 
doi:10.1006/taap.1999.8872 (2000). 
237 Schwerdtle, T., Walter, I., Mackiw, I. & Hartwig, A. Induction of oxidative DNA damage 
by arsenite and its trivalent and pentavalent methylated metabolites in cultured human 
cells and isolated DNA. Carcinogenesis 24, 967-974 (2003). 
238 Styblo, M. et al. Comparative toxicity of trivalent and pentavalent inorganic and 
methylated arsenicals in rat and human cells. Arch Toxicol 74, 289-299 (2000). 
239 Valenzuela, O. L. et al. Urinary trivalent methylated arsenic species in a population 
chronically exposed to inorganic arsenic. Environmental health perspectives 113, 250-
254 (2005). 
240 Farzan, S. F. et al. Gene-arsenic interaction in longitudinal changes of blood pressure: 
Findings from the Health Effects of Arsenic Longitudinal Study (HEALS) in Bangladesh. 
Toxicology and applied pharmacology 288, 95-105, doi:10.1016/j.taap.2015.07.017 
(2015). 
 
